Heteroaromatic derivatives as NIK inhibitors

ABSTRACT

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

FIELD OF THE INVENTION

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer (in particular B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

BACKGROUND OF THE INVENTION

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer and inflammatory disorders. Nuclear factor-kappa B (NF-κB) is a transcription factor regulating the expression of various genes involved in the immune response, cell proliferation, adhesion, apoptosis, and carcinogenesis. NF-κB dependent transcriptional activation is a tightly controlled signaling pathway, through sequential events including phosphorylation and protein degradation. NIK is a serine/threonine kinase which regulates NF-κB pathway activation. There are two NF-κB signaling pathways, the canonical and the non-canonical. NIK is indispensable for the non-canonical signaling pathway where it phosphorylates IKKα, leading to the partial proteolysis of p100; liberating p52 which then heterodimerizes with RelB, translocates to the nucleus and mediates gene expression. The non-canonical pathway is activated by only a handful of ligands such as CD40 ligands, B-cell activating factor (BAFF), lymphotoxin β receptor ligands and TNF-related weak inducer of apoptosis (TWEAK) and NIK has been shown to be required for activation of the pathway by these ligands. Because of its key role, NIK expression is tightly regulated. Under normal non-stimulated conditions NIK protein levels are very low, this is due to its interaction with a range of TNF receptor associated factors (TRAF2 and TRAF3), which are ubiquitin ligases and result in degradation of NIK. It is believed that when the non-canonical pathway is stimulated by ligands, the activated receptors now compete for TRAFs, dissociating the TRAF-NIK complexes and thereby increasing the levels of NIK. (Thu and Richmond, Cytokine Growth F. R. 2010, 21, 213-226)

Research has shown that blocking the NF-κB signaling pathway in cancer cells can cause cells to stop proliferating, to die and to become more sensitive to the action of other anti-cancer therapies. A role for NIK has been shown in the pathogenesis of both hematological malignancies and solid tumours.

The NF-κB pathway is dysregulated in multiple myeloma due to a range of diverse genetic abnormalities that lead to the engagement of the canonical and non-canonical pathways (Annuziata et al. Cancer Cell 2007, 12, 115-130; Keats et al. Cancer Cell 2007, 12, 131-144; Demchenko et al. Blood 2010, 115, 3541-3552). Myeloma patient samples frequently have increased levels of NIK activity. This can be due to chromosomal amplification, translocations (that result in NIK proteins that have lost TRAF binding domains), mutations (in the TRAF binding domain of NIK) or TRAF loss of function mutations. Researchers have shown that myeloma cell lines can be dependent on NIK for proliferation; in these cell lines if NIK activity is reduced by either shRNA or compound inhibition, this leads to a failure in NF-κB signaling and the induction of cell death (Annuziata 2007).

In a similar manner, mutations in TRAF and increased levels of NIK have also been seen in samples from Hodgkin lymphoma (HL) patients. Once again proliferation of cell lines derived from HL patients is susceptible to inhibition of NIK function by both shRNA and compounds (Ranuncolo et al. Blood First Edition Paper, 2012, DOI 10.1182/blood-2012-01-405951).

NIK levels are also enhanced in adult T cell leukemia (ATL) cells and targeting NIK with shRNA reduced ATL growth in vivo (Saitoh et al. Blood 2008, 111, 5118-5129). It has been demonstrated that the API2-MALT 1 fusion oncoprotein created by the recurrent translocation t(11; 18)(q21; q21) in mucosa-associated lymphoid tissue (MALT) lymphoma induces proteolytic cleavage of NF-κB-inducing kinase (NIK) at arginine 325. NIK cleavage generates a C-terminal NIK fragment that retains kinase activity and is resistant to proteasomal degradation (due to loss of TRAF binding region). The presence of this truncated NIK leads to constitutive non-canonical NF-κB signaling, enhanced B cell adhesion, and apoptosis resistance. Thus NIK inhibitors could represent a new treatment approach for refractory t(11; 18)-positive MALT lymphoma (Rosebeck et al. Science 2011, 331, 468-472).

NIK aberrantly accumulates in diffuse large B-cell lymphoma (DLBCL) cells due to constitutive activation of B-cell activation factor (BAFF) through interaction with autochthonous B-lymphocyte stimulator (BLyS) ligand. NIK accumulation in human DLBCL cell lines and patient tumor samples suggested that constitutive NIK kinase activation is likely to be a key signaling mechanism involved in abnormal lymphoma tumor cell proliferation. Growth assays showed that using shRNA to inhibit NIK kinase protein expression in GCB- and ABC-like DLBCL cells decreased lymphoma cell growth in vitro, implicating NIK-induced NF-κB pathway activation as having a significant role in DLBCL proliferation (Pham et al. Blood 2011, 117, 200-210). More recently, also loss-of-function mutations in TRAF3 have been characterized in human and canine DLBCL (Bushell et al., Blood 2015, 125, 999-1005).

Recently, similar mutations in the non-canonical NFkB signaling pathway (TRAF2, TRAF3, NIK, BIRC3) were found in ibrutinib-refractory mantle cell lymphoma cell lines (Rahal et al., Nat Med 2014, 1, 87-92).

As mentioned a role of NIK in tumour cell proliferation is not restricted to hematological cells, there are reports that NIK protein levels are stabilised in some pancreatic cancer cell lines and as seen in blood cells proliferation of these pancreatic cancer lines are susceptible to NIK siRNA treatment (Nishina et al. Biochem. Bioph. Res. Co. 2009, 388, 96-101). Constitutive activation of NF-κB, is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines, including elevated NIK protein levels in specific lines (Yamamoto et al. Cancer Sci. 2010, 101, 2391-2397). In melanoma tumours, tissue microarray analysis of NIK expression revealed that there was a statistically significant elevation in NIK expression when compared with benign tissue. Moreover, shRNA techniques were used to knock-down NIK, the resultant NIK-depleted melanoma cell lines exhibited decreased proliferation, increased apoptosis, delayed cell cycle progression and reduced tumor growth in a mouse xenograft model (Thu et al. Oncogene 2012, 31(20), 2580-92). A wealth of evidence showed that NF-κB is often constitutively activated in non-small cell lung cancer tissue specimens and cell lines. Depletion of NIK by RNAi induced apoptosis and affected efficiency of anchorage-independent NSCLC cell growth.

In addition research has shown that NF-κB controls the expression of many genes involved in inflammation and that NF-κB signaling is found to be chronically active in many inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, sepsis and others. Thus pharmaceutical agents capable of inhibiting NIK and thereby reducing NF-κB signaling pathway can have a therapeutic benefit for the treatment of diseases and disorders for which over-activation of NF-κB signaling is observed.

Dysregulated NF-κB activity is associated with colonic inflammation and cancer, and it has been shown that Nlrp12 deficient mice were highly susceptible to colitis and colitis-associated colon cancer. In this context work showed that NLRP12 functions as a negative regulator of the NF-κB pathway through its interaction and regulation of NIK and TRAF3, and as a checkpoint of critical pathways associated with inflammation and inflammation-associated tumorigenesis (Allen et al. Immunity 2012, 36, 742-754).

Tumor necrosis factor (TNF)-α, is secreted in response to inflammatory stimuli in diseases such as rheumatoid arthritis and inflammatory bowel disease. In a series of experiments in colonic epithelial cells and mouse embryonic fibroblasts, TNF-α mediates both apoptosis and inflammation, stimulating an inflammatory cascade through the non-canonical pathway of NF-κB activation, leading to increased nuclear RelB and p52. TNF-α induced the ubiquitination of TRAFs, which interacts with NIK, leading to increased levels of phospho-NIK (Bhattacharyya et al. J Biol. Chem. 2011, 285, 39511-39522).

Inflammatory responses are a key component of chronic obstructive pulmonary disease (COPD) as such it has been shown that NIK plays a key role in exacerbating the disease following infection with the Gram-negative bacterium nontypeable Hemophilus influenza (Shuto et al. PNAS 2001, 98, 8774-8779). Likewise cigarette smoke (CS) contains numerous reactive oxygen/nitrogen species, reactive aldehydes, and quinones, which are considered to be some of the most important causes of the pathogenesis of chronic inflammatory lung diseases, such as COPD and lung cancer. Increased levels of NIK and p-IKKα have been observed in peripheral lungs of smokers and patients with COPD. In addition it has been shown that endogenous NIK is recruited to promoter sites of pro-inflammatory genes to induce post-translational modification of histones, thereby modifying gene expression profiles, in response to CS or TNFα (Chung et al. PLoS ONE 2011, 6(8): e23488. doi:10.1371/joumal.pone.0023488). A shRNA screen was used in an in vitro model of oxidative stress induced cell death (as a model of COPD) to interrogate a human drugable genome siRNA library in order to identify genes that modulate the cellular response to stress. NIK was one of the genes identified in this screen as a potential new therapeutic target to modulate epithelial apoptosis in chronic lung diseases (Wixted et al. Toxicol. In Vitro 2010, 24, 310-318).

Diabetic individuals can be troubled by a range of additional manifestations associated with inflammation. One such complication is cardiovascular disease and it has been shown that there are elevated levels of p-NIK, p-IKK-α/β and p-IκB-α in diabetic aortic tissues (Bitar et al. Life Sci. 2010, 86, 844-853). In a similar manner, NIK has been shown to regulate proinflammatory responses of renal proximal tubular epithelial cells via mechanisms involving TRAF3. This suggests a role for NF-κB noncanonical pathway activation in modulating diabetes-induced inflammation in renal tubular epithelium (Zhao et al. Exp. Diabetes Res. 2011, 1-9. doi: 10.1155/2011/192564). The same group has shown that NIK plays a critical role in noncanonical NF-κB pathway activation, induced skeletal muscle insulin resistance in vitro, suggesting that NIK could be an important therapeutic target for the treatment of insulin resistance associated with inflammation in obesity and type 2 diabetes (Choudhary et al. Endocrinology 2011, 152, 3622-3627).

NF-κB is an important component of both autoimmunity and bone destruction in rheumatoid arthritis (RA). Mice lacking functional NIK have no peripheral lymph nodes, defective B and T cells, and impaired receptor activator of NF-κB ligand-stimulated osteoclastogenesis. Aya et al. (J. Clin. Invest. 2005, 115, 1848-1854) investigated the role of NIK in murine models of inflammatory arthritis using Nik−/− mice. The serum transfer arthritis model was initiated by preformed antibodies and required only intact neutrophil and complement systems in recipients. While Nik−/− mice had inflammation equivalent to that of Nik+/+ controls, they showed significantly less periarticular osteoclastogenesis and less bone erosion. In contrast, Nik−/− mice were completely resistant to antigen-induced arthritis (AIA), which requires intact antigen presentation and lymphocyte function but not lymph nodes. Additionally, transfer of Nik+/+ splenocytes or T cells to Rag2−/− mice conferred susceptibility to AIA, while transfer of Nik−/− cells did not. Nik−/− mice were also resistant to a genetic, spontaneous form of arthritis, generated in mice expressing both the KRN T cell receptor and H-2 g7. The same group used transgenic mice with OC-lineage expression of NIK lacking its TRAF3 binding domain (NT3), to demonstrate that constitutive activation of NIK drives enhanced osteoclastogenesis and bone resorption, both in basal conditions and in response to inflammatory stimuli (Yang et al. PLoS ONE 2010, 5(11): e15383. doi:10.1371/joumal.pone.0015383). Thus this group concluded that NIK is important in the immune and bone-destructive components of inflammatory arthritis and represents a possible therapeutic target for these diseases.

It has also been hypothesized that manipulating levels of NIK in T cells may have therapeutic value. Decreasing NIK activity in T cells might significantly ameliorate autoimmune responses and alloresponses, like GVHD (Graft Versus Host Disease) and transplant rejection, without crippling the immune system as severely as do inhibitors of canonical NF-κB activation.

WO2003030909 describes the preparation of 2- and 4-aminopyrimidines N-substituted by a bicyclic ring for use as kinase inhibitors in the treatment of cancer.

WO2002079197 describes 4-aryl-substituted 2-pyrimidinamines and 2-pyridinamines, useful as inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases.

DESCRIPTION OF THE INVENTION

The present invention concerns novel compounds of Formula (I):

tautomers and stereoisomeric forms thereof, wherein

R¹ represents C₁₋₄alkyl;

R² represents C₁₋₆alkyl, C₁₋₆alkyl substituted with one R⁵, or C₁₋₆alkyl substituted with one, two or three fluoro atoms;

Y represents CR⁴ or N;

R⁴ represents hydrogen or halo;

R⁵ represents Het^(3a), —NR^(6a)R^(6b), or —OR⁷;

R^(6a) represents hydrogen or C₁₋₄alkyl;

R^(6b) represents hydrogen; C₁₋₄alkyl; C₃₋₆cycloalkyl; —C(═O)—C₁₋₄alkyl; —C(═O)—Het⁴; —S(═O)₂—C₁₋₄alkyl; —C(═O)—C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH and —NR^(16a)R^(6b); or C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH and —S(═O)₂—C₁₋₄alkyl;

R⁷ represents hydrogen, C₁₋₄alkyl, —C₁₋₄akyl-NR^(8a)R^(8b), —C(═O)—R⁹, —S(═O)₂—OH, —P(═O)₂—OH, —(C═O)—CH(NH₂)—C₁₋₄alkyl-Ar¹, or —C₁₋₄alkyl-Het^(3b);

R^(8a) represents hydrogen or C₁₋₄alkyl;

R^(8b) represents hydrogen, C₁₋₄alkyl, or C₃₋₆cycloalkyl;

R⁹ represents C₁₋₆alkyl, or C₁₋₆alkyl substituted with one substituent selected from the group consisting of —NH₂, —COOH, and Het⁶;

R^(16a) and R^(16b) each independently represents hydrogen, C₁₋₄alkyl or C₃₋₆cycloalkyl;

R³ represents a 5-membered heteroaromatic ring containing one, two or three heteroatoms each independently selected from O, S, and N;

wherein said 5-membered heteroaromatic ring may optionally be substituted, where possible, on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; C₃₋₆cycloalkyl; Het^(1a); R¹⁸; R²¹; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₅alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; —C₄alkyl-O—C₁₋₄alkyl substituted with one or two —OH substituents; C₁₋₄alkyl substituted with one R¹⁸; C₂₋₆alkenyl; and C₂₋₆alkenyl substituted with one R¹³; provided that when Het^(1a) or R¹⁸ are directly attached to the N-atom of the 5-membered heteroaromatic ring, said Het^(1a) or R¹⁸ are attached to the N-atom via a ring carbon atom; and

wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; cyano; C₁₋₆alkyl; —O—C₁₋₄alkyl; —C(═O)—R¹⁰; —S(═O)₂—C₁₋₄alkyl; —S(═O)(═N—R^(20a))—C₁₋₄alkyl; —O—C₁₋₄alkyl substituted with one, two or three halo atoms; —O—C₁₋₄alkyl-R¹²; C₃₋₆cycloalkyl; —O—C₃₋₆cycloalkyl; Het^(1a); —O-Het^(1b); R¹⁸; R²¹; —P(═O)—(C₁₋₄alkyl)₂; —NH—C(═O)—C₁₋₄alkyl; —NH—C(═O)—Het^(1g); —NR^(17a)R^(17b); C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; C₁₋₄alkyl substituted with one R¹⁸; C₂₋₆alkenyl; and C₂₋₆alkenyl substituted with one R¹³;

R¹⁰ represents —OH, —O—C₁₋₄alkyl, —NR^(11a)R^(11b) or Het²;

R¹⁸ represents a 5-membered aromatic ring containing one, two or three N-atoms; wherein said 5-membered aromatic ring may optionally be substituted with one substituent selected from the group consisting of C₁₋₄alkyl and C₃₋₆cycloalkyl;

R²¹ represents 3,6-dihydro-2H-pyran-4-yl or 1,2,3,6-tetrahydro-4-pyridinyl, wherein 1,2,3,6-tetrahydro-4-pyridinyl may optionally be substituted on the N-atom with C₁₋₄alkyl or C₃₋₆cycloalkyl;

Het^(1a), Het^(1c) and Het^(1d) each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N; or a 6- to 11-membered bicyclic saturated heterocyclyl, including fused, spiro and bridged cycles, containing one, two or three heteroatoms each independently selected from O, S, S(═O)_(p) and N;

wherein said 4- to 7-membered monocyclic saturated heterocyclyl or said 6- to 11-membered bicyclic saturated heterocyclyl may optionally be substituted, where possible, on one, two or three ring N-atoms with a substituent each independently selected from the group consisting of C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkyl substituted with one, two or three halo atoms, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH, —C(═O)—OH, —C(═O)—NR^(22a)R^(22b) and —O—C₁₋₄alkyl; and

wherein said 4- to 7-membered monocyclic saturated heterocyclyl or said 6- to 11-membered bicyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of —OH, oxo, halo, C₁₋₄alkyl, cyano, —C(═O)—C₁₋₄alkyl, —O—C₁₋₄alkyl, —NH₂, —NH(C₁₋₄alkyl), and —N(C₁₋₄alkyl)₂;

Het^(1b), Het^(1e), Het^(1g) and Het⁴ each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl, attached to the remainder of the molecule of Formula (I) through any available ring carbon atom, said Het^(1b), Het^(1e), Het^(1g) and Het⁴ containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N;

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted, where possible, on one or two ring N-atoms with a substituent each independently selected from the group consisting of C₁₋₄alkyl, C₃₋₆cycloalkyl, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH and —O—C₁₋₄alkyl; and

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of —OH, halo, C₁₋₄alkyl, cyano, —C(═O)—C₁₋₄alkyl, —O—C₁₋₄alkyl, —NH₂, —NH(C₁₋₄alkyl), and —N(C₁₋₄alkyl)₂;

Het² represents a heterocyclyl of formula (b-1):

(b-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional heteroatom selected from O, S, S(═O)_(p) and N, or a N-linked 6- to 11-membered bicyclic saturated heterocyclyl, including fused, spiro and bridged cycles, optionally containing one or two additional heteroatoms each independently selected from O, S, S(═O)_(p) and N;

wherein in case (b-1) contains one or two additional N-atoms, said one or two N-atoms may optionally be substituted with C₁₋₄alkyl; and

wherein (b-1) may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of halo, —OH, cyano, C₁₋₄alkyl, —O—C₁₋₄alkyl, —NH₂, —NH(C₁₋₄alkyl), —N(C₁₋₄alkyl)₂, and C₁₋₄alkyl-OH;

R^(11b) represents hydrogen; Het^(1e); C₁₋₄alkyl; C₁₋₄alkyl-Het; C₁₋₄alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and —O—C₁₋₄alkyl; C₃₋₆cycloalkyl; or C₃₋₆cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and —O—C₁₋₄alkyl;

R¹³ represents —O—C₁₋₄alkyl, —C(═O)OH, —C(═O)NR^(15a)R^(15b), —NR^(19a)R^(19b), C₃₋₆cycloalkyl, Het^(1d), Het⁷, —S(═O)₂—C₁₋₄alkyl, —S(═O)(═N—R^(20c))—C₁₋₄alkyl, or —C(═O)—Het^(1f);

R¹² represents —OH, —O—C₁₋₄alkyl, —NR^(14a)R^(14b), —C(═O)NR^(14c)R^(14d), —S(═O)₂—C₁₋₄alkyl, —S(═O)(═N—R^(20b))—C₁₋₄alkyl, C₃₋₆cycloalkyl, Ar², or Het^(1e);

Ar¹ represents phenyl optionally substituted with one hydroxy;

Ar² represents phenyl optionally substituted with one C₁₋₄alkyl;

Het^(3a), Het^(3b), Het⁵, Het⁶ and Het^(1f) each independently represents a heterocyclyl of formula (c-1):

(c-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional heteroatom selected from O, S, S(═O)_(p) and N; wherein in case (c-1) contains one additional N-atom, said additional N-atom may optionally be substituted with C₁₋₄alkyl or C₃₋₆cycloalkyl; and

wherein (c-1) may optionally be substituted on one or two ring C-atoms atoms with one or two substituents each independently selected from the group consisting of halo, C₁₋₄alkyl, and C₃₋₆cycloalkyl;

Het⁷ represents 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridinyl;

R^(11a), R^(14a), R^(14c), R^(15a), R^(17a), R^(19a) and R^(22a) each independently represents hydrogen, C₁₋₄alkyl, or C₃₋₆cycloalkyl;

R^(14b), R^(14d), R^(15b), R^(17b), R^(19b) and R^(22b) each independently represents hydrogen; C₁₋₄alkyl; C₃₋₆cycloalkyl; or C₁₋₄alkyl substituted with one substituent selected from the group consisting of halo, —OH and —O—C₁₋₄alkyl;

R^(20a), R^(20b) and R^(20c) each independently represents hydrogen; C₁₋₄alkyl; C₃₋₆cycloalkyl; or

C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH and —O—C₁₋₄alkyl;

p represents 1 or 2;

and the pharmaceutically acceptable addition salts, and the solvates thereof.

The present invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof, and a pharmaceutically acceptable carrier or excipient.

Additionally, the invention relates to a compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof, for use as a medicament, and to a compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof, for use in the treatment or in the prevention of cancer, inflammatory disorders, autoimmune disorders, and metabolic disorders such as diabetes and obesity.

In a particular embodiment, the invention relates to a compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof, for use in the treatment or in the prevention of a haematological malignancy or solid tumour.

In a specific embodiment said haematological malignancy is selected from the group consisting of multiple myeloma, Hodgkin lymphoma, T-cell leukaemia, mucosa-associated lymphoid tissue lymphoma, diffuse large B-cell lymphoma and mantle cell lymphoma. In another specific embodiment of the present invention, the solid tumour is selected from the group consisting of pancreatic cancer, breast cancer, melanoma and non-small cell lung cancer.

The invention also relates to the use of a compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof, in combination with an additional pharmaceutical agent for use in the treatment or prevention of cancer, inflammatory disorders, autoimmune disorders, and metabolic disorders such as diabetes and obesity. Furthermore, the invention relates to a process for preparing a pharmaceutical composition according to the invention, characterized in that a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof.

The invention also relates to a product comprising a compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof, and an additional pharmaceutical agent, as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of cancer, inflammatory disorders, autoimmune disorders, and metabolic disorders such as diabetes and obesity.

Additionally, the invention relates to a method of treating or preventing a cell proliferative disease in a warm-blooded animal which comprises administering to the said animal an effective amount of a compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof, as defined herein, or a pharmaceutical composition or combination as defined herein.

Some of the compounds of the present invention may undergo metabolism to a more active form in vivo (prodrugs).

DETAILED DESCRIPTION OF THE INVENTION

The term ‘halo’ or ‘halogen’ as used herein represents fluoro, chloro, bromo and iodo.

The prefix ‘C_(x-y)’ (where x and y are integers) as used herein refers to the number of carbon atoms in a given group. Thus, a C₁₋₆alkyl group contains from 1 to 6 carbon atoms, a C₃₋₆cycloalkyl group contains from 3 to 6 carbon atoms, and so on.

The term ‘C₁₋₄alkyl’ as used herein as a group or part of a group represents a straight or branched chain saturated hydrocarbon radical having from 1 to 4 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl and the like.

The term ‘C₁₋₆alkyl’ as used herein as a group or part of a group represents a straight or branched chain saturated hydrocarbon radical having from 1 to 6 carbon atoms such as the groups defined for C₁₋₄alkyl and n-pentyl, n-hexyl, 2-methylbutyl and the like.

The term “C₂₋₆alkenyl” as used herein as a group or part of a group represents a straight or branched chain hydrocarbon group containing from 2 to 6 carbon atoms and containing a carbon carbon double bond such as, but not limited to, ethenyl, propenyl, butenyl, pentenyl, 1-propen-2-yl, hexenyl and the like.

The term ‘C₃₋₆cycloalkyl’ as used herein as a group or part of a group represents cyclic saturated hydrocarbon radicals having from 3 to 6 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

In general, whenever the term “substituted” is used in the present invention, it is meant, unless otherwise is indicated or is clear from the context, to indicate that one or more hydrogens, in particular from 1 to 4 hydrogens, more in particular from 1 to 3 hydrogens, preferably 1 or 2 hydrogens, more preferably 1 hydrogen, on the atom or radical indicated in the expression using “substituted” are replaced with a selection from the indicated group, provided that the normal valency is not exceeded, and that the substitution results in a chemically stable compound, i.e. a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into a therapeutic agent.

Combinations of substituents and/or variables are permissible only if such combinations result in chemically stable compounds. “Stable compound” is meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into a therapeutic agent.

The skilled person will understand that the term “optionally substituted” means that the atom or radical indicated in the expression using “optionally substituted” may or may not be substituted (this means substituted or unsubstituted respectively).

When two or more substituents are present on a moiety they may, where possible and unless otherwise is indicated or is clear from the context, replace hydrogens on the same atom or they may replace hydrogen atoms on different atoms in the moiety.

It will be clear for the skilled person that, unless otherwise is indicated or is clear from the context, a substituent on a heterocyclyl group may replace any hydrogen atom on a ring carbon atom or on a ring heteroatom (e.g. a hydrogen on a nitrogen atom may be replaced by a substituent), for example in saturated heterocyclyl groups or 5-membered aromatic rings as used in the definition of R^(is).

C(O) or C(═O) represents a carbonyl moiety.

S(═O)₂ or SO₂ represents a sulfonyl moiety.

“oxo” means

for example piperidine substituted with oxo in position 2 is represented by the following structure:

The skilled person will understand that —S(═O)(═N—R^(20a))—C₁₋₄alkyl corresponds with

Within the context of this invention ‘saturated’ means ‘fully saturated’, if not otherwise specified.

Het^(1a), Het^(1c) and Het^(1d), may be attached to the remainder of the molecule of Formula (I) through any available ring carbon or nitrogen atom as appropriate, if not otherwise specified.

The 5-membered aromatic ring containing one, two or three N-atoms as referred to in the definition of R¹⁸, may be attached to the remainder of the molecule of Formula (I) through any available ring carbon or nitrogen atom as, if not otherwise specified.

It will be clear that in case a saturated cyclic moiety is substituted on two ring carbon atoms with one substituent, in total two carbon-linked substituents are present on the saturated cyclic moiety (one substituent on each carbon atom).

It will be clear that in case a saturated cyclic moiety is substituted on two ring carbon atoms with two substituents, in total four carbon-linked substituents are present on the saturated cyclic moiety (two substituents on each carbon atom).

It will be clear that in case a saturated cyclic moiety is substituted on three ring carbon atoms with two substituents, in total six carbon-linked substituents are present on the saturated cyclic moiety (two substituents on each carbon atom).

It will be clear that in case a saturated cyclic moiety is substituted on two ring N-atoms with a substituent, in total two N-linked substituents are present on the saturated cyclic moiety (a substituent on each N-atom).

It will be clear that a saturated cyclic moiety may, where possible, have substituents on both carbon and N-atoms, unless otherwise is indicated or is clear from the context.

Within the context of this invention, bicyclic saturated heterocyclyl groups include fused, spiro and bridged saturated heterocycles.

Fused bicyclic groups are two cycles that share two atoms and the bond between these atoms.

Spiro bicyclic groups are two cycles that are joined at a single atom.

Bridged bicyclic groups are two cycles that share more than two atoms.

Examples of N-linked 6- to 11-membered fused bicyclic saturated heterocyclyl groups, include, but are not limited to,

and the like.

Examples of N-linked 6- to 11-membered spiro bicyclic saturated heterocyclyl groups, include, but are not limited to

and the like.

Examples of N-linked 6- to 11-membered bridged bicyclic saturated heterocyclyl groups, include, but are not limited to

and the like.

The skilled person will realize that the definition of Het^(1a), Het^(1c) and Het^(1d) also includes C-linked bicycles (attached to the remainder of the molecule of Formula (I) through any available ring carbon atom).

It should be understood that the exemplified bicyclic saturated heterocyclyl groups referred to above may optionally be substituted, where possible, on carbon and/or nitrogen atoms according to any of the embodiments.

Non-limiting examples of 4- to 7-membered monocyclic saturated heterocyclyl moieties containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N (as in the definition of Het^(1a), Het^(1c), and Het^(1d)) are shown below:

and the like.

Each of which may optionally be substituted, where possible, on carbon and/or nitrogen atoms according to any of the embodiments.

Non-limiting examples of 4- to 7-membered monocyclic saturated heterocyclyl moieties, attached to the remainder of the molecule of Formula (I) through any available ring carbon atom (C-linked), and containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N (as in the definition of Het^(1b), Het^(1e), Het^(1g) and Het⁴) are shown below:

and the like.

Each of which may optionally be substituted, where possible, on carbon and/or nitrogen atoms according to any of the embodiments.

Non-limiting examples of N-linked 4- to 7-membered monocyclic saturated heterocyclyl moieties optionally containing one additional heteroatom selected from O, S, S(═O), and N (as in the definition of (b-1) and (c-1)) are shown below:

and the like.

Each of which may optionally be substituted, where possible, on carbon and/or nitrogen atoms according to any of the embodiments.

Non-limiting examples of 5-membered aromatic ring containing one, two or three N-atoms as referred to in the definition of R⁸ are shown below:

and the like.

Each of which may optionally be substituted, where possible, on carbon and/or nitrogen atoms according to any of the embodiments.

Non-limiting examples of 5-membered heteroaromatic ring containing one, two or three heteroatoms each independently selected from O, S, and N (as in the definition of R³) are shown below:

and the like.

Each of which may optionally be substituted, where possible, on carbon atoms and/or one nitrogen atom according to any of the embodiments.

The skilled person will understand that R³ is attached to the remainder of the molecule of Formula (I) (—NH— moiety) via a ring carbon atom.

Whenever substituents are represented by chemical structure, “ - - - ” represents the bond of attachment to the remainder of the molecule of Formula (I).

Lines (such as “ - - - ”) drawn into ring systems indicate that the bond may be attached to any of the suitable ring atoms.

When any variable occurs more than one time in any constituent, each definition is independent.

When any variable occurs more than one time in any formula (e.g. Formula (I)), each definition is independent.

The term “subject” as used herein, refers to an animal, preferably a mammal (e.g. cat, dog, primate or human), more preferably a human, who is or has been the object of treatment, observation or experiment.

The term “therapeutically effective amount” as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medicinal doctor or other clinician, which includes alleviation or reversal of the symptoms of the disease or disorder being treated.

The term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.

The term “treatment”, as used herein, is intended to refer to all processes wherein there may be a slowing, interrupting, arresting or stopping of the progression of a disease, but does not necessarily indicate a total elimination of all symptoms.

The term “compound(s) of the (present) invention” or “compound(s) according to the (present) invention” as used herein, is meant to include the compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof.

As used herein, any chemical formula with bonds shown only as solid lines and not as solid wedged or hashed wedged bonds, or otherwise indicated as having a particular configuration (e.g. R, S) around one or more atoms, contemplates each possible stereoisomer, or mixture of two or more stereoisomers.

Hereinbefore and hereinafter, the term “compound(s) of Formula (I)” is meant to include the tautomers thereof and the stereoisomeric forms thereof.

The terms “stereoisomers”, “stereoisomeric forms” or “stereochemically isomeric forms” hereinbefore or hereinafter are used interchangeably.

The invention includes all stereoisomers of the compounds of the invention either as a pure stereoisomer or as a mixture of two or more stereoisomers.

Enantiomers are stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a racemate or racemic mixture.

Atropisomers (or atropoisomers) are stereoisomers which have a particular spatial configuration, resulting from a restricted rotation about a single bond, due to large steric hindrance. All atropisomeric forms of the compounds of Formula (I) are intended to be included within the scope of the present invention.

Diastereomers (or diastereoisomers) are stereoisomers that are not enantiomers, i.e. they are not related as mirror images. If a compound contains a double bond, the substituents may be in the E or the Z configuration.

Substituents on bivalent cyclic saturated or partially saturated radicals may have either the cis- or trans-configuration; for example if a compound contains a disubstituted cycloalkyl group, the substituents may be in the cis or trans configuration.

Therefore, the invention includes enantiomers, atropisomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and mixtures thereof, whenever chemically possible.

The meaning of all those terms, i.e. enantiomers, atropisomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and mixtures thereof are known to the skilled person.

The absolute configuration is specified according to the Cahn-Ingold-Prelog system.

The configuration at an asymmetric atom is specified by either R or S. Resolved stereoisomers whose absolute configuration is not known can be designated by (+) or (−) depending on the direction in which they rotate plane polarized light. For instance, resolved enantiomers whose absolute configuration is not known can be designated by (+) or (−) depending on the direction in which they rotate plane polarized light.

When a specific stereoisomer is identified, this means that said stereoisomer is substantially free, i.e. associated with less than 50%, preferably less than 20%, more preferably less than 10%, even more preferably less than 5%, in particular less than 2% and most preferably less than 1%, of the other stereoisomers. Thus, when a compound of Formula (I) is for instance specified as (R), this means that the compound is substantially free of the (S) isomer; when a compound of Formula (I) is for instance specified as E, this means that the compound is substantially free of the Z isomer; when a compound of Formula (I) is for instance specified as cis, this means that the compound is substantially free of the trans isomer.

Some of the compounds according to Formula (I) may also exist in their tautomeric form. Such forms in so far as they may exist, although not explicitly indicated in the above Formula (I) are intended to be included within the scope of the present invention. It follows that a single compound may exist in both stereoisomeric and tautomeric form.

Pharmaceutically-acceptable addition salts include acid addition salts and base addition salts. Such salts may be formed by conventional means, for example by reaction of a free acid or a free base form with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. in vacuo, by freeze-drying or by filtration). Salts may also be prepared by exchanging a counter-ion of a compound of the invention in the form of a salt with another counter-ion, for example using a suitable ion exchange resin.

The pharmaceutically acceptable addition salts as mentioned hereinabove or hereinafter are meant to comprise the therapeutically active non-toxic acid and base addition salt forms which the compounds of Formula (I) and solvates thereof, are able to form.

Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids. Conversely said salt forms can be converted by treatment with an appropriate base into the free base form.

The compounds of Formula (I) and solvates thereof containing an acidic proton may also be converted into their non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases.

Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline; the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like. Conversely the salt form can be converted by treatment with acid into the free acid form.

The term solvate comprises the solvent addition forms as well as the salts thereof, which the compounds of Formula (I) are able to form. Examples of such solvent addition forms are e.g. hydrates, alcoholates and the like.

The compounds of the invention as prepared in the processes described below may be synthesized in the form of mixtures of enantiomers, in particular racemic mixtures of enantiomers, that can be separated from one another following art-known resolution procedures. A manner of separating the enantiomeric forms of the compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound would be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

The present invention also embraces isotopically-labeled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature (or the most abundant one found in nature).

All isotopes and isotopic mixtures of any particular atom or element as specified herein are contemplated within the scope of the compounds of the invention, either naturally occurring or synthetically produced, either with natural abundance or in an isotopically enriched form. Exemplary isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine and iodine, such as ²H, ³H, ¹¹C, ¹³C, ¹⁴C, ¹³N, ¹⁵O, ¹⁷O, ¹⁸O, ³²P, ³³P, ³⁵S, ¹⁸F, ³⁶Cl, ¹²²I, ¹²³I, ¹²⁵I, ¹³¹I, ⁷⁵Br, ⁷⁶Br, ⁷⁷Br and ⁸²Br. Preferably, the radioactive isotope is selected from the group of ²H, ³H, ¹¹C and ¹⁸F. More preferably, the radioactive isotope is ²H. In particular, deuterated compounds are intended to be included within the scope of the present invention.

Certain isotopically-labeled compounds of the present invention (e.g., those labeled with ³H and ¹⁴C) are useful in compound and for substrate tissue distribution assays.

Tritiated (³H) and carbon-14 (¹⁴C) isotopes are useful for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., ²H may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Positron emitting isotopes such as ¹⁵O, ¹³N, C and ¹⁸F are useful for positron emission tomography (PET) studies to examine substrate receptor occupancy.

The present invention relates in particular to compounds of Formula (I) as defined herein, tautomers and stereoisomeric forms thereof, wherein

R¹ represents C₁₋₄alkyl;

R² represents C₁₋₆alkyl, or C₁₋₆alkyl substituted with one R⁵; Y represents CR⁴;

R⁴ represents hydrogen or halo;

R⁵ represents Het^(3a), —NR^(6a)R^(6b), or —OR⁷;

R^(6a) represents hydrogen or C₁₋₄alkyl;

R^(6b) represents hydrogen; C₁₋₄alkyl; C₃₋₆cycloalkyl; —C(═O)—C₁₋₄alkyl; —C(═O)—Het⁴;

—S(═O)₂—C₁₋₄alkyl; —C(═O)—C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH and —NR^(6a)R^(16b); or C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH and —S(═O)₂—C₁₋₄alkyl;

R⁷ represents hydrogen, C₁₋₄alkyl, —C₁₋₄alkyl-NR^(8a)R^(8b), —C(═O)—R⁹, —S(═O)₂—OH, —P(═O)₂—OH, —(C═O)—CH(NH₂)—C₁₋₄alkyl-Ar¹, or —C₄alkyl-Het^(3b);

R^(8a) represents hydrogen or C₁₋₄alkyl;

R^(8b) represents hydrogen, C₁₋₄alkyl, or C₃₋₆cycloalkyl;

R⁹ represents C₁₋₆alkyl, or C₁₋₆alkyl substituted with one substituent selected from the group consisting of —NH₂, —COOH, and Het⁶;

R^(16a) and R^(16b) each independently represents hydrogen, C₁₋₄alkyl or C₃₋₆cycloalkyl;

R³ represents a 5-membered heteroaromatic ring containing one, two or three heteroatoms each independently selected from O, S, and N;

wherein said 5-membered heteroaromatic ring may optionally be substituted, where possible, on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; C₃₋₆cycloalkyl; Het^(1a); R¹⁸; R²¹; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; C₁₋₄alkyl substituted with one R¹⁸; C₂₋₆alkenyl; and C₂₋₆alkenyl substituted with one R¹³; provided that when Het^(1a) or R¹⁸ are directly attached to the N-atom of the 5-membered heteroaromatic ring, said Het^(1a) or R¹⁸ are attached to the N-atom via a ring carbon atom; and

wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; cyano; C₁₋₆alkyl; —O—C₁₋₄alkyl; —C(═O)—R¹⁰; —S(═O)₂—C₁₋₄alkyl; —S(═O)(═N—R^(20a))—C₁₋₄alkyl; —O—C₁₋₄alkyl substituted with one, two or three halo atoms; —O—C₁₋₄alkyl-R¹²; C₃₋₆cycloalkyl; —O—C₃₋₆cycloalkyl; Het^(1a); —O-Het^(1b); R¹⁸; R²¹; —P(═O)—(C₁₋₄alkyl)₂; —NH—C(═O)—C₁₋₄alkyl; —NH—C(═O)—Het^(1g); —NR^(17a)R^(17b); C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; C₁₋₄allyl substituted with one R¹⁸; C₂₋₆alkenyl; and C₂₋₆alkenyl substituted with one R¹³;

R¹⁰ represents —OH, —O—C₁₋₄alkyl, —NR^(11a)R^(11b) or Het²;

R¹⁸ represents a 5-membered aromatic ring containing one, two or three N-atoms; wherein said 5-membered aromatic ring may optionally be substituted with one substituent selected from the group consisting of C₁₋₄alkyl and C₃₋₆cycloalkyl;

R²¹ represents 3,6-dihydro-2H-pyran-4-yl or 1,2,3,6-tetrahydro-4-pyridinyl, wherein 1,2,3,6-tetrahydro-4-pyridinyl may optionally be substituted on the N-atom with C₁₋₄alkyl or C₃₋₆cycloalkyl;

Het^(1a), Het^(1c) and Het^(1d) each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N; or a 6- to 11-membered bicyclic saturated heterocyclyl, including fused, spiro and bridged cycles, containing one, two or three heteroatoms each independently selected from O, S, S(═O)_(p) and N;

wherein said 4- to 7-membered monocyclic saturated heterocyclyl or said 6- to 11-membered bicyclic saturated heterocyclyl may optionally be substituted, where possible, on one, two or three ring N-atoms with a substituent each independently selected from the group consisting of C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkyl substituted with one, two or three halo atoms, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH, —C(═O)—OH, —C(═O)—NR^(22a)R^(22b) and —O—C₁₋₄alkyl; and

wherein said 4- to 7-membered monocyclic saturated heterocyclyl or said 6- to 11-membered bicyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of —OH, oxo, halo, C₁₋₄alkyl, cyano, —C(═O)—C₁₋₄alkyl, —O—C₁₋₄alkyl, —NH₂, —NH(C₁₋₄alkyl), and —N(C₁₋₄alkyl)₂;

Het^(1b), Het^(1c), Het^(1g) and Het⁴ each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl, attached to the remainder of the molecule of Formula (I) through any available ring carbon atom, said Het^(1b), Het^(1e), Het^(1g) and Het⁴ containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N;

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted, where possible, on one or two ring N-atoms with a substituent each independently selected from the group consisting of C₁₋₄alkyl, C₃₋₆cycloalkyl, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH and —O—C₁₋₄alkyl; and

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of —OH, halo, C₁₋₄alkyl, cyano, —C(═O)—C₁₋₄alkyl, —O—C₁₋₄alkyl, —NH₂, —NH(C₁₋₄alkyl), and —N(C₁₋₄alkyl)₂;

Het² represents a heterocyclyl of formula (b-1):

(b-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional heteroatom selected from O, S, S(═O)_(p) and N, or a N-linked 6- to 11-membered bicyclic saturated heterocyclyl, including fused, spiro and bridged cycles, optionally containing one or two additional heteroatoms each independently selected from O, S, S(═O)_(p) and N;

wherein in case (b-1) contains one or two additional N-atoms, said one or two N-atoms may optionally be substituted with C₁₋₄alkyl; and

wherein (b-1) may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of halo, —OH, cyano, C₁₋₄alkyl, —O—C₁₋₄alkyl, —NH₂, —NH(C₁₋₄alkyl), —N(C₁₋₄alkyl)₂, and C₁₋₄alkyl-OH;

R^(11b) represents hydrogen; Het^(1e); C₁₋₄alkyl; C₁₋₄alkyl-Het⁵; C₁₋₄alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and —O—C₁₋₄alkyl; C₃₋₆cycloalkyl; or C₃₋₆cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and —O—C₁₋₄alkyl;

R¹³ represents —O—C₁₋₄alkyl, —C(═O)OH, —C(═O)NR^(1a)R^(5b), —NR^(19a)R^(19b), C₃₋₆cycloalkyl, Het^(1d), —S(═O)₂—C₁₋₄alkyl, —S(═O)(═N—R^(20c))—C₁₋₄alkyl, or —C(═O)—Het^(f);

R¹² represents —OH, —O—C₁₋₄alkyl, —NR^(14a)R^(14b), —C(═O)NR^(14c)R^(14d), —S(═O)₂—C₄alkyl, —S(═O)(═N—R^(20b))—C₁₋₄alkyl, C₃₋₆cycloalkyl, Ar², or Het^(1e);

Ar¹ represents phenyl optionally substituted with one hydroxy;

Ar² represents phenyl optionally substituted with one C₁₋₄alkyl;

Het^(3a), Het^(3b), Het⁵, Het⁶ and Het^(1f) each independently represents a heterocyclyl of formula (c-1):

(c-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional heteroatom selected from O, S, S(═O)_(p) and N; wherein in case (c-1) contains one additional N-atom, said additional N-atom may optionally be substituted with C₁₋₄alkyl or C₃₋₆cycloalkyl; and

wherein (c-1) may optionally be substituted on one or two ring C-atoms atoms with one or two substituents each independently selected from the group consisting of halo, C₁₋₄alkyl, and C₃₋₆cycloalkyl;

R^(11a), R^(14a), R^(14c), R^(15a), R^(17a), R^(19a) and R^(22a) each independently represents hydrogen, C₁₋₄alkyl, or C₃₋₆cycloalkyl;

R^(14b), R^(14d), R^(15b), R^(17b), R^(19b) and R^(22b) each independently represents hydrogen; C₁₋₄alkyl; C₃₋₆cycloalkyl; or C₁₋₄alkyl substituted with one substituent selected from the group consisting of halo, —OH and —O—C₁₋₄alkyl;

R^(20a), R^(20b) and R^(20c) each independently represents hydrogen; C₁₋₄alkyl; C₃₋₆cycloalkyl; or C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH and —O—C₁₋₄alkyl;

p represents 1 or 2;

and the pharmaceutically acceptable addition salts, and the solvates thereof.

The present invention relates in particular to compounds of Formula (I) as defined herein, tautomers and stereoisomeric forms thereof, wherein

R¹ represents C₁₋₄alkyl;

R² represents C₁₋₆alkyl substituted with one R⁵;

Y represents CR⁴ or N;

R⁴ represents hydrogen or halo;

R⁵ represents Het^(3a), —NR^(6a)R^(6b), or —OR⁷;

R^(6a) represents hydrogen or C₁₋₄alkyl;

R^(6b) represents hydrogen; or C₁₋₄alkyl substituted with one —OH substituent;

R⁷ represents hydrogen or —C(═O)—R⁹;

R⁹ represents C₁₋₆alkyl;

R³ represents a 5-membered heteroaromatic ring containing one, two or three heteroatoms each independently selected from O, S, and N;

wherein said 5-membered heteroaromatic ring may optionally be substituted, where possible, on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; C₃₋₆cycloalkyl; Het^(1a); C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₅alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; —C₁₋₄alkyl-O—C₁₋₄alkyl substituted with one or two —OH substituents; C₁₋₄alkyl substituted with one R¹⁸; and C₂₋₆alkenyl; provided that when Het^(1a) is directly attached to the N-atom of the 5-membered heteroaromatic ring, said Het^(1a) is attached to the N-atom via a ring carbon atom; and

wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; cyano; C₁₋₆alkyl; —O—C₁₋₄alkyl; —C(═O)—R¹⁰; —O—C₁₋₄alkyl-R¹²; C₃₋₆cycloalkyl; —O—C₃₋₆cycloalkyl; Het^(1a); —O-Het^(1b); —P(═O)—(C₁₋₄alkyl)₂; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; and C₁₋₆alkyl substituted with one R¹³;

R¹⁰ represents —NR^(11a)R^(11b) or Het²;

R¹⁸ represents a 5-membered aromatic ring containing one, two or three N-atoms; wherein said 5-membered aromatic ring may optionally be substituted with one substituent selected from the group consisting of C₁₋₄alkyl and C₃₋₆cycloalkyl;

Het^(1a), Het^(1c) and Het^(1d) each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N; or a 6- to 11-membered bicyclic saturated heterocyclyl, including fused cycles, containing one, two or three heteroatoms each independently selected from O and N;

wherein said 4- to 7-membered monocyclic saturated heterocyclyl or said 6- to 11-membered bicyclic saturated heterocyclyl may optionally be substituted, where possible, on one, two or three ring N-atoms with a substituent each independently selected from the group consisting of C₁₋₄alkyl, C₁₋₄alkyl substituted with one, two or three halo atoms, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —C(═O)—OH, —C(═O)—NR^(22a)R^(22b) and —O—C₁₋₄alkyl; and

wherein said 4- to 7-membered monocyclic saturated heterocyclyl or said 6- to 11-membered bicyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of oxo, halo and C₁₋₄alkyl;

Het^(1b) and Het^(1e) each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl, attached to the remainder of the molecule of Formula (I) through any available ring carbon atom, said Het^(b) and Het^(1e) containing one or two O-atoms;

Het² represents a heterocyclyl of formula (b-1):

(b-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional N-atom;

wherein in case (b-1) contains one additional N-atom, said N-atom may optionally be substituted with C₁₋₄alkyl;

R^(11b) represents Het^(1e); C₁₋₄alkyl; or C₃₋₆cycloalkyl;

R¹³ represents —O—C₁₋₄alkyl, —C(═O)OH, —C(═O)NR^(1a)R^(15b), —NR^(19a)R^(19b), C₃₋₆cycloalkyl, Het^(1d), Het⁷, —S(═O)₂—C₁₋₄alkyl, or —C(═O)—Het^(1f);

R¹² represents —O—C₁₋₄alkyl or Het^(1c);

Het^(3a) and Het^(1f) each independently represents a heterocyclyl of formula (c-1):

(c-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional N-atom;

wherein in case (c-1) contains one additional N-atom, said additional N-atom may optionally be substituted with C₃₋₆cycloalkyl; and

wherein (c-1) may optionally be substituted on one or two ring C-atoms atoms with one or two halo substituents;

Het⁷ represents 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridinyl;

R^(11a), R^(15a), R^(19a) and R^(22a) each independently represents hydrogen,

C₁₋₄alkyl, or C₃₋₆cycloalkyl;

R^(15b), R^(19b) and R^(22b) each independently represents C₁₋₄alkyl or C₃₋₆cycloalkyl;

p represents 2;

and the pharmaceutically acceptable addition salts, and the solvates thereof.

The present invention relates in particular to compounds of Formula (I) as defined herein, tautomers and stereoisomeric forms thereof, wherein

R¹ represents C₁₋₄alkyl;

R² represents C₁₋₆alkyl, or C₁₋₆alkyl substituted with one R⁵;

Y represents CR⁴;

R⁴ represents hydrogen or halo;

-   -   R⁵ represents Het^(3a), —NR^(6a)R^(6b), or —OR⁷;

R^(6a) represents hydrogen or C₁₋₄alkyl;

R^(6b) represents hydrogen; C₁₋₄alkyl; C₃₋₆cycloalkyl; —C(═O)—C₁₋₄alkyl; —C(═O)—C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH and —NR^(16a)R^(16b); or C₁₋₄alkyl substituted with one —OH substituent;

R⁷ represents hydrogen, C₁₋₄alkyl, —C₁₋₄alkyl-NR^(8a)R^(b), or —C(═O)—R⁹;

R^(8a) represents hydrogen or C₁₋₄alkyl;

R^(8b) represents hydrogen, C₁₋₄alkyl, or C₃₋₆cycloalkyl;

R⁹ represents C₁₋₆alkyl, or C₁₋₆alkyl substituted with one substituent selected from the group consisting of —NH₂, and —COOH;

R^(16a) and R^(16b) each independently represents hydrogen, C₁₋₄alkyl or C₃₋₆cycloalkyl;

R³ represents a 5-membered heteroaromatic ring containing one, two or three heteroatoms each independently selected from O, S, and N;

wherein said 5-membered heteroaromatic ring may optionally be substituted, where possible, on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; C₃₋₆cycloalkyl; Het^(1a); R¹⁸; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; C₁₋₄alkyl substituted with one R¹⁸; C₂₋₆alkenyl; and C₂₋₆alkenyl substituted with one R¹³; provided that when Het^(1a) or R¹⁸ are directly attached to the N-atom of the 5-membered heteroaromatic ring, said Het^(1a) or R¹⁸ are attached to the N-atom via a ring carbon atom; and

wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; cyano; C₁₋₆alkyl; —O—C₁₋₄alkyl; —C(═O)—R¹⁰; —O—C₁₋₄alkyl substituted with one, two or three halo atoms; —O—C₁₋₄alkyl-R¹²; C₃₋₆cycloalkyl; —O—C₃₋₆cycloalkyl; Het a; —O-Het^(1b); R¹⁸; —P(═O)—(C₁₋₄alkyl)₂; —NH—C(═O)—C₁₋₄alkyl; —NH—C(═O)—Het^(1g); —NR^(17a)R^(17b); C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; C₁₋₄alkyl substituted with one R¹⁸; C₂₋₆alkenyl; and C₂₋₆alkenyl substituted with one R¹³;

R¹⁰ represents —OH, —O—C₁₋₄alkyl, —NR^(11a)R^(11b) or Het²;

R¹⁸ represents a 5-membered aromatic ring containing one, two or three N-atoms; wherein said 5-membered aromatic ring may optionally be substituted with one substituent selected from the group consisting of C₁₋₄alkyl and C₃₋₆cycloalkyl;

Het^(1a), and Het^(1d) each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N;

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted, where possible, on one, two or three ring N-atoms with a substituent each independently selected from the group consisting of C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkyl substituted with one, two or three halo atoms, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH, —C(═O)—OH, —C(═O)—NR^(22a)R^(22b) and —O—C₁₋₄alkyl; and

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of —OH, oxo, halo, C₁₋₄alkyl, cyano, —C(═O)—C₁₋₄alkyl, —O—C₁₋₄alkyl, —NH₂, —NH(C₁₋₄alkyl), and —N(C₁₋₄alkyl)₂;

Het^(1b), Het^(1e), and Het^(1g) each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl, attached to the remainder of the molecule of Formula (I) through any available ring carbon atom, said Het^(1b), Het^(1e), and Het^(1g) containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N;

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted, where possible, on one or two ring N-atoms with a substituent each independently selected from the group consisting of C₁₋₄alkyl, C₃₋₆cycloalkyl, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH and —O—C₁₋₄alkyl; and

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of —OH, halo, C₁₋₄alkyl, cyano, —C(═O)—C₁₋₄alkyl, —O—C₁₋₄alkyl, —NH₂, —NH(C₁₋₄alkyl), and —N(C₁₋₄alkyl)₂;

Het² represents a heterocyclyl of formula (b-1):

(b-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional heteroatom selected from O, S, S(═O)_(p) and N; wherein in case (b-1) contains one additional N-atom, said N-atom may optionally be substituted with C₁₋₄alkyl; and

wherein (b-1) may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of halo, —OH, cyano, C₁₋₄alkyl, —O—C₁₋₄alkyl, —NH₂, —NH(C₁₋₄alkyl), —N(C₁₋₄alkyl)₂, and C₁₋₄alkyl-OH;

R^(11b) represents hydrogen; Het^(1e); C₁₋₄alkyl; C₁₋₄alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and —O—C₁₋₄alkyl; C₃₋₆cycloalkyl; or C₃₋₆cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and —O—C₁₋₄alkyl;

R¹³ represents —O—C₁₋₄alkyl, —C(═O)OH, —C(═O)NR^(1a)R^(15b), —NR^(19a)R^(19b), C₃₋₆cycloalkyl, Het^(1d), —S(═O)₂—C₁₋₄alkyl, or —C(═O)—Het^(f);

R¹² represents —OH, —O—C₁₋₄alkyl, —NR^(14a)R^(14b), —C(═O)NR^(14c)R^(14d), —S(═O)₂—C₁₋₄alkyl, C₃₋₆cycloalkyl;

Het^(3a), and Het^(1f) each independently represents a heterocyclyl of formula (c-1):

(c-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional heteroatom selected from O, S, S(═O)_(p) and N; wherein in case (c-1) contains one additional N-atom, said additional N-atom may optionally be substituted with C₁₋₄alkyl or C₃₋₆cycloalkyl; and

wherein (c-1) may optionally be substituted on one or two ring C-atoms atoms with one or two substituents each independently selected from the group consisting of halo, C₁₋₄alkyl, and C₃₋₆cycloalkyl;

R^(11a), R^(14a), R^(14c), R^(15a), R^(17a), R^(19a) and R^(22a) each independently represents hydrogen, C₁₋₄alkyl, or C₃₋₆cycloalkyl;

R^(14b), R^(14d), R^(15b), R^(17b), R^(19b) and R^(22b) each independently represents hydrogen; C₁₋₄alkyl; C₃₋₆cycloalkyl; or C₁₋₄alkyl substituted with one substituent selected from the group consisting of halo, —OH and —O—C₁₋₄alkyl;

p represents 1 or 2;

and the pharmaceutically acceptable addition salts, and the solvates thereof.

The present invention relates in particular to compounds of Formula (I) as defined herein, tautomers and stereoisomeric forms thereof, wherein

R¹ represents C₁₋₄alkyl;

R² represents C₁₋₆alkyl substituted with one R⁵;

Y represents CR⁴;

R⁴ represents hydrogen or halo;

R⁵ represents Het^(3a), —NR^(6a)R^(6b), or —OR⁷;

R^(6a) represents C₁₋₄alkyl;

R^(6b) represents C₁₋₄alkyl substituted with one —OH substituent;

R⁷ represents hydrogen, or —C(═O)—R⁹;

R⁹ represents C₁₋₆alkyl;

R³ represents a 5-membered heteroaromatic ring containing two or three heteroatoms each independently selected from O, S, and N;

wherein said 5-membered heteroaromatic ring may optionally be substituted, where possible, on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; Het^(1a); C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; C₁₋₄alkyl substituted with one R¹⁸; and C₂₋₆alkenyl; provided that when Het^(1a) is directly attached to the N-atom of the 5-membered heteroaromatic ring, said Het¹a is attached to the N-atom via a ring carbon atom; and

wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; cyano; C₁₋₆alkyl; —O—C₁₋₄alkyl; —C(═O)—R¹⁰; C₃₋₆cycloalkyl; Het^(1a); —P(═O)—(C₁₋₄alkyl)₂; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; and C₁₋₆alkyl substituted with one R¹³;

R¹⁰ represents —NR^(11a)R^(11b) or Het²;

R¹⁸ represents a 5-membered aromatic ring containing one, two or three N-atoms; wherein said 5-membered aromatic ring may optionally be substituted with one C₁₋₄alkyl;

Het^(1a), and Het^(1d) each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N;

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted, where possible, on one ring N-atom with a substituent each independently selected from the group consisting of C₁₋₄alkyl, C₁₋₄alkyl substituted with one, two or three halo atoms, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —C(═O)—NR^(22a)R^(22b) and —O—C₁₋₄alkyl; and

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of oxo, halo, and C₁₋₄alkyl;

Het^(1e) represents a 4- to 7-membered monocyclic saturated heterocyclyl, attached to the remainder of the molecule of Formula (I) through any available ring carbon atom, said Het^(1e) containing one or two O-atoms;

Het² represents 1-piperidinyl;

R^(11b) represents Het^(1e); C₁₋₄alkyl; C₃₋₆cycloalkyl;

R¹³ represents —O—C₁₋₄alkyl, —C(═O)OH, —C(═O)NR^(5a)R^(15b), —NR^(19a)R^(19b), C₃₋₆cycloalkyl, Het^(1d), —S(═O)₂—C₁₋₄alkyl, or —C(═O)—Het^(1f);

Het^(3a), and Het^(1f) each independently represents a heterocyclyl of formula (c-1):

(c-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional N-atom;

wherein in case (c-1) contains one additional N-atom, said additional N-atom may optionally be substituted with C₃₋₆cycloalkyl; and

wherein (c-1) may optionally be substituted on one or two ring C-atoms atoms with one or two halo substituents;

R^(11a), R^(15a), R^(19a) and R^(22a) each independently represents hydrogen, C₁₋₄alkyl, or C₃₋₆cycloalkyl;

R^(15b), R^(19b) and R^(22b) each independently represents C₁₋₄alkyl; or C₃₋₆cycloalkyl; p represents 2;

and the pharmaceutically acceptable addition salts, and the solvates thereof.

The present invention relates in particular to compounds of Formula (I) as defined herein, tautomers and stereoisomeric forms thereof, wherein

R¹ represents C₁₋₄alkyl;

R² represents C₁₋₆alkyl substituted with one R⁵;

Y represents CR⁴;

R⁴ represents hydrogen or halo;

R⁵ represents Het^(3a), —NR^(6a)R^(6b), or —OR⁷;

R^(6a) represents C₁₋₄alkyl;

R^(6b) represents C₁₋₄alkyl substituted with one —OH substituent;

R⁷ represents hydrogen, or —C(═O)—R⁹;

R⁹ represents C₁₋₆alkyl;

R³ represents a 5-membered heteroaromatic ring containing two or three heteroatoms each independently selected from O, S, and N;

wherein said 5-membered heteroaromatic ring may optionally be substituted, where possible, on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; Het^(1a); C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₅alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; C₁₋₄alkyl substituted with one R¹⁸; and C₂₋₆alkenyl; provided that when Het^(1a) is directly attached to the N-atom of the 5-membered heteroaromatic ring, said Het^(1a) is attached to the N-atom via a ring carbon atom; and

wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; cyano; C₁₋₆alkyl; —O—C₁₋₄alkyl; —C(═O)—R¹⁰; C₃₋₆cycloalkyl; Het^(1a); —P(═O)—(C₁₋₄alkyl)₂; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; and C₁₋₆alkyl substituted with one R¹³;

R¹⁰ represents —NR^(11a)R^(11b) or Het²;

R¹⁸ represents a 5-membered aromatic ring containing one, two or three N-atoms; wherein said 5-membered aromatic ring may optionally be substituted with one C₁₋₄alkyl;

Het^(1a), and Het^(1d) each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N;

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted, where possible, on one ring N-atom with a substituent each independently selected from the group consisting of C₁₋₄alkyl, C₁₋₄alkyl substituted with one, two or three halo atoms, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —C(═O)—NR^(22a)R^(22b) and —O—C₁₋₄alkyl; and

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of oxo, halo, and C₁₋₄alkyl;

Het^(1e) represents a 4- to 7-membered monocyclic saturated heterocyclyl, attached to the remainder of the molecule of Formula (I) through any available ring carbon atom, said Het^(1e) containing one or two O-atoms;

Het² represents 1-piperidinyl;

Het⁷ represents 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridinyl;

R^(11b) represents Het^(1e); C₁₋₄alkyl; C₃₋₆cycloalkyl;

R¹³ represents —O—C₁₋₄alkyl, —C(═O)OH, —C(═O)NR^(15a)R^(15b), —NR^(19a)R^(19b), C₃₋₆cycloalkyl, Het^(1d), Het⁷, —S(═O)₂—C₁₋₄alkyl, or —C(═O)—Het^(1f);

Het^(3a), and Het^(1f) each independently represents a heterocyclyl of formula (c-1):

(c-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional N-atom;

wherein in case (c-1) contains one additional N-atom, said additional N-atom may optionally be substituted with C₃₋₆cycloalkyl; and

wherein (c-1) may optionally be substituted on one or two ring C-atoms atoms with one or two halo substituents;

R^(11a), R^(15a), R^(19a) and R^(22a) each independently represents hydrogen, C₁₋₄alkyl, or C₃₋₆cycloalkyl;

R^(15b), R^(19b) and R^(22b) each independently represents C₁₋₄alkyl; or C₃₋₆cycloalkyl; p represents 2;

and the pharmaceutically acceptable addition salts, and the solvates thereof.

The present invention relates in particular to compounds of Formula (I) as defined herein, tautomers and stereoisomeric forms thereof, wherein

R¹ represents C₁₋₄alkyl;

R² represents C₁₋₆alkyl substituted with one, two or three fluoro atoms;

Y represents CR⁴;

R⁴ represents hydrogen or halo;

R³ represents a 5-membered heteroaromatic ring containing two or three heteroatoms each independently selected from O, S, and N;

wherein said 5-membered heteroaromatic ring may optionally be substituted, where possible, on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; Het^(1a); C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₅alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; C₁₋₄alkyl substituted with one R¹⁸; and C₂₋₆alkenyl; provided that when Het^(1a) is directly attached to the N-atom of the 5-membered heteroaromatic ring, said Het^(1a) is attached to the N-atom via a ring carbon atom; and

wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; cyano; C₁₋₆alkyl; —O—C₁₋₄alkyl; —C(═O)—R¹⁰; C₃₋₆cycloalkyl; Het^(1a); —P(═O)—(C₁₋₄alkyl)₂; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; and C₁₋₆alkyl substituted with one R¹³;

R¹⁰ represents —NR^(11a)R^(11b) or Het²;

R¹⁸ represents a 5-membered aromatic ring containing one, two or three N-atoms; wherein said 5-membered aromatic ring may optionally be substituted with one C₁₋₄alkyl;

Het^(1a), and Het^(1d) each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N;

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted, where possible, on one ring N-atom with a substituent each independently selected from the group consisting of C₁₋₄alkyl, C₁₋₄alkyl substituted with one, two or three halo atoms, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —C(═O)—NR^(22a)R^(2b) and —O—C₁₋₄alkyl; and

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of oxo, halo, and C₁₋₄alkyl;

Het^(1e) represents a 4- to 7-membered monocyclic saturated heterocyclyl, attached to the remainder of the molecule of Formula (I) through any available ring carbon atom, said Het^(1e) containing one or two O-atoms;

Het² represents 1-piperidinyl;

Het⁷ represents 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridinyl;

R^(11b) represents Het^(1e); C₁₋₄alkyl; C₃₋₆cycloalkyl;

R¹³ represents —O—C₁₋₄alkyl, —C(═O)OH, —C(═O)NR^(15a)R^(15b), —NR^(19a)R^(19b), C₃₋₆cycloalkyl, Het^(1d), Het⁷, —S(═O)₂—C₁₋₄alkyl, or —C(═O)—Het^(f);

Het^(3a), and Het^(1f) each independently represents a heterocyclyl of formula (c-1):

(c-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional N-atom;

wherein in case (c-1) contains one additional N-atom, said additional N-atom may optionally be substituted with C₃₋₆cycloalkyl; and

wherein (c-1) may optionally be substituted on one or two ring C-atoms atoms with one or two halo substituents;

R^(11a), R^(15a), R^(19a) and R^(22a) each independently represents hydrogen, C₁₋₄alkyl, or C₃₋₆cycloalkyl;

R^(15b), R^(19b) and R^(22b) each independently represents C₁₋₄alkyl; or C₃₋₆cycloalkyl; p represents 2;

and the pharmaceutically acceptable addition salts, and the solvates thereof.

The present invention relates in particular to compounds of Formula (I) as defined herein, tautomers and stereoisomeric forms thereof, wherein

R¹ represents C₁₋₄alkyl;

R² represents C₁₋₆alkyl substituted with one R⁵;

Y represents CR⁴;

R⁴ represents hydrogen;

R⁵ represents —OR⁷;

R⁷ represents hydrogen, or —C(═O)—R⁹;

R⁹ represents C₁₋₆alkyl;

R³ represents a 5-membered heteroaromatic ring containing two or three heteroatoms each independently selected from S, and N;

wherein said 5-membered heteroaromatic ring may optionally be substituted, where possible, on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₆alkyl substituted with one R¹³; and C₁₋₄alkyl substituted with one R¹⁸; and

wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; C₁₋₆alkyl; —C(═O)—R¹⁰; and C₁₋₄alkyl substituted with one, two or three —OH substituents;

R¹⁰ represents —NR^(11a)R^(11b);

R¹⁸ represents a 5-membered aromatic ring containing two N-atoms; wherein said 5-membered aromatic ring may optionally be substituted with one C₁₋₄alkyl;

Het^(1d) represents a 4- to 7-membered monocyclic saturated heterocyclyl containing one or O-atom;

R^(11b) represents C₁₋₄alkyl or C₃₋₆cycloalkyl;

R¹³ represents —O—C₁₋₄alkyl, —C(═O)NR^(15a)R^(15b), or Het^(1d);

R^(11a) and R^(15a) each independently represents hydrogen or C₁₋₄alkyl;

R^(15b) represents C₃₋₆cycloalkyl;

and the pharmaceutically acceptable addition salts, and the solvates thereof.

The present invention relates in particular to compounds of Formula (I) as defined herein, tautomers and stereoisomeric forms thereof, wherein

R¹ represents C₁₋₄alkyl;

R² represents C₁₋₆alkyl substituted with one R⁵;

Y represents CR⁴;

R⁴ represents hydrogen;

R⁵ represents —OR⁷;

R⁷ represents hydrogen, or —C(═O)—R⁹;

R⁹ represents C₁₋₆alkyl;

R³ represents a 5-membered heteroaromatic ring containing two or three heteroatoms each independently selected from S, and N;

wherein said 5-membered heteroaromatic ring may optionally be substituted, where possible, on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₆alkyl substituted with one R¹³; and C₁₋₄alkyl substituted with one R¹⁸; and

wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; C₁₋₆alkyl; —C(═O)—R¹⁰; and C₁₋₄alkyl substituted with one, two or three —OH substituents;

R¹⁰ represents —NR^(11a)R^(11b);

R¹⁸ represents a 5-membered aromatic ring containing two N-atoms; wherein said 5-membered aromatic ring may optionally be substituted with one C₁₋₄alkyl;

Het⁷ represents 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridinyl;

R^(11b) represents C₁₋₄alkyl or C₃₋₆cycloalkyl;

R¹³ represents Het⁷;

and the pharmaceutically acceptable addition salts, and the solvates thereof.

The present invention relates in particular to compounds of Formula (I) as defined herein, tautomers and stereoisomeric forms thereof, wherein

R¹ represents C₁₋₄alkyl;

R² represents C₁₋₆alkyl substituted with one R⁵;

Y represents N;

R⁴ represents hydrogen;

R⁵ represents —OR⁷;

R⁷ represents hydrogen, or —C(═O)—R⁹;

R⁹ represents C₁₋₆alkyl;

R³ represents a 5-membered heteroaromatic ring containing two or three heteroatoms each independently selected from S, and N;

wherein said 5-membered heteroaromatic ring may optionally be substituted, where possible, on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₆alkyl substituted with one R¹³; and C₁₋₄alkyl substituted with one R¹⁸; and

wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; C₁₋₆alkyl; —C(═O)—R¹⁰; and C₁₋₄alkyl substituted with one, two or three —OH substituents;

R¹⁰ represents —NR^(11a)R^(11b);

R¹⁸ represents a 5-membered aromatic ring containing two N-atoms; wherein said 5-membered aromatic ring may optionally be substituted with one C₁₋₄alkyl;

Het^(1d) represents a 4- to 7-membered monocyclic saturated heterocyclyl containing one or O-atom;

R^(11b) represents C₁₋₄alkyl or C₃₋₆cycloalkyl;

R¹³ represents —O—C₁₋₄alkyl, —C(═O)NR^(15a)R^(15b), or Het^(1d);

R^(11a) and R^(15a) each independently represents hydrogen or C₁₋₄alkyl;

R^(15b) represents C₃₋₆cycloalkyl;

and the pharmaceutically acceptable addition salts, and the solvates thereof.

The present invention relates in particular to compounds of Formula (I) as defined herein, tautomers and stereoisomeric forms thereof, wherein

R¹ represents methyl;

R² represents methyl substituted with one R⁵;

Y represents CR⁴;

R⁴ represents hydrogen;

R⁵ represents —OR⁷;

R⁷ represents hydrogen;

R³ represents pyrazolyl optionally substituted on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₆alkyl substituted with one R¹³; and C₁₋₄alkyl substituted with one R¹⁸; and

wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; C₁₋₆alkyl; —C(═O)—R¹⁰; and C₁₋₄alkyl substituted with one, two or three —OH substituents;

R¹⁰ represents —NR^(11a)R^(11b); R¹⁸ represents

Het^(1d) represents tetrahydrofuranyl;

R^(11b) represents C₁₋₄alkyl or C₃₋₆cycloalkyl;

R¹³ represents —O—C₁₋₄alkyl, —C(═O)NR^(15a)R^(15b), or Het^(1d);

R^(11a) and R^(15a) each independently represents hydrogen or C₁₋₄alkyl;

R^(15b) represents C₃₋₆cycloalkyl;

and the pharmaceutically acceptable addition salts, and the solvates thereof.

Another embodiment of the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments wherein one or more of the following restrictions apply:

(a) R² represents C₁₋₆alkyl substituted with one R⁵;

(b) R^(6a) represents C₁₋₄alkyl;

(c) R^(6b) represents C₁₋₄alkyl substituted with one —OH substituent;

(d) R⁷ represents hydrogen, or —C(═O)—R⁹;

(e) R⁹ represents C₁₋₆alkyl;

(f) R³ represents a 5-membered heteroaromatic ring containing two or three heteroatoms each independently selected from O, S, and N;

wherein said 5-membered heteroaromatic ring may optionally be substituted, where possible, on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; Het¹a; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; C₁₋₄alkyl substituted with one R¹⁸; and C₂₋₆alkenyl; provided that when Het¹a is directly attached to the N-atom of the 5-membered heteroaromatic ring, said Het^(1a) is attached to the N-atom via a ring carbon atom; and

wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; cyano; C₁₋₆alkyl; —O—C₁₋₄alkyl; —C(═O)—R¹⁰; C₃₋₆cycloalkyl; Het¹a; —P(═O)—(C₁₋₄alkyl)₂; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; and C₁₋₆alkyl substituted with one R¹³;

(g) R¹⁰ represents —NR^(11a)R^(11b) or Het²;

(h) R¹⁸ represents a 5-membered aromatic ring containing one, two or three N-atoms; wherein said 5-membered aromatic ring may optionally be substituted with one C₁₋₄alkyl;

(i) Het^(1a), and Het¹-d each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N;

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted, where possible, on one ring N-atom with a substituent each independently selected from the group consisting of C₁₋₄alkyl, C₁₋₄alkyl substituted with one, two or three halo atoms, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —C(═O)—NR^(22a)R^(22b) and —O—C₁₋₄alkyl; and

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of oxo, halo, and C₁₋₄alkyl;

(j) Het^(1e) represents a 4- to 7-membered monocyclic saturated heterocyclyl, attached to the remainder of the molecule of Formula (I) through any available ring carbon atom, said Het^(1e) containing one or two O-atoms;

(k) Het² represents 1-piperidinyl;

(l) R^(1b) represents Het^(1e); C₁₋₄alkyl; C₃₋₆cycloalkyl;

(m) R¹³ represents —O—C₁₋₄alkyl, —C(═O)OH, —C(═O)NR^(15a)R^(15b), —NR^(19a)R^(19b)C₃₋₆cycloalkyl, Het^(1d), —S(═O)₂—C₁₋₄alkyl, or —C(═O)—Het^(f);

(n) Het^(3a), and Het^(1f) each independently represents a heterocyclyl of formula (c-1):

(c-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional N-atom;

wherein in case (c-1) contains one additional N-atom, said additional N-atom may optionally be substituted with C₃₋₆cycloalkyl; and

wherein (c-1) may optionally be substituted on one or two ring C-atoms atoms with one or two halo substituents;

(o) R^(11a), R^(15a), R^(19a) and R^(22a) each independently represents hydrogen, C₁₋₄alkyl, or C₃₋₆cycloalkyl;

(p) R^(15b), R^(19b) and R^(22b) each independently represents C₁₋₄alkyl; or C₃₋₆cycloalkyl; (q) p represents 2.

Another embodiment of the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments wherein one or more of the following restrictions apply:

(a) R² represents C₁₋₆alkyl substituted with one R⁵;

(b) R^(6a) represents C₁₋₄alkyl;

(c) R^(6b) represents C₁₋₄alkyl substituted with one —OH substituent;

(d) R⁷ represents hydrogen, or —C(═O)—R⁹;

(e) R⁹ represents C₁₋₆alkyl;

(f) R³ represents a 5-membered heteroaromatic ring containing two or three heteroatoms each independently selected from O, S, and N;

wherein said 5-membered heteroaromatic ring may optionally be substituted, where possible, on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; Het^(1a); C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₅alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; C₁₋₄alkyl substituted with one R¹⁸; and C₂₋₆alkenyl; provided that when Het^(1a) is directly attached to the N-atom of the 5-membered heteroaromatic ring, said Het a is attached to the N-atom via a ring carbon atom; and

wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; cyano; C₁₋₆alkyl; —O—C₁₋₄alkyl; —C(═O)—R¹⁰; C₃₋₆cycloalkyl; Het^(1a); —P(═O)—(C₁₋₄alkyl)₂; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; and C₁₋₆alkyl substituted with one R¹³;

(g) R¹⁰ represents —NR^(11a)R^(11b) or Het²;

(h) R¹⁸ represents a 5-membered aromatic ring containing one, two or three N-atoms; wherein said 5-membered aromatic ring may optionally be substituted with one C₁₋₄alkyl;

(i) Het^(1a), and Het^(1d) each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N;

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted, where possible, on one ring N-atom with a substituent each independently selected from the group consisting of C₁₋₄alkyl, C₁₋₄alkyl substituted with one, two or three halo atoms, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —C(═O)—NR^(22a)R^(22b) and —O—C₁₋₄alkyl; and

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of oxo, halo, and C₁₋₄alkyl;

(j) Het^(1e) represents a 4- to 7-membered monocyclic saturated heterocyclyl, attached to the remainder of the molecule of Formula (I) through any available ring carbon atom, said Het^(1e) containing one or two O-atoms;

(k) Het² represents 1-piperidinyl;

(l) R^(11b) represents Het^(1e); C₁₋₄alkyl; C₃₋₆cycloalkyl;

(m) R¹³ represents —O—C₁₋₄alkyl, —C(═O)OH, —C(═O)NR^(5a)R^(15b), —NR^(19a)R^(19b), C₃₋₆cycloalkyl, Het^(1d), —S(═O)₂—C₁₋₄alkyl, or —C(═O)—Het^(f);

(n) Het^(3a), and Het^(1f) each independently represents a heterocyclyl of formula (c-1):

(c-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional N-atom;

wherein in case (c-1) contains one additional N-atom, said additional N-atom may optionally be substituted with C₃₋₆cycloalkyl; and

wherein (c-1) may optionally be substituted on one or two ring C-atoms atoms with one or two halo substituents;

(o) R^(11a), R^(15a), R^(19a) and R^(22a) each independently represents hydrogen, C₁₋₄alkyl, or C₃₋₆cycloalkyl;

(p) R^(15b), R^(19b) and R^(22b) each independently represents C₁₋₄alkyl; or C₃₋₆cycloalkyl; (q) p represents 2.

Another embodiment of the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments wherein one or more of the following restrictions apply:

(a) R² represents C₁₋₆alkyl substituted with one R⁵;

(b) R⁴ represents hydrogen;

(c) R⁵ represents —OR⁷;

(d) R⁷ represents hydrogen, or —C(═O)—R⁹;

(e) R⁹ represents C₁₋₆alkyl;

(f) R³ represents a 5-membered heteroaromatic ring containing two or three heteroatoms each independently selected from S, and N;

wherein said 5-membered heteroaromatic ring may optionally be substituted, where possible, on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₆alkyl substituted with one R¹³; and C₁₋₄alkyl substituted with one R¹⁸; and

wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; C₁₋₆alkyl; —C(═O)—R¹⁰; and C₁₋₄alkyl substituted with one, two or three —OH substituents;

(g) R¹⁰ represents —NR^(11a)R^(11b);

(h) R¹⁸ represents a 5-membered aromatic ring containing two N-atoms; wherein said 5-membered aromatic ring may optionally be substituted with one C₁₋₄alkyl;

(i) Het^(1d) represents a 4- to 7-membered monocyclic saturated heterocyclyl containing one or O-atom;

(j) R^(11b) represents C₁₋₄alkyl or C₃₋₆cycloalkyl;

(k) R¹³ represents —O—C₁₋₄alkyl, —C(═O)NR^(15a)R^(15b), or Het^(1d);

(l) R^(11a) and R^(15a) each independently represents hydrogen or C₁₋₄alkyl;

(m) R^(15b) represents C₃₋₆cycloalkyl.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R^(6b) represents hydrogen; C₁₋₄alkyl; C₃₋₆cycloalkyl; —C(═O)—C₁₋₄alkyl; —C(═O)—C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH and —NR^(16a)R^(6b); or C₁₋₄alkyl substituted with one —OH substituent;

R⁷ represents hydrogen, C₁₋₄alkyl, —C₁₋₄alkyl-NR^(8a)R^(8b), or —C(═O)—R⁹;

R⁹ represents C₁₋₆alkyl, or C₁₋₆alkyl substituted with one substituent selected from the group consisting of —NH₂, and —COOH;

R³ represents a 5-membered heteroaromatic ring containing one, two or three heteroatoms each independently selected from O, S, and N;

wherein said 5-membered heteroaromatic ring may optionally be substituted, where possible, on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; C₃₋₆cycloalkyl; Het^(1a); R¹⁸; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; C₁₋₄alkyl substituted with one R¹⁸; C₂₋₆alkenyl; and C₂₋₆alkenyl substituted with one R¹³; provided that when Het^(1a) or R¹⁸ are directly attached to the N-atom of the 5-membered heteroaromatic ring, said Het a or R¹⁸ are attached to the N-atom via a ring carbon atom; and

wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; cyano; C₁₋₆alkyl; —O—C₁₋₄alkyl; —C(═O)—R¹⁰; —O—C₁₋₄alkyl substituted with one, two or three halo atoms; —O—C₁₋₄alkyl-R¹²; C₃₋₆cycloalkyl; —O—C₃₋₆cycloalkyl; Het^(1a); —O-Het^(1b); R¹⁸; —P(═O)—(C₁₋₄alkyl)₂; —NH—C(═O)—C₁₋₄alkyl; —NH—C(═O)—Het^(1g); —NR^(17a)R^(17b); C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; C₁₋₄alkyl substituted with one R¹⁸; C₂₋₆alkenyl; and C₂₋₆alkenyl substituted with one R¹³;

Het^(1a), and Het^(1d) each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N;

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted, where possible, on one, two or three ring N-atoms with a substituent each independently selected from the group consisting of C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkyl substituted with one, two or three halo atoms, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH, —C(═O)—OH, —C(═O)—NR^(22a)R^(22b) and —O—C₁₋₄alkyl; and

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of —OH, oxo, halo, C₁₋₄alkyl, cyano, —C(═O)—C₁₋₄alkyl, —O—C₁₋₄alkyl, —NH₂, —NH(C₁₋₄alkyl), and —N(C₁₋₄alkyl)₂;

Het^(1b), Het^(1e), and Het^(1g) each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl, attached to the remainder of the molecule of Formula (I) through any available ring carbon atom, said Het^(1b), Het^(1e), and Het^(1g) containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N; wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted, where possible, on one or two ring N-atoms with a substituent each independently selected from the group consisting of C₁₋₄alkyl, C₃₋₆cycloalkyl, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH and —O—C₁₋₄alkyl; and

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of —OH, halo, C₁₋₄alkyl, cyano, —C(═O)—C₁₋₄alkyl, —O—C₁₋₄alkyl, —NH₂, —NH(C₁₋₄alkyl), and —N(C₁₋₄alkyl)₂; Het² represents a heterocyclyl of formula (b-1):

(b-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional heteroatom selected from O, S, S(═O)_(p) and N; wherein in case (b-1) contains one additional N-atom, said N-atom may optionally be substituted with C₁₋₄alkyl; and

wherein (b-1) may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of halo, —OH, cyano, C₁₋₄alkyl, —O—C₁₋₄alkyl, —NH₂, —NH(C₁₋₄alkyl), —N(C₁₋₄alkyl)₂, and C₁₋₄alkyl-OH; R^(11b) represents hydrogen; Het^(1e); C₁₋₄alkyl; C₁₋₄alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and —O—C₁₋₄alkyl; C₃₋₆cycloalkyl; or C₃₋₆cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and —O—C₁₋₄alkyl;

R¹³ represents —O—C₁₋₄alkyl, —C(═O)OH, —C(═O)NR^(15a)R^(15b), —NR^(19a)R^(19b), C₃₋₆cycloalkyl, Het^(1d), —S(═O)₂—C₁₋₄alkyl, or —C(═O)—Het^(f);

R¹² represents —OH, —O—C₁₋₄alkyl, —NR^(4a)R^(14b), —C(═O)NR^(14c)R^(14d), —S(═O)₂—C₄alkyl, C₃₋₆cycloalkyl;

Het^(3a), and Het^(1f) each independently represents a heterocyclyl of formula (c-1):

(c-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional heteroatom selected from O, S, S(═O)_(p) and N; wherein in case (c-1) contains one additional N-atom, said additional N-atom may optionally be substituted with C₁₋₄alkyl or C₃₋₆cycloalkyl; and

wherein (c-1) may optionally be substituted on one or two ring C-atoms atoms with one or two substituents each independently selected from the group consisting of halo, C₁₋₄alkyl, and C₃₋₆cycloalkyl.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

R² represents C₁₋₆alkyl substituted with one R⁵;

R⁴ represents hydrogen;

R⁵ represents —OR⁷;

R⁷ represents hydrogen, or —C(═O)—R⁹;

R⁹ represents C₁₋₆alkyl;

R³ represents a 5-membered heteroaromatic ring containing two or three heteroatoms each independently selected from S, and N;

wherein said 5-membered heteroaromatic ring may optionally be substituted, where possible, on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₆alkyl substituted with one R¹³; and C₁₋₄alkyl substituted with one R¹⁸; and

wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; C₁₋₆alkyl; —C(═O)—R¹⁰; and C₁₋₄alkyl substituted with one, two or three —OH substituents;

R¹⁰ represents —NR^(11a)R^(11b);

R¹⁸ represents a 5-membered aromatic ring containing two N-atoms; wherein said 5-membered aromatic ring may optionally be substituted with one C₁₋₄alkyl; Het^(1d) represents a 4- to 7-membered monocyclic saturated heterocyclyl containing one or O-atom;

R^(11b) represents C₁₋₄alkyl or C₃₋₆cycloalkyl;

R¹³ represents —O—C₁₋₄alkyl, —C(═O)NR^(15a)R^(15b), or Het^(1d);

R^(11a) and R^(15a) each independently represents hydrogen or C₁₋₄alkyl;

R^(15b) represents C₃₋₆cycloalkyl.

In an embodiment, the present invention relates to a subgroup of Formula (I), hereby named compounds of Formula (I′):

wherein R¹ represents C₁₋₄alkyl;

R² represents C₁₋₆alkyl substituted with one R⁵;

in particular wherein R¹ represents C₁₋₄alkyl;

R² represents C₁₋₆alkyl substituted with one R⁵;

R⁵ represents —OR⁷;

more in particular wherein R¹ represents C₁₋₄alkyl;

R² represents C₁₋₆alkyl substituted with one R⁵;

R⁵ represents —OR⁷;

R⁷ represents hydrogen;

and wherein all other variables are defined according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

R¹ represents methyl;

R² represents methyl or —CH₂—OH.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R¹ represents methyl; R² represents —CH₂—OH.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R⁴ represents hydrogen or fluoro.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R⁴ represents hydrogen.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

R⁷ represents hydrogen.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

R⁵ represents —OR⁷; and

R⁷ represents hydrogen.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R¹⁸ is attached to the remainder of the molecule of Formula (I) via a carbon atom.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R¹⁸ represents

each optionally substituted on carbon and/or nitrogen atoms according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R¹⁸ represents

each substituted on the NH with C₁₋₄alkyl.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het^(1a), Het^(1c) and Het^(1d) each independently represents morpholinyl, piperidinyl, pyrrolidinyl, oxetanyl, azetidinyl, piperazinyl, tetrahydro-2H-pyranyl, tetrahydrofuranyl, or hexahydro-1,4-oxazepinyl,

each optionally substituted on carbon and/or nitrogen atoms according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het^(1a), Het^(1c) and Het^(1d) represent morpholinyl, in particular 1-morpholinyl, optionally substituted where possible on carbon and/or nitrogen atoms according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het^(1a), Het^(1c) and Het^(1d) each independently represents

each optionally substituted on carbon and/or nitrogen atoms according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het^(1d) represents morpholinyl, in particular 1-morpholinyl, optionally substituted where possible on carbon and/or nitrogen atoms according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het^(1b), Het^(1e), Het^(1g) and Het⁴ each independently represents morpholinyl, piperidinyl, pyrrolidinyl, oxetanyl, azetidinyl, piperazinyl, tetrahydro-2H-pyranyl, tetrahydrofuranyl, or hexahydro-1,4-oxazepinyl, attached to the remainder of the molecule of Formula (I) through any available ring carbon atom,

each optionally substituted on carbon and/or nitrogen atoms according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het^(1b), Het^(1e), Het^(1g) and Het⁴ each independently represents piperidinyl, tetrahydro-2H-pyranyl, or pyrrolidinyl, attached to the remainder of the molecule of Formula (I) through any available ring carbon atom,

each optionally substituted on carbon and/or nitrogen atoms according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het^(1b), Het^(1e), Het^(1g) and Het⁴ each independently represents

each optionally substituted on carbon and/or nitrogen atoms according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het^(1b), Het^(1e), Het^(1g) and Het⁴ represent

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het^(1e) represents

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het^(1g) represents

optionally substituted on carbon and/or nitrogen atoms according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het^(1e) represents

each optionally substituted on carbon and/or nitrogen atoms according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het^(b) represents

each optionally substituted on carbon and/or nitrogen atoms according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het² represents

each optionally substituted on carbon and/or nitrogen atoms according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het² represents

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het^(3a), Het^(3b), Het⁵, Het⁶ and Het^(1f) each independently represents

each optionally substituted on carbon and/or nitrogen atoms according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het⁴ represents pyrrolidinyl, piperidinyl, tetrahydropyranyl, azetidinyl, or 1,1-dioxidethiopyranyl;

each optionally substituted on carbon and/or nitrogen atoms according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het⁵ represents

each optionally substituted according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het⁶ represents

each optionally substituted on carbon and/or nitrogen atoms according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het^(3a), and Het^(1f) each independently represents

each optionally substituted on carbon and/or nitrogen atoms according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het^(1a), Het^(1c) and Het^(1d) each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N;

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted, where possible, on one, two or three ring N-atoms with a substituent each independently selected from the group consisting of C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkyl substituted with one, two or three halo atoms, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH, —C(═O)—OH, —C(═O)—NR^(22a)R^(22b) and —O—C₁₋₄alkyl; and

wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of —OH, oxo, halo, C₁₋₄alkyl, cyano, —C(═O)—C₁₋₄alkyl, —O—C₁₋₄alkyl, —NH₂, —NH(C₁₋₄alkyl), and —N(C₁₋₄alkyl)₂;

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het² represents a heterocyclyl of formula (b-1):

(b-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional heteroatom selected from O, S, S(═O)_(p) and N; wherein in case (b-1) contains one additional N-atom, said N-atom may optionally be substituted with C₁₋₄alkyl; and

wherein (b-1) may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of halo, —OH, cyano, C₁₋₄alkyl, —O—C₁₋₄alkyl, —NH₂, —NH(C₁₋₄alkyl), —N(C₁₋₄alkyl)₂, and C₁₋₄alkyl-OH.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

Het^(1a) represents a 4- to 7-membered monocyclic saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N; or a 6- to 11-membered bicyclic saturated heterocyclyl, including fused, spiro and bridged cycles, containing one, two or three heteroatoms each independently selected from O, S, S(═O)_(p) and N;

wherein said 4- to 7-membered monocyclic saturated heterocyclyl or said 6- to 11-membered bicyclic saturated heterocyclyl may optionally be substituted, where possible, on one, two or three ring N-atoms with a substituent each independently selected from the group consisting of C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkyl substituted with one, two or three halo atoms, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH, —C(═O)—OH, —C(═O)—NR^(22a)R^(22b) and —O—C₁₋₄alkyl; and

wherein said 4- to 7-membered monocyclic saturated heterocyclyl or said 6- to 11-membered bicyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of —OH, oxo, halo, C₁₋₄alkyl, cyano, —C(═O)—C₁₋₄alkyl, —O—C₁₋₄alkyl, —NH₂, —NH(C₁₋₄alkyl), and —N(C₁₋₄alkyl)₂;

Het^(1c) and Het^(1d) each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N; or in case Het¹C and Het^(1d) are attached to the remainder of the molecule of Formula (I) through an N-atom, Het^(1c) and Het^(1d) may also represent a N-linked 6- to 11-membered bicyclic saturated heterocyclyl, including fused, spiro and bridged cycles, optionally containing one or two additional heteroatoms each independently selected from O, S, S(═O)_(p) and N;

wherein said 4- to 7-membered monocyclic saturated heterocyclyl or said N-linked 6- to 11-membered bicyclic saturated heterocyclyl may optionally be substituted, where possible, on one or two ring N-atoms with a substituent each independently selected from the group consisting of C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkyl substituted with one, two or three halo atoms, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH, —C(═O)—OH, —C(═O)—NR^(22a)R^(22b) and —O—C₁₋₄alkyl; and wherein said 4- to 7-membered monocyclic saturated heterocyclyl or said N-linked 6- to 11-membered bicyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of —OH, oxo, halo, C₁₋₄alkyl, cyano, —C(═O)—C₁₋₄alkyl, —O—C₁₋₄alkyl, —NH₂, —NH(C₁₋₄alkyl), and —N(C₁₋₄alkyl)₂.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R³ represents pyrazolyl optionally substituted according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

R³ represents a 5-membered heteroaromatic ring selected from the following structures

each optionally substituted according to any of the other embodiments (on the carbon and/or nitrogen atoms).

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R³ represents pyrazolyl optionally substituted on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; C₃₋₆cycloalkyl; Het^(1a); R¹⁸; R²¹; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; C₁₋₄alkyl substituted with one R¹⁸; C₂₋₆alkenyl; and C₂₋₆alkenyl substituted with one R¹³; provided that when Het^(1a) or R¹⁸ are directly attached to the N-atom of the 5-membered heteroaromatic ring, said Het^(1a) or R¹⁸ are attached to the N-atom via a ring carbon atom; and

wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; cyano; C₁₋₆alkyl; —O—C₁₋₄alkyl; —C(═O)—R¹⁰; —S(═O)₂—C₁₋₄alkyl; —S(═O)(═N—R^(20a))—C₁₋₄alkyl; —O—C₁₋₄alkyl substituted with one, two or three halo atoms; —O—C₁₋₄alkyl-R¹²; C₃₋₆cycloalkyl; —O—C₃₋₆cycloalkyl; Het^(1a); —O-Het^(1b); R¹⁸; R²¹; —P(═O)—(C₁₋₄alkyl)₂; —NH—C(═O)—C₁₋₄alkyl; —NH—C(═O)—Het^(1g); —NR^(17a)R^(17b); C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; C₁₋₄alkyl substituted with one R¹⁸; C₂₋₆alkenyl; and C₂₋₆alkenyl substituted with one R¹³.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

R³ represents pyrazolyl optionally substituted on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; C₃₋₆cycloalkyl; Het^(1a); R¹⁸; R²¹; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₆alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; —C₁₋₄alkyl-O—C₁₋₄alkyl substituted with one or two —OH substituents; C₁₋₄alkyl substituted with one R¹⁸; C₂₋₆alkenyl; and C₂₋₆alkenyl substituted with one R¹³; provided that when Het^(1a) or R¹⁸ are directly attached to the N-atom of the 5-membered heteroaromatic ring, said Het^(1a) or R¹⁸ are attached to the N-atom via a ring carbon atom; and

wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; cyano; C₁₋₆alkyl; —O—C₁₋₄alkyl; —C(═O)—R¹⁰; —S(═O)₂—C₁₋₄alkyl; —S(═O)(═N—R^(20a))—C₁₋₄alkyl; —O—C₁₋₄alkyl substituted with one, two or three halo atoms; —O—C₁₋₄alkyl-R¹²; C₃₋₆cycloalkyl; —O—C₃₋₆cycloalkyl; Het^(1a); —O-Het^(1b); R¹; R²¹; —P(═O)—(C₁₋₄alkyl)₂; —NH—C(═O)—C₁₋₄alkyl; —NH—C(═O)—Het^(1g); —NR^(17a)R^(17b); C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; C₁₋₄alkyl substituted with one R¹⁸; C₂₋₆alkenyl; and C₂₋₆alkenyl substituted with one R¹³.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R¹³ represents —O—C₁₋₄alkyl, —C(═O)NR^(15a)R^(15b), —NR^(19a)R^(19b), C₃₋₆cycloalkyl, Het^(1d), —S(═O)₂—C₁₋₄alkyl, —S(═O)(═N—R^(20c))—C₁₋₄alkyl, or —C(═O)—Het^(1f).

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R¹³ represents —O—C₁₋₄alkyl, —C(═O)NR^(15a)R^(15b), —NR^(19a)R^(19b), C₃₋₆cycloalkyl, Het^(1d), Het⁷, —S(═O)₂—C₁₋₄alkyl, —S(═O)(═N—R^(20c))—C₁₋₄alkyl, or —C(═O)—Het^(1f).

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

R¹⁸ represents

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Y represents CR⁴.

In an embodiment, the present invention relates to a subgroup of Formula (I), hereby named compounds of Formula (I-x), and the pharmaceutically acceptable addition salts, and the solvates thereof:

wherein all variables are defined according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and the pharmaceutically acceptable addition salts, and the solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Y represents N.

In an embodiment, the present invention relates to a subgroup of Formula (I), hereby named compounds of Formula (I-y), and the pharmaceutically acceptable addition salts, and the solvates thereof:

wherein all variables are defined according to any of the other embodiments.

In an embodiment, the present invention relates to a subgroup of Formula (I), hereby named compounds of Formula (I″), and the pharmaceutically acceptable addition salts, and the solvates thereof:

wherein all variables are defined according to any of the other embodiments.

In an embodiment, the present invention relates to a subgroup of Formula (I) as defined in the general reaction schemes.

In an embodiment the compound of Formula (I) is selected from the group consisting of compounds 19, 42, 49, 107, 113, 114, 118, 120, 132, 145, 156, 164, 183 and 177, tautomers and stereoisomeric forms thereof, and the pharmaceutically acceptable addition salts, and the solvates thereof.

In an embodiment the compound of Formula (I) is selected from the group consisting of compounds 19, 42, 49, 107, 113, 114, 118, 120, 132, 145, 156, 164, 183 and 177.

In an embodiment the compound of Formula (I) is selected from the group consisting of any of the exemplified compounds,

tautomers and stereoisomeric forms thereof,

and the free bases, the pharmaceutically acceptable addition salts, and the solvates thereof.

All possible combinations of the above-indicated embodiments are considered to be embraced within the scope of this invention.

Methods for the Preparation of Compounds of Formula (I)

In this section, as in all other sections unless the context indicates otherwise, references to Formula (I) also include all other sub-groups and examples thereof as defined herein.

The general preparation of some typical examples of the compounds of Formula (I) is described hereunder and in the specific examples, and are generally prepared from starting materials which are either commercially available or prepared by standard synthetic processes commonly used by those skilled in the art. The following schemes are only meant to represent examples of the invention and are in no way meant to be a limit of the invention.

Alternatively, compounds of the present invention may also be prepared by analogous reaction protocols as described in the general schemes below, combined with standard synthetic processes commonly used by those skilled in the art of organic chemistry.

The skilled person will realise that functionalization reactions illustrated in the Schemes below for compounds of Formula (I) wherein Y is CR⁴, may also be carried out for compounds wherein Y is N. The skilled person will realise this applies, for example and without limitation, to steps 3 and 4 of scheme 2 and scheme 20.

The skilled person will realize that in the reactions described in the Schemes, although this is not always explicitly shown, it may be necessary to protect reactive functional groups (for example hydroxy, amino, or carboxy groups) where these are desired in the final product, to avoid their unwanted participation in the reactions. For example in Scheme 6, the NH moiety on the pyrimidinyl or the cyanoindoline moiety can be protected with a t-butoxycarbonyl protecting group. In general, conventional protecting groups can be used in accordance with standard practice. The protecting groups may be removed at a convenient subsequent stage using methods known from the art. This is illustrated in the specific examples.

The skilled person will realize that in the reactions described in the Schemes, it may be advisable or necessary to perform the reaction under an inert atmosphere, such as for example under N₂-gas atmosphere.

It will be apparent for the skilled person that it may be necessary to cool the reaction mixture before reaction work-up (refers to the series of manipulations required to isolate and purify the product(s) of a chemical reaction such as for example quenching, column chromatography, extraction).

The skilled person will realize that heating the reaction mixture under stirring may enhance the reaction outcome. In some reactions microwave heating may be used instead of conventional heating to shorten the overall reaction time.

The skilled person will realize that another sequence of the chemical reactions shown in the Schemes below, may also result in the desired compound of formula (I).

The skilled person will realize that intermediates and final compounds shown in the schemes below may be further functionalized according to methods well-known by the person skilled in the art.

It will be clear for a skilled person that in case a variable in a specific general scheme is not defined, the variable is defined according to the scope of the present invention, or as defined in any one of the other general schemes.

In general, compounds of Formula (I) wherein R² is R^(2a) being C₁₋₆alkyl, and wherein all the other variables are defined according to the scope of the present invention, hereby named compounds of Formula (Ia), can be prepared according to the following reaction Scheme 1. In Scheme 1 halo¹ is defined as Cl, Br or I; and PG¹ represents a suitable protecting group, such as for example tert-(butoxycarbonyl). All other variables in Scheme 1 are defined according to the scope of the present invention.

In Scheme 1, the following reaction conditions apply:

The skilled person will understand that the reactions described in Scheme 1 will also be applicable starting from an intermediate of formula (III-a) (as described in Scheme 23).

In general, compounds of Formula (I) wherein R² is R^(2a) being C₁₋₆alkyl, a-1 is a 5-membered heteroaromatic ring containing one, two or three heteroatoms each independently selected from O, S, and N, substituted with —C(═O)—R¹⁰ and additionally optionally substituted with other substituents according to the scope of the present invention, and wherein all the other variables are as defined according to the scope of the present invention, hereby named compounds of Formula (Ib), can be prepared according to the following reaction Scheme 2. In Scheme 2, halo¹ is defined as Cl, Br or I; PG¹ represents a suitable protecting group, such as for example tert-(butoxycarbonyl). All other variables in Scheme 2 are defined as before or according to the scope of the present invention.

In Scheme 2, the following reaction conditions apply:

In general, compounds of Formula (I) wherein R² is R^(2b) being C₁₋₆alkyl substituted with one OH, and wherein all the other variables are as defined according to the scope of the present invention, hereby named compounds of Formula (Ic), can be prepared according to the following reaction Scheme 3. In Scheme 3 halo¹ is defined as Cl, Br or I; PG¹ represents a suitable protecting group, such as for example tert-(butoxycarbonyl) and PG² represents a suitable protecting group, such as for example tert-butyl-dimethylsilyl. All other variables in Scheme 3 are defined as before or according to the scope of the present invention.

In Scheme 3, the following reaction conditions apply:

In general, compounds of Formula (I) wherein R² is R^(2b) being C₁₋₆alkyl substituted with one OH, R³ is 5-membered heteroaromatic ring containing one, two or three heteroatoms each independently selected from O, S, and N, substituted with —C(═O)—R¹⁰ and additionally optionally substituted with other substituents according to the scope of the present invention, and wherein all the other variables are as defined according to the scope of the present invention, hereby named compounds of Formula (Id), can be prepared according to the following reaction Scheme 4. In Scheme 4, halo¹ is defined as Cl, Br or I; PG¹ represents a suitable protecting group, such as for example tert-(butoxycarbonyl) and PG² represents a suitable protecting group, such as for example tert-butyl-dimethylsilyl. All other variables in Scheme 4 are defined as before or according to the scope of the present invention.

In Scheme 4, the following reaction conditions apply:

In general, compounds of Formula (I) wherein R² is R^(2c) being C₁₋₆alkyl substituted with one Het^(3a) or —NR^(6a)R^(6b), wherein R^(6b) is R^(6b)a being H, C₁₋₄alkyl and C₃₋₆cycloalkyl and wherein all the other variables are as defined according to the scope of the present invention, hereby named compounds of Formula (Ie) and Formula (If), can be prepared according to the following reaction Scheme 5. In Scheme 5 PG¹ represents a suitable protecting group, such as for example tert-(butoxycarbonyl). All other variables in Scheme 5 are defined according to the scope of the present invention.

In Scheme 5, the following reaction conditions apply:

In general, compounds of Formula (I) wherein R² is C₁₋₆alkyl substituted with one OR^(7a), R^(7a) being —C(═O)—R⁹ or —(C═O)—CH(NH₂)—C₁₋₄alkyl-Art), and wherein all the other variables are as defined according to the scope of the present invention, hereby named compounds of Formula (Ig), can be prepared according to the following reaction Scheme 6. In Scheme 6 PG³ represents a suitable protecting group, such as for example a tert-(butoxycarbonyl), a tert-butyl or a benzyl. All other variables in Scheme 6 are defined according to the scope of the present invention.

In Scheme 6, the following reaction conditions apply:

In general, compounds of Formula (I) wherein R² is C₁₋₆alkyl substituted with one OR^(7b), R^(7b) being C₁₋₄alkyl, and wherein all the other variables are as defined according to the scope of the present invention, hereby named compounds of Formula (Ih), can be prepared according to the following reaction Scheme 7. In Scheme 7 halo¹ is defined as Cl, Br or I; PG¹ represents a suitable protecting group, such as for example tert-(butoxycarbonyl) and PG² represents a suitable protecting group, such as for example tert-butyl-dimethylsilyl; W represents a leaving group, such as for example a methane sulfonate or toluene sulfonate or an halogen (Cl, Br or I). All other variables in Scheme 7 are defined as before or according to the scope of the present invention.

In Scheme 7, the following reaction conditions apply:

In general, compounds of Formula (I) wherein R² is C₁₋₆alkyl substituted with one OR^(7c), R^(7c) being C₁₋₄alkyl-NR^(8a)R^(8b) or C₁₋₄alkyl-Het^(3b), and wherein all the other variables are as defined according to the scope of the present invention, hereby named compounds of Formula (Ii) and Formula (Ij), can be prepared according to the following reaction Scheme 8. In Scheme 8 halo¹ is defined as Cl, Br or I; PG¹ represents a suitable protecting group, such as for example tert-(butoxycarbonyl); W¹ represents a leaving group, such as for example a methane sulfonate or toluene sulfonate or an halogen (Cl, Br or I); W² represents a leaving group, such as for example a mesyl or a tosyl. All other variables in Scheme 8 are defined as before or according to the scope of the present invention.

In Scheme 8, the following reaction conditions apply:

In general, intermediates of Formula (II) and (III) wherein R² is R^(2a) being C₁₋₆alkyl, and wherein all the other variables are as defined according to the scope of the present invention, hereby named compounds of Formula (II) and (III), can be prepared according to the following reaction Scheme 9. In Scheme 9 halo¹ is defined as Cl, Br, I; halo² is defined as Cl, Br, I; PG¹ represents a suitable protecting group, such as for example tert-(butoxycarbonyl), W¹ represents a leaving group, such as for example a methane sulfonate or toluene sulfonate or an halogen (Cl, Br or I). All other variables in Scheme 9 are defined as before or according to the scope of the present invention.

In Scheme 9, the following reaction conditions apply:

In general, intermediates of Formula (XII) and (XIII) wherein R² is R^(2b) being C₁₋₆alkyl substituted with one OH, and wherein all the other variables are as defined according to the scope of the present invention, hereby named compounds of Formula (XII) and (XIII), can be prepared according to the following reaction Scheme 10. In Scheme 10 halo¹ is defined as Cl, Br, I; halo² is defined as Cl, Br, I; PG¹ represents a suitable protecting group, such as for example tert-(butoxycarbonyl) and PG² represents a suitable protecting group, such as for example tert-butyl-dimethylsilyl; W¹ represents a leaving group, such as for example a methane sulfonate or toluene sulfonate or an halogen (Cl, Br or I). All other variables in Scheme 10 are defined as before or according to the scope of the present invention.

In Scheme 10, the following reaction conditions apply:

In general, compounds of Formula (I) wherein R² is as shown in the scheme 11, and wherein all the other variables are as defined according to the scope of the present invention, hereby named compounds of Formula (Ik) can be prepared according to the following reaction Scheme 11. In Scheme 11 PG¹ represents a suitable protecting group, such as for example tert-(butoxycarbonyl). All other variables in Scheme 11 are defined as before or according to the scope of the present invention.

In Scheme 11, the following reaction conditions apply:

In general, compounds of Formula (I) wherein R² is as shown in the scheme 12, and wherein all the other variables are as defined according to the scope of the present invention, hereby named compounds of Formula (Il) can be prepared according to the following reaction Scheme 12. In Scheme 12 PG¹ represents a suitable protecting group, such as for example tert-(butoxycarbonyl). All other variables in Scheme 12 are defined as before or according to the scope of the present invention.

In Scheme 12, the following reaction conditions apply:

In general, compounds of Formula (I) wherein R² is as shown in the scheme 13 and wherein all the other variables are as defined according to the scope of the present invention, hereby named compounds of Formula (Im) can be prepared according to the following reaction Scheme 13. In Scheme 13 PG¹ represents a suitable protecting group, such as for example tert-(butoxycarbonyl). All other variables in Scheme 13 are defined as before or according to the scope of the present invention.

In Scheme 13, the following reaction conditions apply:

In general, compounds of Formula (I) wherein R² is being C₁₋₆alkyl substituted with one Het^(3a) or —NR^(6a)R^(6b), wherein R^(6a) is being H, R is being —C(═O)—C₁₋₄alkyl; —C(═O)-Het⁴; —S(═O)₂—C₁₋₄alkyl and wherein all the other variables are as defined according to the scope of the present invention, hereby named compounds of Formula (In), Formula (Io) and Formula (Ip), can be prepared according to the following reaction Scheme 14. In Scheme 14, PG¹ represents a suitable protecting group, such as for example tert-(butoxycarbonyl). All other variables in Scheme 14 are defined as before or according to the scope of the present invention.

In Scheme 14, the following reaction conditions apply:

In general, compounds of Formula (I) wherein R² is being C₁₋₆alkyl substituted with one Het^(3a) or —NR^(6a)R^(6b), wherein R^(6a) is being C₁₋₄alkyl, R^(6b) is being —C(═O)—C₁₋₄alkyl; —C(═O)—Het⁴; —S(═O)₂—C₁₋₄alkyl and wherein all the other variables are as defined according to the scope of the present invention, hereby named compounds of Formula (Iq), Formula (Ir) and Formula (Is), can be prepared according to the following reaction Scheme 15. In Scheme 15, PG¹ represents a suitable protecting group, such as for example tert-(butoxycarbonyl). All other variables in Scheme 15 are defined as before or according to the scope of the present invention.

In Scheme 15, the following reaction conditions apply:

In general, compounds of Formula (I) wherein R² is C₁₋₆alkyl substituted with one OR^(7d), R^(7d) being —S(═O)₂—OH or —P(═O)—(OH)₂, and wherein all the other variables are as defined according to the scope of the present invention, hereby named compounds of Formula (It) and Formula (Iu), can be prepared according to the following reaction Scheme 16. All other variables in Scheme 16 are defined as before or according to the scope of the present invention. In Scheme 16, the following reaction conditions apply:

In general, compounds of Formula (I) wherein R² is R^(2a) being C₁₋₆alkyl, R³ is restricted to a-2 being a pyrazolyl substituted on one ring N-atom with a group consisting of C₁₋₄alkyl substituted with —C(═O)NR^(15a)R^(1b) or —C(═O)—Het^(1f), and additionally optionally substituted with other substituents according to the scope of the present invention, and wherein all the other variables are as defined according to the scope of the present invention, hereby named compounds of Formula (Iv), can be prepared according to the following reaction Scheme 17. In Scheme 17, PG¹ represents a suitable protecting group, such as for example tert-(butoxycarbonyl). All other variables in Scheme 17 are defined as before or according to the scope of the present invention.

In Scheme 17, the following reaction conditions apply:

In general, compounds of Formula (I) wherein R² is R^(2b) being C₁₋₆alkyl substituted with one OH, R³ is restricted to a-2 being a pyrazolyl substituted on one ring N-atom with a group consisting of C₁₋₄alkyl substituted with —C(═O)NR^(15a)R^(15b) or —C(═O)—Het^(1f) and additionally optionally substituted with other substituents according to the scope of the present invention, and wherein all the other variables are as defined according to the scope of the present invention, hereby named compounds of Formula (Ix), can be prepared according to the following reaction Scheme 18. In Scheme 18, PG¹ represents a suitable protecting group, such as for example tert-(butoxycarbonyl) and PG² represents a suitable protecting group, such as for example tert-butyl-dimethylsilyl. All other variables in Scheme 18 are defined according to the scope of the present invention. In Scheme 18, the following reaction conditions apply:

In general, intermediates of Formula (XII) wherein all the variables are as defined according to the scope of the present invention or as defined before, can be prepared according to the following reaction Scheme 19. All other variables in Scheme 19 are as defined before.

In Scheme 19, the following reaction conditions apply:

In general, compounds of Formula (I) wherein R² is R^(2d) being C₁₋₆alkyl substituted one fluorine, Y is CR⁴, and wherein all the other variables are as defined according to the scope of the present invention, hereby named compounds of Formula (Iz), can be prepared according to the following reaction Scheme 18.

In Scheme 20, the following reaction conditions apply:

In general, compounds of Formula (I) wherein R² is R^(2b) being C₁₋₆alkyl substituted with one OH, Y is N, and wherein all the other variables are as defined according to the scope of the present invention, hereby named compounds of Formula (Iz), can be prepared according to the following reaction Scheme 21. In Scheme 21, halo¹ is defined as Cl, Br or I; PG¹ represents a suitable protecting group, such as for example tert-(butoxycarbonyl) and PG² represents a suitable protecting group, such as for example tert-butyl-dimethylsilyl. All other variables in Scheme 21 are defined according to the scope of the present invention.

In Scheme 21, the following reaction conditions apply:

In general, compounds of Formula (I) wherein R² is R^(2b) being C₁₋₆alkyl substituted with one OH, Y is CR⁴, and wherein all the other variables are as defined according to the scope of the present invention, hereby named compounds of Formula (Ic), can be prepared according to the following reaction Scheme 22. All other variables in Scheme 22 are defined according to the scope of the present invention or as above.

In Scheme 22, the following reaction conditions apply:

Intermediate of Formula (IIIa) wherein R² is R^(2e) being C₁₋₆alkyl or C₁₋₆alkyl substituted with one, two or three fluoro atoms, and wherein all the other variables are defined according to the scope of the present invention, can be prepared according to the following reaction All other variables in Scheme 23 are defined according to the scope of the present invention.

In general, compounds of Formula (I) wherein R² is R^(2c) being C₁₋₆alkyl substituted with NH₂ and wherein all the other variables are as defined according to the scope of the present invention, hereby named compounds of Formula (If-a), can be prepared according to the following reaction Scheme 24. In Scheme 24, PG¹ represents a suitable protecting group, such as for example tert-(butoxycarbonyl). All other variables in Scheme 24 are defined according to the scope of the present invention.

In Scheme 24, the following reaction conditions apply:

In general, intermediate of formula C wherein all the variables are as defined according to the scope of the present invention or as defined above can be prepared according to the following reaction Scheme 25.

It will be appreciated that where appropriate functional groups exist, compounds of various formulae or any intermediates used in their preparation may be further derivatised by one or more standard synthetic methods employing condensation, substitution, oxidation, reduction, or cleavage reactions. Particular substitution approaches include conventional alkylation, arylation, heteroarylation, acylation, sulfonylation, halogenation, nitration, formylation and coupling procedures.

The compounds of Formula (I) may be synthesized in the form of racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of Formula (I) containing a basic nitrogen atom may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali. An alternative manner of separating the enantiomeric forms of the compounds of Formula (I) involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.

In the preparation of compounds of the present invention, protection of remote functionality (e.g., primary or secondary amine) of intermediates may be necessary. The need for such protection will vary depending on the nature of the remote functionality and the conditions of the preparation methods. Suitable amino-protecting groups (NH-Pg) include acetyl, trifluoroacetyl, t-butoxycarbonyl (Boc), benzyloxycarbonyl (CBz) and 9-fluorenylmethyleneoxycarbonyl (Fmoc). The need for such protection is readily determined by one skilled in the art. For a general description of protecting groups and their use, see T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 4th ed., Wiley, Hoboken, N.J., 2007.

Pharmacology

It has been found that the compounds of the present invention inhibit NF-κB-inducing kinase (NIK—also known as MAP3K14). Some of the compounds of the present invention may undergo metabolism to a more active form in vivo (prodrugs). Therefore the compounds according to the invention and the pharmaceutical compositions comprising such compounds may be useful for treating or preventing diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders. In particular, the compounds according to the present invention and the pharmaceutical compositions thereof may be useful in the treatment of a haematological malignancy or solid tumour. In a specific embodiment said haematological malignancy is selected from the group consisting of multiple myeloma, non-Hodgkin's lymphoma, Hodgkin lymphoma, T-cell leukaemia, mucosa-associated lymphoid tissue lymphoma, diffuse large B-cell lymphoma and mantle cell lymphoma, in a particular embodiment mantle cell lymphoma. In another specific embodiment of the present invention, the solid tumour is selected from the group consisting of pancreatic cancer, breast cancer, melanoma and non-small cell lung cancer.

Examples of cancers which may be treated (or inhibited) include, but are not limited to, a carcinoma, for example a carcinoma of the bladder, breast, colon (e.g. colorectal carcinomas such as colon adenocarcinoma and colon adenoma), kidney, urothelial, uterus, epidermis, liver, lung (for example adenocarcinoma, small cell lung cancer and non-small cell lung carcinomas, squamous lung cancer), oesophagus, head and neck, gall bladder, ovary, pancreas (e.g. exocrine pancreatic carcinoma), stomach, gastrointestinal (also known as gastric) cancer (e.g. gastrointestinal stromal tumours), cervix, endometrium, thyroid, prostate, or skin (for example squamous cell carcinoma or dermatofibrosarcoma protuberans); pituitary cancer, a hematopoietic tumour of lymphoid lineage, for example leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, B-cell lymphoma (e.g. diffuse large B-cell lymphoma, mantle cell lymphoma), T-cell leukaemia/lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma, or Burkett's lymphoma; a hematopoietic tumour of myeloid lineage, for example leukemias, acute and chronic myelogenous leukemias, chronic myelomonocytic leukemia (CMML), myeloproliferative disorder, myeloproliferative syndrome, myelodysplastic syndrome, or promyelocytic leukemia; multiple myeloma; thyroid follicular cancer; hepatocellular cancer, a tumour of mesenchymal origin (e.g. Ewing's sarcoma), for example fibrosarcoma or rhabdomyosarcoma; a tumour of the central or peripheral nervous system, for example astrocytoma, neuroblastoma, glioma (such as glioblastoma multiforme) or schwannoma; melanoma; seminoma; teratocarcinoma; osteosarcoma; xeroderma pigmentosum; keratoctanthoma; thyroid follicular cancer; or Kaposi's sarcoma.

Particular examples of cancers which may be treated (or inhibited) include B-cell malignancies, such as multiple myeloma, hodgkins lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma or chronic lymphocytic leukemia, with mutations in the non-canonical NFkB signalling pathway (eg in NIK (MAP3K14), TRAF3, TRAF2, BIRC2 or BIRC3 genes).

Hence, the invention relates to compounds of Formula (I), the tautomers and the stereoisomeric forms thereof, and the pharmaceutically acceptable addition salts, and the solvates thereof, for use as a medicament.

The invention also relates to the use of a compound of Formula (I), a tautomer or a stereoisomeric form thereof, or a pharmaceutically acceptable addition salt, or a solvate thereof, or a pharmaceutical composition according to the invention, for the manufacture of a medicament.

The present invention also relates to a compound of Formula (I), a tautomer or a stereoisomeric form thereof, or a pharmaceutically acceptable addition salt, or a solvate thereof, or a pharmaceutical composition according to the invention, for use in the treatment, prevention, amelioration, control or reduction of the risk of disorders associated with NF-κB-inducing kinase dysfunction in a mammal, including a human, the treatment or prevention of which is affected or facilitated by inhibition of NF-κB-inducing kinase.

Also, the present invention relates to the use of a compound of Formula (I), a tautomer or a stereoisomeric form thereof, or a pharmaceutically acceptable addition salt, or a solvate thereof, or a pharmaceutical composition according to the invention, for the manufacture of a medicament for treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with NF-κB-inducing kinase dysfunction in a mammal, including a human, the treatment or prevention of which is affected or facilitated by inhibition of NF-κB-inducing kinase.

The invention also relates to a compound of Formula (I), a tautomer or a stereoisomeric form thereof, or a pharmaceutically acceptable addition salt, or a solvate thereof, for use in the treatment or prevention of any one of the diseases mentioned hereinbefore. The invention also relates to a compound of Formula (I), a tautomer or a stereoisomeric form thereof, or a pharmaceutically acceptable addition salt, or a solvate thereof, for use in treating or preventing any one of the diseases mentioned hereinbefore.

The invention also relates to the use of a compound of Formula (I), a tautomer or a stereoisomeric form thereof, or a pharmaceutically acceptable addition salt, or a solvate thereof, for the manufacture of a medicament for the treatment or prevention of any one of the disease conditions mentioned hereinbefore.

The compounds of the present invention can be administered to mammals, preferably humans, for the treatment or prevention of any one of the diseases mentioned hereinbefore.

In view of the utility of the compounds of Formula (I), a tautomer or a stereoisomeric form thereof, or a pharmaceutically acceptable addition salt, or a solvate thereof, there is provided a method of treating warm-blooded animals, including humans, suffering from any one of the diseases mentioned hereinbefore.

Said method comprises the administration, i.e. the systemic or topical administration, preferably oral administration, of a therapeutically effective amount of a compound of Formula (I), a tautomer or a stereoisomeric form thereof, or a pharmaceutically acceptable addition salt, or a solvate thereof, to warm-blooded animals, including humans.

Therefore, the invention also relates to a method for the treatment of any one of the diseases mentioned hereinbefore comprising administering a therapeutically effective amount of compound according to the invention to a patient in need thereof.

One skilled in the art will recognize that a therapeutically effective amount of the compounds of the present invention is the amount sufficient to have therapeutic activity and that this amount varies inter alias, depending on the type of disease, the concentration of the compound in the therapeutic formulation, and the condition of the patient. Generally, the amount of a compound of the present invention to be administered as a therapeutic agent for treating the disorders referred to herein will be determined on a case by case by an attending physician.

Those of skill in the treatment of such diseases could determine the effective therapeutic daily amount from the test results presented hereinafter. An effective therapeutic daily amount would be from about 0.005 mg/kg to 50 mg/kg, in particular 0.01 mg/kg to 50 mg/kg body weight, more in particular from 0.01 mg/kg to 25 mg/kg body weight, preferably from about 0.01 mg/kg to about 15 mg/kg, more preferably from about 0.01 mg/kg to about 10 mg/kg, even more preferably from about 0.01 mg/kg to about 1 mg/kg, most preferably from about 0.05 mg/kg to about 1 mg/kg body weight. A particular effective therapeutic daily amount might be from about 10 mg/kg body weight to 40 mg/kg body weight. A particular effective therapeutic daily amount might be 1 mg/kg body weight, 2 mg/kg body weight, 4 mg/kg body weight, or 8 mg/kg body weight. The amount of a compound according to the present invention, also referred to here as the active ingredient, which is required to achieve a therapeutically effect may vary on case-by-case basis, for example with the particular compound, the route of administration, the age and condition of the recipient, and the particular disorder or disease being treated. A method of treatment may also include administering the active ingredient on a regimen of between one and four intakes per day. In these methods of treatment the compounds according to the invention are preferably formulated prior to administration. As described herein below, suitable pharmaceutical formulations are prepared by known procedures using well known and readily available ingredients.

The present invention also provides compositions for preventing or treating the disorders referred to herein. Said compositions comprising a therapeutically effective amount of a compound of Formula (I), a tautomer or a stereoisomeric form thereof, or a pharmaceutically acceptable addition salt, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent.

While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical composition. Accordingly, the present invention further provides a pharmaceutical composition comprising a compound according to the present invention, together with a pharmaceutically acceptable carrier or diluent. The carrier or diluent must be “acceptable” in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.

The pharmaceutical compositions of this invention may be prepared by any methods well known in the art of pharmacy, for example, using methods such as those described in Gennaro et al. Remington's Pharmaceutical Sciences (18^(th) ed., Mack Publishing Company, 1990, see especially Part 8: Pharmaceutical preparations and their Manufacture). A therapeutically effective amount of the particular compound, in base form or addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for systemic administration such as oral, percutaneous or parenteral administration; or topical administration such as via inhalation, a nose spray, eye drops or via a cream, gel, shampoo or the like. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions: or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause any significant deleterious effects on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on or as an ointment.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

The present compounds can be used for systemic administration such as oral, percutaneous or parenteral administration; or topical administration such as via inhalation, a nose spray, eye drops or via a cream, gel, shampoo or the like. The compounds are preferably orally administered. The exact dosage and frequency of administration depends on the particular compound of Formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disorder and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention.

The compounds of the present invention may be administered alone or in combination with one or more additional therapeutic agents. Combination therapy includes administration of a single pharmaceutical dosage formulation which contains a compound according to the present invention and one or more additional therapeutic agents, as well as administration of the compound according to the present invention and each additional therapeutic agent in its own separate pharmaceutical dosage formulation. For example, a compound according to the present invention and a therapeutic agent may be administered to the patient together in a single oral dosage composition such as a tablet or capsule, or each agent may be administered in separate oral dosage formulations.

Therefore, an embodiment of the present invention relates to a product containing as first active ingredient a compound according to the invention and as further active ingredient one or more medicinal agent, more particularly, with one or more anticancer agent or adjuvant, as a combined preparation for simultaneous, separate or sequential use in the treatment of patients suffering from cancer.

Accordingly, for the treatment of the conditions mentioned hereinbefore, the compounds of the invention may be advantageously employed in combination with one or more other medicinal agents (also referred to as therapeutic agents), more particularly, with other anti-cancer agents or adjuvants in cancer therapy. Examples of anti-cancer agents or adjuvants (supporting agents in the therapy) include but are not limited to:

-   -   platinum coordination compounds for example cisplatin optionally         combined with amifostine, carboplatin or oxaliplatin;     -   taxane compounds for example paclitaxel, paclitaxel protein         bound particles (Abraxane™) or docetaxel;     -   topoisomerase I inhibitors such as camptothecin compounds for         example irinotecan, SN-38, topotecan, topotecan hcl;     -   topoisomerase II inhibitors such as anti-tumour         epipodophyllotoxins or podophyllotoxin derivatives for example         etoposide, etoposide phosphate or teniposide;     -   anti-tumour vinca alkaloids for example vinblastine, vincristine         or vinorelbine;     -   anti-tumour nucleoside derivatives for example 5-fluorouracil,         leucovorin, gemcitabine, gemcitabine hcl, capecitabine,         cladribine, fludarabine, nelarabine;     -   alkylating agents such as nitrogen mustard or nitrosourea for         example cyclophosphamide, chlorambucil, carmustine, thiotepa,         mephalan (melphalan), lomustine, altretamine, busulfan,         dacarbazine, estramustine, ifosfamide optionally in combination         with mesna, pipobroman, procarbazine, streptozocin,         temozolomide, uracil;     -   anti-tumour anthracycline derivatives for example daunorubicin,         doxorubicin optionally in combination with dexrazoxane, doxil,         idarubicin, mitoxantrone, epirubicin, epirubicin hcl,         valrubicin;     -   molecules that target the IGF-1 receptor for example         picropodophilin;     -   tetracarcin derivatives for example tetrocarcin A;     -   glucocorticoiden for example prednisone;     -   antibodies for example trastuzumab (HER2 antibody), rituximab         (CD20 antibody), gemtuzumab, gemtuzumab ozogamicin, cetuximab,         pertuzumab, bevacizumab, alemtuzumab, eculizumab, ibritumomab         tiuxetan, nofetumomab, panitumumab, tositumomab, CNTO 328;     -   estrogen receptor antagonists or selective estrogen receptor         modulators or inhibitors of estrogen synthesis for example         tamoxifen, fulvestrant, toremifene, droloxifene, faslodex,         raloxifene or letrozole;     -   aromatase inhibitors such as exemestane, anastrozole, letrazole,         testolactone and vorozole;     -   differentiating agents such as retinoids, vitamin D or retinoic         acid and retinoic acid metabolism blocking agents (RAMBA) for         example accutane;     -   DNA methyl transferase inhibitors for example azacytidine or         decitabine;     -   antifolates for example pemetrexed disodium;     -   antibiotics for example antinomycin D, bleomycin, mitomycin C,         dactinomycin, carminomycin, daunomycin, levamisole, plicamycin,         mithramycin;     -   antimetabolites for example clofarabine, aminopterin, cytosine         arabinoside or methotrexate, azacytidine, cytarabine,         floxuridine, pentostatin, thioguanine;     -   apoptosis inducing agents and antiangiogenic agents such as         Bcl-2 inhibitors for example YC 137, BH 312, ABT 737, gossypol,         HA 14-1, TW 37 or decanoic acid;     -   tubuline-binding agents for example combrestatin, colchicines or         nocodazole;     -   kinase inhibitors (e.g. EGFR (epithelial growth factor receptor)         inhibitors, MTKI (multi target kinase inhibitors), mTOR         inhibitors) for example flavoperidol, imatinib mesylate,         erlotinib, gefitinib, dasatinib, lapatinib, lapatinib         ditosylate, sorafenib, sunitinib, sunitinib maleate,         temsirolimus;     -   farnesyltransferase inhibitors for example tipifamib;     -   histone deacetylase (HDAC) inhibitors for example sodium         butyrate, suberoylanilide hydroxamic acid (SAHA), depsipeptide         (FR 901228), NVP-LAQ824, R306465, quisinostat, trichostatin A,         vorinostat;     -   Inhibitors of the ubiquitin-proteasome pathway for example         PS-341, Velcade (MLN-341) or bortezomib;     -   Yondelis;     -   Telomerase inhibitors for example telomestatin;     -   Matrix metalloproteinase inhibitors for example batimastat,         marimastat, prinostat or metastat;     -   Recombinant interleukins for example aldesleukin, denileukin         diftitox, interferon alfa 2a, interferon alfa 2b, peginterferon         alfa 2b;     -   MAPK inhibitors;     -   Retinoids for example alitretinoin, bexarotene, tretinoin;     -   Arsenic trioxide;     -   Asparaginase;     -   Steroids for example dromostanolone propionate, megestrol         acetate, nandrolone (decanoate, phenpropionate), dexamethasone;     -   Gonadotropin releasing hormone agonists or antagonists for         example abarelix, goserelin acetate, histrelin acetate,         leuprolide acetate;     -   Thalidomide, lenalidomide;     -   Mercaptopurine, mitotane, pamidronate, pegademase, pegaspargase,         rasburicase;     -   BH3 mimetics for example ABT-199;     -   MEK inhibitors for example PD98059, AZD6244, CI-1040;     -   colony-stimulating factor analogs for example filgrastim,         pegfilgrastim, sargramostim; erythropoietin or analogues thereof         (e.g. darbepoetin alfa); interleukin 11; oprelvekin;         zoledronate, zoledronic acid; fentanyl; bisphosphonate;         palifermin;     -   a steroidal cytochrome P450 17alpha-hydroxylase-17,20-lyase         inhibitor (CYP17), e.g. abiraterone, abiraterone acetate.

The one or more other medicinal agents and the compound according to the present invention may be administered simultaneously (e.g. in separate or unitary compositions) or sequentially in either order. In the latter case, the two or more compounds will be administered within a period and in an amount and manner that is sufficient to ensure that an advantageous or synergistic effect is achieved. It will be appreciated that the preferred method and order of administration and the respective dosage amounts and regimes for each component of the combination will depend on the particular other medicinal agent and compound of the present invention being administered, their route of administration, the particular tumour being treated and the particular host being treated. The optimum method and order of administration and the dosage amounts and regime can be readily determined by those skilled in the art using conventional methods and in view of the information set out herein.

The weight ratio of the compound according to the present invention and the one or more other anticancer agent(s) when given as a combination may be determined by the person skilled in the art. Said ratio and the exact dosage and frequency of administration depends on the particular compound according to the invention and the other anticancer agent(s) used, the particular condition being treated, the severity of the condition being treated, the age, weight, gender, diet, time of administration and general physical condition of the particular patient, the mode of administration as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that the effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. A particular weight ratio for the present compound of Formula (I) and another anticancer agent may range from 1/10 to 10/1, more in particular from 1/5 to 5/1, even more in particular from 1/3 to 3/1.

The platinum coordination compound is advantageously administered in a dosage of 1 to 500 mg per square meter (mg/m²) of body surface area, for example 50 to 400 mg/m², particularly for cisplatin in a dosage of about 75 mg/m² and for carboplatin in about 300 mg/m² per course of treatment.

The taxane compound is advantageously administered in a dosage of 50 to 400 mg per square meter (mg/m²) of body surface area, for example 75 to 250 mg/m², particularly for paclitaxel in a dosage of about 175 to 250 mg/m² and for docetaxel in about 75 to 150 mg/m² per course of treatment.

The camptothecin compound is advantageously administered in a dosage of 0.1 to 400 mg per square meter (mg/m²) of body surface area, for example 1 to 300 mg/m², particularly for irinotecan in a dosage of about 100 to 350 mg/m² and for topotecan in about 1 to 2 mg/m² per course of treatment.

The anti-tumour podophyllotoxin derivative is advantageously administered in a dosage of 30 to 300 mg per square meter (mg/m²) of body surface area, for example 50 to 250 mg/m², particularly for etoposide in a dosage of about 35 to 100 mg/m² and for teniposide in about 50 to 250 mg/m² per course of treatment.

The anti-tumour vinca alkaloid is advantageously administered in a dosage of 2 to 30 mg per square meter (mg/m²) of body surface area, particularly for vinblastine in a dosage of about 3 to 12 mg/m², for vincristine in a dosage of about 1 to 2 mg/m², and for vinorelbine in dosage of about 10 to 30 mg/m² per course of treatment.

The anti-tumour nucleoside derivative is advantageously administered in a dosage of 200 to 2500 mg per square meter (mg/m²) of body surface area, for example 700 to 1500 mg/m², particularly for 5-FU in a dosage of 200 to 500 mg/m², for gemcitabine in a dosage of about 800 to 1200 mg/m² and for capecitabine in about 1000 to 2500 mg/m² per course of treatment.

The alkylating agents such as nitrogen mustard or nitrosourea is advantageously administered in a dosage of 100 to 500 mg per square meter (mg/m²) of body surface area, for example 120 to 200 mg/m², particularly for cyclophosphamide in a dosage of about 100 to 500 mg/m², for chlorambucil in a dosage of about 0.1 to 0.2 mg/kg, for carmustine in a dosage of about 150 to 200 mg/m², and for lomustine in a dosage of about 100 to 150 mg/m² per course of treatment.

The anti-tumour anthracycline derivative is advantageously administered in a dosage of 10 to 75 mg per square meter (mg/m²) of body surface area, for example 15 to 60 mg/m², particularly for doxorubicin in a dosage of about 40 to 75 mg/m², for daunorubicin in a dosage of about 25 to 45 mg/m², and for idarubicin in a dosage of about 10 to 15 mg/m² per course of treatment.

The antiestrogen agent is advantageously administered in a dosage of about 1 to 100 mg daily depending on the particular agent and the condition being treated. Tamoxifen is advantageously administered orally in a dosage of 5 to 50 mg, preferably 10 to 20 mg twice a day, continuing the therapy for sufficient time to achieve and maintain a therapeutic effect. Toremifene is advantageously administered orally in a dosage of about 60 mg once a day, continuing the therapy for sufficient time to achieve and maintain a therapeutic effect. Anastrozole is advantageously administered orally in a dosage of about 1 mg once a day. Droloxifene is advantageously administered orally in a dosage of about 20-100 mg once a day. Raloxifene is advantageously administered orally in a dosage of about 60 mg once a day. Exemestane is advantageously administered orally in a dosage of about 25 mg once a day.

Antibodies are advantageously administered in a dosage of about 1 to 5 mg per square meter (mg/m²) of body surface area, or as known in the art, if different. Trastuzumab is advantageously administered in a dosage of 1 to 5 mg per square meter (mg/m²) of body surface area, particularly 2 to 4 mg/m² per course of treatment.

These dosages may be administered for example once, twice or more per course of treatment, which may be repeated for example every 7, 14, 21 or 28 days.

The following examples further illustrate the present invention.

EXAMPLES

Several methods for preparing the compounds of this invention are illustrated in the following examples. All starting materials were obtained from commercial suppliers and used without further purification, or alternatively, can be easily prepared by a skilled person according to well-known methods.

When a stereocenter is indicated with ‘RS’ this means that a racemic mixture was obtained.

For intermediates that were used in a next reaction step as a crude or as a partially purified intermediate, theoretical mol amounts are indicated in the reaction protocols described below.

Hereinafter, the terms: ‘ACN’ means acetonitrile, ‘AcOH’ means acetic acid, ‘Ar’ means argon, ‘BINAP’ means 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl, ‘BOC’ means tert-butyloxycarbonyl, ‘Boc₂O’ means di-tert-butyl dicarbonate, ‘Celite®’ means diatomaceous earth, ‘Cu(OTf)₂’ means Copper(II) triflate, ‘DCM’ means dichloromethane, ‘DIPEA’ means diisopropylethylamine, ‘h’ means hours(s), ‘min’ means minute(s), ‘Int.’ means intermediate; ‘aq.’ Means aqueous; ‘DMAP’ means dimethylaminopyridine, ‘DMF’ means dimethylformamide, ‘DIBAL-H’ means diisobutylaluminium hydride, ‘EDC hydrochloride’ means 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, ‘Et₂O’ means diethylether, ‘Et’ means ethyl, ‘Me’ means methyl, ‘EtOAc’ or ‘AcOEt’ means ethyl acetate, ‘HPLC’ means High-performance Liquid Chromatography, ‘iPrOH’ means isopropyl alcohol, ‘HATU’ means 1-[bis(dimethylamino)methylene]-1H-[1,2,3]triazolo[4,5-b]pyridin-1-ium 3-oxide hexafluorophosphate, ‘HFIP’ means hexafluoroisopropanol, ‘HOBT’ means 1-Hydroxy-1H-benzotriazole, ‘MsCl’ means methanesulfonyl chloride, ‘LC/MS’ means Liquid Chromatography/Mass Spectrometry, ‘Me-THF’ means methyl-tetrahydrofuran, ‘MeOH’ means methanol, ‘EtOH’ means ethanol, ‘NBS’ means N-bromosuccinimide, ‘NCS’ means N-chlorosuccinimide, ‘NMR’ means Nuclear Magnetic Resonance, ‘Pd/C 10%’ means palladium on carbon loading 10%, ‘Pd(OAc)₂’ means palladium (II) acetate, ‘Pd(PPh₃)₄’ means tetrakis(triphenylphosphine)palladium (0), ‘Pd(dppf)Cl₂’ means [1,1′-Bis(diphenylphosphino)ferrocene]-dichloropalladium(II), ‘rt’ or ‘RT’ means room temperature, ‘SFC’ means supercritical fluid chromatography, ‘ee’ means enantiomeric excess, ‘TBAF’ means tetrabutylammonium fluoride, ‘TBDMS’ or ‘SMDBT’ means tert-butyldimethylsilyl, ‘TEA’ means triethylamine, ‘TFA’ means trifluoroacetic acid, ‘THF’ means tetrahydrofuran, ‘CV’ means column volumes, ‘Quant.’ means quantitative, ‘equiv.’ means equivalent(s), ‘M.P.’ or ‘m.p.’ means melting point, ‘OR’ means optical rotation, ‘SFC’ means supercritical fluid chromatography, ‘DIPE’ means diisopropyl ethylether, ‘RaNi’ means Raney Nickel, ‘NaHCO₃’ means sodium hydrogenocarbonate, ‘BRETTPHOS’ means 2-(dicyclohexylphosphino)-3,6-dimethoxy-2′, 4′, 6′-triisopropyl-1,1′-biphenyl, ‘DMSO’ means dimethylsulfoxide, ‘NaBH₃(OAc)₃’ means sodium triacetoxyborohydride, ‘DMA-DMF’ means N,N-dimethylformamidedimethylacetal, ‘v/v’ means volume/volume percent, ‘T’ means temperature, ‘TLC’ means thin layer chromatography, ‘iPrNH₂’ means isopropylamine, ‘2nd generation Xphos precatalyst’ means (chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II)).

It is well known to one skilled in the art that protecting groups such as TBDMS can routinely be removed with TBAF in a variety of solvents such as for example THF. Similarly, conditions for removal of BOC protecting groups are well known to one skilled in the art, commonly including for example TFA in a solvent such as for example DCM, or HCl in a solvent such as for example dioxane.

The skilled person will realize that in some cases where an organic layer was obtained at the end of an experimental protocol, it was necessary to dry the organic layer with a typical drying agent such as for example MgSO₄, or by azeotropic distillation, and to evaporate the solvent before using the product as a starting material in the next reaction step.

A. Preparation of the Intermediates Example A1 Preparation of Intermediate 1

To a solution of 2,4-dibromo-6-cyanoaniline (200.00 g, 724.82 mmol) and DMAP (17.71 g, 144.96 mmol) in DCM (3 L), Boc₂O (474.58 g, 2.17 mol) was added and the reaction mixture was stirred at 45° C. for 4 h. The crude mixture was successively washed with saturated NaHCO₃ (2×1 L) and brine (2×1 L), dried over MgSO₄, filtered and concentrated under vacuum to give 323 g of intermediate 1 (56% yield, yellow solid, 86% purity evaluated by LC/MS). The product was used in the next step without any further purification.

Preparation of Intermediate 2

A mixture of intermediate 1 (620.00 g, 1.30 mol) and K₂CO₃ (539.02 g, 3.90 mol) in MeOH (6 L) was stirred at 65° C. for 3 h. The reaction mixture was cooled to 25° C. filtered and concentrated under vacuum. Then, the residue was dissolved in EtOAc (4 L) and the organic layer was washed with brine (2 L), dried over MgSO₄, and filtered. The filtrate was evaporated under vacuum to 1/8 solvent, filtered to collect the solid and dried under reduced pressure to give 300 g of intermediate 2 (60% yield, yellow solid). The product was used in the next step without any further purification.

Preparation of Intermediate 3

Intermediate 2 (100.00 g, 265.93 mmol), 2-(((tert-butyl-dimethyl-silanyl)oxy) methyl) prop-2-en-1-ol (80.72 g, 398.90 mmol) and tributylphosphane (107.61 g, 531.86 mmol) were dissolved in THF (2 L) and cooled to 0° C. A solution of (NE)-N-(piperidine-1-carbonylimino) piperidine-1-carboxamide (147.61 g, 585.05 mmol) in THF (50 mL) was added dropwise under N₂ and stirred at 0° C. for 1 h, then 25° C. for 12 h. The resulting mixture was triturated with petroleum ether (3 L), filtered and concentrated under vacuum. Then, the residue was dissolved in EtOAc (6 L), washed successively with water (2×2 L) and brine (2×2 L), dried over MgSO₄, filtered and concentrated under vacuum. Three reactions (each 100 g) were carried out in parallel. The resulting residues were purified by column chromatography on silica gel (SiO₂, mobile phase: petroleum ether/EtOAc, 10:1). The desired fractions were collected and the solvent was concentrated to dryness under vacuum to give 350 g of intermediate 3 (78% yield, yellow oil).

Preparation of Intermediate 3a

Triethylamine (196.3 mL; 1.408 mol) was added to a solution of 2-(((tert-butyl-dimethyl-silanyl)oxy) methyl) prop-2-en-1-ol (114 g, 563.3 mmol) in DCM (IL) at 0° C. Methanesulfonylchloride (56.0 mL; 704.2 mmol) was added slowly to the mixture and this mixture was stirred for 2 h at 0° C. The reaction was quenched with saturated aqueous solution of NaHCO₃ (100 ml) and extracted with DCM (500 ml*2). The organic layer was dried over MgSO₄, filtered, and concentrated under vacuum. The residue was purified by silica gel chromatography (Petroleum ether/ethyl acetate from 0/100 to 5/1) to give 50 g (32%; light yellow oil) of intermediate 3a.

Alternative Preparation of Intermediate 3a

A solution of 1,3-Hydroxy-2-methylenepropane (100 g) in dry THF (200 mL) was added dropwise at 0° C. to a suspension of sodium hydride (0.95 eq.) in dry THF (600 mL). After 30 min a solution of tert-butyldimethylsilylchloride (0.95 eq.) in dry THF (200 mL) was added dropwise to the mixture. After approximately 18 hours at 0-5° C. the reaction was complete by GC and water (500 mL) was added slowly keeping the temperature between 0-5° C. After phase separation, the aqueous layer was back-extracted with ethyl acetate (500 mL) and the combined organic layers were washed with water (500 mL). The organic phase was concentrated to a residue which was azeotropically dried by co-evaporation with THF affording 252.7 g of the crude monoTBDMS-protected diol. A portion of the crude monoTBDMS-protected diol (152.4 g) was dissolved in dry dichloromethane (610 mL) and triethylamine (1.4 eq.) was added. The mixture was then stirred at 0° C. for 30 min and methanesulfonic anhydride (1.2 eq.) was added as a solution in dichloromethane (950 mL) and the mixture was stirred for 1 h between −5 and 5° C. An additional aliquot of methanesulfonic anhydride (0.1 eq.) and triethylamine (0.2 eq.) were added and, after 1 additional hour, water (500 mL) was added. After phase separation, the organic layer was washed twice with water (500 mL) and concentrated to a residue, which was re-diluted with THF and partially concentrated to obtain a solution of intermediate 3a (311.1 g, 57 weight % intermediate 3a in the solution).

Alternative Preparation of Intermediate 3

Intermediate 2 (140 g; 372.3 mmol) was dissolved in acetonitrile (1.3 L). Intermediate 3a (104.4 g; 372.3 mmol), potassium carbonate (128.6 g; 930.7 mmol), and sodium iodide (5.58 g; 37.2 mmol) were added. The mixture was stirred at 80° C. for 12 h, cooled and concentrated under reduced pressure. The residue was dissolved in water (1 L) and extracted with ethyl acetate (1 L×2). The combined organic phase was washed with brine (1 L), dried over Na₂SO₄ and filtered. The filtrate was concentrated under vacuum to give a crude product. The residue was purified by silica gel chromatography (Petroleum ether/ethyl acetate from 100/0 to 40/1) to give 180 g (86%; clear oil) of intermediate 3.

Preparation of Intermediate 4 and intermediate 4′

A suspension of intermediate 3 (120.00 g, 214.14 mmol), sodium acetate (45.67 g, 556.76 mmol), sodium formate (37.86 g, 556.76 mmol), Pd(OAc)₂ (4.81 g, 21.41 mmol) and tetraethylammonium chloride (44.35 g, 267.67 mmol) in DMF (1.26 L) was degassed under vacuum, purged with Ar three times, and stirred at 85° C. for 2 h. The resulting mixture was filtered through a pad of Celite® and the solid was washed with DCM (2 L). The filtrate was concentrated under vacuum. The residue was dissolved in ethyl acetate (4 L), washed successively with water (2×2 L) and brine (2×2 L), dried over MgSO₄, filtered and concentrated under vacuum. Then, the residue was purified by column chromatography on silica gel (SiO₂, mobile phase: petroleum ether/EtOAc, 15:1). The desired fractions were collected and the solvent was concentrated to dryness under vacuum to give a mixture of intermediates 5 and 5′. Three reactions (each on 100-120 g of intermediate 3) were carried out in parallel which gave in total 160 g of a mixture of intermediates 4 and 4′ (38:62).

Alternative Preparation of Intermediate 4

To a mixture of intermediates 4 and 4′ in CH₃CN (1.60 L), 1-bromopyrrolidine-2,5-dione (212.20 g, 1.19 mol) was added and stirred at 40° C. for 16 h. The solvent was removed by evaporation under reduced pressure. The residue was dissolved in ethyl acetate (2 L), washed successively with NaHCO₃ (2×1 L) and brine (2×1 L), dried over MgSO₄ and filtered. The filtrate was evaporated under vacuum and purified by column chromatography on silica gel (SiO₂, mobile phase: petroleum ether/EtOAc, 50:1). The desired fractions were collected and the solvent was concentrated to dryness under vacuum to give 110.00 g of intermediate 4 (56% yield, yellow oil, 97% purity evaluated by LC/MS).

Alternative Preparation A of Intermediate 4′

To a solution of intermediate 3 (295.00 g, 473.70 mmol), sodium acetate (101.05 g, 1.23 mol), sodium formate dihydrate (128.15 g, 1.23 mol) and [1,1′-bis(diphenylphosphino) ferrocene] palladium, (II) chloride complex with dichloromethane (19.34 g, 23.70 mmol) in DMF (2 L), tetra-N-butylammonium chloride (164.60 g, 592.20 mmol) was added under N₂ at rt. The reaction mixture was stirred overnight at 60° C., then, filtered through a pad of Celite® and the solid was washed with DCM (400 mL). The filtrate was concentrated under vacuum. The resulting residue was dissolved in EtOAc (4 L) and the organic layer was washed successively with water (2 L) and brine (2 L), dried over Na₂SO₄, filtered and concentrated to give the crude product as black oil. This residue was purified by column chromatography on silica gel (SiO₂, mobile phase: petroleum ether/EtOAc, gradient from 100:0 to 10:1). The desired fractions were collected and the solvent was concentrated to dryness under vacuum to give 155 g of intermediate 4′ (70% yield, yellow oil).

Alternative Preparation B of Intermediate 4′

Intermediate 242 (50.0 g) was dissolved in DMF (250 mL). Sodium formate dehydrate (2.6 eq.), sodium acetate (2.6 eq.), tetraethylammonium chloride (1.25 eq.) and palladium acetate (0.05 eq.) were added. The mixture was degassed with nitrogen (3 times) and was then warmed at 45-50° C. until complete conversion (typically 24 hours monitored by HPLC). Water (350 mL) was then added followed by heptane (350 mL). The mixture was filtered and, after phase separation, the aqueous layer was extracted with heptane (350 mL). The combined organic layers were washed with water (250 mL) and then filtered on a diatomite pad (25 g; diatomaceous earth). The filtrate was concentrated to 100-150 mL, cooled to −10 to −5° C. for 2 hours and filtered to afford 37.6 g of intermediate 4′. An additional amount of intermediate 4′ could be recovered by filtering the mother liquors on a silica gel pad to remove impurities, and subsequently cool down the filtrate to −10° C. to crystallize out an additional amount of intermediate 4′.

Preparation of Intermediate 4′R

Intermediates 4′R was obtained from a chiral chromatography separation of intermediate 4′ (column CHIRALPAK IC 5 cm*25 cm; mobile phase: hexane/EtOH:80/20; Flow rate: 60.0 mL/min; Wavelength: UV 254 nm; Temperature: 35° C.).

Preparation of Intermediate 4R and intermediate 4S

Intermediate 4 (500 g) was purified via Normal Phase Chiral separation (Stationary phase: Daicel Chiralpak IC 2000 gram 10 microhm, mobile phase: heptane/EtOH, Isocratic 80% heptane, 20% EtOH). The fractions containing the products were mixed and concentrated to afford 266 g of intermediate 4R (53% yield, ee>98%) and 225 g of intermediate 4S (45% yield, ee>98%).

Alternatively, intermediate 4 (10 g) was purified by chiral SFC (Stationary phase: CHIRALPAK IC 5 m 250×30 mm, mobile phase: 85% CO₂, 15% iPrOH). The pure fractions were collected and evaporated to dryness yielding 4.3 g of intermediate 4R (43% yield, ee=100%) and 4.5 g of intermediate 4S (45% yield, ee=100%).

Alternative Preparation of Intermediate 4R

To a solution of intermediate 4′R (10.0 g) in ACN (100 mL) 1,3-dibromo-5,5-dimethylhydantoin (0.75 eq.) was added and the mixture was stirred at 20° C. for 24-28 hours, monitoring the conversion by HPLC. After complete conversion, aqueous 5% NaHCO₃ was added (250 mL) and the mixture was stirred for 30 minutes. Toluene (250 mL) was then added and, after 30 min stirring at room temperature, the mixture was allowed to settle and the layers were separated. The organic layer was washed twice with water (100 mL) and used directly in the next step (conversion 99.6%).

Example A2 Preparation of Intermediate 5

To a solution of intermediate 4 (127.00 g, 234.70 mmol) in 1,4-dioxane (1.2 L), bis(pinacolato)diboron (74.50 g, 293.40 mmol) and potassium acetate (69.11 g, 704.24 mmol) were added. Then, [1,1′-bis(diphenylphosphino) ferrocene] palladium, (II) chloride (8.59 g, 11.74 mmol) was added and stirred for 4 h at 85° C. under N₂ atmosphere. The mixture was cooled, partitioned between EtOAc (2 L) and water (500 mL) and filtered through a pad of Celite®. The organic and aqueous layers were separated. The organic layer was washed successively with water (300 mL), brine (300 mL), dried over Na₂SO₄ and concentrated under vacuum. The residue was dissolved in a mixture of DCM/EtOAc (90:10, 600 mL), filtered through a plug of flash silica gel, washed with DCM/EtOAc (90:10, 3 L). The filtrate was evaporated to give 125 g of crude intermediate 5 (brown oil) which was directly engaged in the next step.

Preparation of Intermediate 5R

To a solution of intermediate 4R (20.00 g, 41.50 mmol) in 1,4-dioxane (200 mL), bis(pinacolato)diboron (13.20 g, 51.90 mmol) and potassium acetate (12.20 g, 124.60 mmol) were added. Then, [1,1′-bis(diphenylphosphino) ferrocene] palladium, (II) chloride complex with dichloromethane (1.70 g, 2.08 mmol) was added and stirred for 4 h at 85° C. under N₂. The mixture was cooled, partitioned between EtOAc (200 mL) and water (100 mL), and filtered through a pad of Celite®. The organic and aqueous layers were separated. The organic layer was washed successively with water (100 mL), brine (100 mL), dried over Na₂SO₄, and concentrated under vacuum. The residue was dissolved in a mixture of DCM/EtOAc (90:10, 200 mL), filtered through a plug of flash silica gel and washed with a mixture of DCM/EtOAc (90:10, 1 L). The filtrate was evaporated to give 25 g of crude intermediate 5R (brown oil) which was directly engaged in the next step.

Preparation of Intermediate 6

A solution of intermediate 5 (160.00 g, 302.70 mmol) in 1,4-dioxane (1.2 L) was treated with a solution of NaHCO₃ (76.30 g, 908.10 mmol) in water (400 mL). Then, 2,4-dichloropyrimidine (67.64 g, 545.06 mmol) and Pd(PPh₃)₄ (17.50 g, 15.13 mmol) were added under N₂. The reaction mixture was stirred at 80° C. under N₂. The mixture was cooled, partitioned between EtOAc (2 L) and water (800 mL), and the mixture was filtered through a pad of Celite®. The organic and aqueous layers were separated. The organic layer was washed successively with water (800 mL) and brine (500 mL), dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash column chromatography on silica gel (SiO₂, mobile phase: petroleum ether/EtOAc, gradient from 100:0 to 10:1). The desired fractions were collected and the solvent was concentrated to dryness under vacuum to give 100 g of intermediate 6 (71% yield in 2 steps, yellow solid).

Preparation of Intermediate 6R and intermediate 6S

Intermediate 6 (52.00 g) was purified by chiral SFC (stationary phase: CHIRALPAK IC 5 m 250×30 mm, mobile phase: 60% CO₂, 40% MeOH). The desired fractions were collected and the solvent was concentrated to dryness under vacuum to give 25 g of intermediate 6R (48% yield) and 25.1 g of intermediate 6S (48% yield).

Intermediate 6R (50.10 g) was further purified by chiral SFC (stationary phase: CHIRALPAK IA 5 m 250*20 mm, mobile phase: 87.5% CO₂, 12.5% MeOH). The pure fractions were mixed and the solvent was evaporated to afford 49.10 g of intermediate 6R.

Alternative Preparation A of Intermediate 6R

A solution of intermediate 5R (25.00 g, 41.90 mmol) in 1,4-dioxane (1.2 L) was treated with a solution of NaHCO₃ (10.50 g, 125.72 mmol) in water (80 mL). Then, 2,4-dichloropyrimidine (9.36 g, 62.86 mmol) and Pd(PPh₃)₄ (2.42 g, 2.09 mmol) were added under N₂. The reaction mixture was stirred at 80° C. under N₂. The mixture was cooled, partitioned between EtOAc (300 mL) and water (100 mL), and filtered through a pad of Celite®. The organic layer was washed with water (100 mL), brine (100 mL), dried over Na₂SO₄ and concentrated under vacuum. The resulting residue was combined with 3 other batches coming from reactions performed on 25 g of intermediate 5R. The residue was purified by flash column chromatography on silica gel (SiO₂, mobile phase: petroleum ether/EtOAc, gradient from 100:0 to 10:1). The desired fractions were collected and the solvent was concentrated to dryness under vacuum to give 63 g of intermediate 6R (70% yield over 2 steps, yellow solid).

Alternative Preparation B of Intermediate 6R

To a solution of intermediate 4R (50.0 g) in toluene (400 mL) was added bis(pinacolato)diboron (1.3 eq.), potassium acetate (3.0 eq.) and Pd(dppf)Cl₂ (0.05 eq.). The mixture was degassed 3 times with nitrogen and heated to 90° C. for 12-14 hours. Subsequently, the mixture was cooled to room temperature and filtered on a celite pad which was washed with toluene (150 mL). The filtrate was washed with water (250 mL) and was then filtered on a silica pad (10 g) to afford a toluene solution containing 49 g of intermediate 5R. To this solution was added 2,4-dichloropyrimidine (1.5 eq.), NaHCO₃ (3.0 eq.), water (25 mL) and Pd(PPh₃)₄ (0.05 eq.). After degassing three times with nitrogen, the mixture was stirred at 90° C. monitoring the conversion by HPLC. After complete conversion (24-48 hours), the mixture was cooled to room temperature, filtered on a celite pad and washed with water (250 mL). To the organic layer was added silica thiol scavenging resin (10 g) and the mixture was stirred at 90° C. for 3 hours, then cooled to room temperature and filtered. The solvent was switched completely to isopropanol by repeated distillation until about 100 mL of isopropanol solution remained. The solution was warmed to 50° C. and 250 mL of methanol were added. After stirring at 50° C. for 4 hours, the mixture was cooled to 0° C. in 4 h, held at the same temperature for 16 hours and finally filtered to obtain 26 g of intermediate 6R.

Preparation of Intermediate 29

To a solution of intermediate 7 (1.50 g, 2.91 mmol) in DCM (30 mL), TFA (7 mL, 91.50 mmol) was added at 0-5° C. and stirred at 0-5° C. for 1 h, then rt for 1 h. The crude product was poured in a mixture of crushed ice and a saturated aqueous solution of NaHCO₃. After extraction with DCM (twice), the organic layers were combined, washed with a saturated solution of NaHCO₃, dried over MgSO₄ and concentrated under vacuum. The residue was purified by column chromatography on silica gel (Irregular SiOH, 40 m, mobile phase: NH₄OH/MeOH/DCM, gradient from 0% NH₄OH, 0% MeOH, 100% DCM to 0.1% NH₄OH, 2% MeOH, 98% DCM). The desired fractions were collected and the solvent was concentrated to dryness under vacuum to give 524 mg of intermediate 7 (65% yield).

Example A3 Preparation of Intermediate 305

In a three neck round bottom flask, SiO₂ (35-70 m) (200 g) was added to a solution of intermediate 6R (45.00 g, 87.36 mmol) in toluene (640 mL) at rt. The reaction mixture was reflux (bath temperature 125° C.) for 6 h under mechanical agitation. Then, SiO₂ (35-70 m) was filtered off, washed successively with THF and EtOAc, and the filtrate was evaporated to dryness to give 37.2 g of crude intermediate 305 which was directly engaged in the next steps.

Alternative Preparation of Intermediate 305

TFA (135 mL, 1.76 mol) was added dropwise at −10° C. (over 50 min) to a solution of intermediate 6R (20.00 g, 38.82 mmol) in DCM (550 mL). The reaction mixture was stirred below 0° C. for 15 min more, then poured in a mixture of crushed ice and a saturated aqueous solution of K₂CO₃. After extraction with DCM (twice), the organic layers were combined, washed with an aqueous solution of K₂CO₃, dried over MgSO₄ and evaporated to dryness. The residue (17.40 g) was purified by chromatography on silica gel (irregular SiOH, 80 g, mobile phase: NH₄OH/MeOH/DCM, gradient from 0% NH₄OH, 0% MeOH, 100% DCM to 0.2% NH₄OH, 2% MeOH, 98% DCM). The desired fractions were collected and the solvent was concentrated to dryness under vacuum to give 12.1 g of intermediate 305 (75% yield).

Example A4 Preparation of Intermediate 436

To a solution of intermediate 5 (3.89 g, 4.92 mmol), 5-fluoro-2,4-dichloropyrimidine (1.07 g, 6.40 mmol) and Cs₂CO₃ (4.81 g, 14.80 mmol) in 1,4-dioxane (25 mL) and distilled water (2.5 mL), Pd(PPh₃)₄ (0.28 g, 0.25 mmol) was added and the reaction mixture was heated overnight at 95° C. The mixture was poured into ice and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO₄, filtered and the solvent was evaporated. The residue was purified by column chromatography on silica gel (240 g, 15-40 μm, mobile phase: heptane/EtOAc, gradient from 1:0 to 0:1). The pure fractions were mixed and the solvent was evaporated to give 1.92 g of intermediate 436 (73% yield).

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials.

Intermediate Mass Yield number Structure (mg) (%) Intermediate 439

1820 83

Example A5 Preparation of Intermediate 7

A mixture of intermediate 6 (2.00 g, 3.88 mmol), 1-methyl-1H-pyrazol-3-amine (565.60 mg, 5.82 mmol) and Cs₂CO₃ (3.79 g, 11.65 mmol) in 1,4-dioxane (40 mL) was purged with N₂. Then Pd(OAc)₂ (87.17 mg, 0.39 mmol) and BINAP (241.76 mg, 0.39 mmol) were added. The mixture was purged with N₂ and stirred at 95° C. for 18 h. An extraction was performed with EtOAc and water. The organic layer was washed with brine, dried and evaporated to give 2.96 g of intermediate 7 (quant. yield, 75% purity based on LC/MS, brown foam) and used as it in the next step.

The intermediates in the Table below were prepared by using an analogous method starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 9

574 brown solid Quant. Intermediate 11

865 (66% purity based on LC/MS) brown solid Quant. Intermediate 13

650 (86% purity based on LC/MS) brown solid Quant. Intermediate 16

350 230 (contaminated by impurities) 56 37 Intermediate 19

280 44 Intermediate 21

304 yellow foam 53 Intermediate 23

272 44 Intermediate 25

311 (78% purity based on LC/MS) 49 Intermediate 27

498 (62% purity based on LC/MS) 48 Intermediate 36

477 viscous oil 78 with T = 90° C. Intermediate 38

482 82 Intermediate 45

208 orange solid 56 with T = 90° C. Intermediate 46

2000  (84% purity based on LC/MS) orange foam Quant. Intermediate 50

505 (80% purity based on NMR) — Intermediate 65

100 27 Intermediate 97

365 brown oil Quant. Intermediate 99

5530  (85% purity based on LC/MS) 90 with T = 110° C. Intermediate 116

24300  (75% purity based on LC/MS) 11100  43 20 T = 120° C. Intermediate 184′ (mixture of 2 diastereoisomers)

560 (58% purity based on LC/MS) 45 T = 120° C. Intermediate 197

397 orange powder 74 with T = 90° C. Intermediate 221

3300  69 T = 120° C. Intermediate 226

2800  68 T = 120° C. Intermediate 234

445 65 T = 120° C. Intermediate 237

2990  49 T = 120° C. Intermediate 243

5111  62 T = 120° C. Intermediate 248

4150  (86% purity based on LC/MS) 58 T = 120° C. Intermediate 277

2300  (64% purity based on LC/MS) 61 T = 120° C. Intermediate 280

730 (92% purity based on LC/MS) 27 T = 120° C. Intermediate 290

4510  (92% purity based on LC/MS) 61 T = 90° C. Intermediate 301

1310  (81% purity based on LC/MS) brown foam Quant. T = 90° C. Intermediate 309

881 brown residue 76 T = 90° C. Intermediate 313

760 yellow oil 94 T = 90° C. Intermediate 317

765 (84% purity based on LC/MS) brown oil 63 T = 90° C. Intermediate 321

301 brown oil 56 T = 90° C. Intermediate 325

534 yellow residue 84 T = 90° C. Intermediate 329

578 73 T = 120° C. Intermediate 333

244 yellow foam 51 T = 90° C. Intermediate 339

178 pale yellow foam 29 T = 85° C. Intermediate 343

370 40 T = 120° C. Intermediate 347

615 77 T = 120° C. Intermediate 360

250 yellow oil 68 T = 90° C. Intermediate 364

578 71 T = 120° C. Intermediate 368

475 yellow residue 42 T = 90° C. Mixture of Intermediate 372 and intermediate 373

400 (85% purity based on LC/MS) Ratio 372/373: 56/44 37 T = 120° C.

Intermediate 377

3600  87 T = 120° C. Intermediate 381

175 pale yellow solid 35 T = 90° C. Intermediate 384

600 (82% purity based on LC/MS) 65 T = 120° C. Intermediate 388

398 62 T = 120° C. Intermediate 402

430 yellow solid 49 T = 90° C. Intermediate 421

348 50 T = 90° C. Intermediate 425

320 51 T = 120° C. Intermediate 429

520 65 T = 120° C. Intermediate 432

300 37 T = 120° C. Intermediate 442

276 (90% purity based on LC/MS) foam Quant. T = 100° C. Intermediate 444

412 yellow foam 89 T = 100° C. Intermediate 446

280 50 T = 100° C. Intermediate 448

700 (59% purity based on LC/MS) black foam Quant. Intermediate 450

465 yellow solid 90 T = 100° C. Intermediate 458

790 88 T = 90° C. Intermediate 462

376 53 T = 90° C. Intermediate 466

435 pale yellow foam 80 T = 90° C. Intermediate 477

452 white foam 75 T = 90° C. Intermediate 481

580 yellow solid 54 T = 90° C. Intermediate 485

377 50 T = 120° C. Intermediate 501

674 brown residue 53 T = 90° C. Intermediate 552

833 25 T = 90° C. Intermediate 697

200 52 T = 85° C. 48 h Intermediate 723

290 82 T = 100° C. 2 h Intermediate 736

 80 21 Intermediate 744

4450  85 Schlenk 120° C. for 90 min

Example A6 Preparation of Intermediate 33

Intermediate 6 (500.00 mg, 0.971 mmol), 1-(1-methyl-4-piperidyl)pyraol-4-amine (279.93 mg, 1.55 mmol), Pd(OAc)₂ (21.79 mg, 97.06 μmol), BINAP (60.44 mg, 97.06 mol) and Cs₂CO₃ (948.76 mg, 2.91 mmol) in 1,4-dioxane (19.87 mL, 232.95 mmol) in a sealed tube were stirred at 120° C. using one single mode microwave (Biotage Initiator EXP 60® with a power output ranging from 0 to 400 W for 30 min). The reaction mixture was poured onto water and DCM, filtered over Celite®. The filtrate was decanted and the organic layer was dried over MgSO₄, filtered and evaporated. The residue was purified by column chromatography on silica gel (Irregular SiOH, 40 m, mobile phase: gradient from 100% DCM to 97% DCM, 3% MeOH, 0.1% NH₄OH). The pure fractions were combined and the solvent was evaporated to give 375 mg of intermediate 33 (yield 59%).

The intermediates in the Table below were prepared by using an analogous method starting from the respective starting materials. For the synthesis of these intermediates, a one single mode microwave was used (Biotage Initiator EXP 60® with a power output ranging from 0 to 400 W for 30 min or alternatively an Anton Parr monowave 300® with a power output ranging from 0 to 850 W for 30 min).

Int. number Structure Mass (mg) Yield (%) Intermediate 40

500 83 Intermediate 42

474 75 Intermediate 48

450 (88% purity based on LC/MS) 68 Intermediate 54

220 36 Intermediate 58

516 84 Intermediate 60

585 Quant. Intermediate 63

305 45 Intermediate 68

369 60 Intermediate 71

212 30 Intermediate 73

610 (93% purity based on LC/MS) 95 Intermediate 75

468 77 Intermediate 77

229 39 Intermediate 79

460 78 Intermediate 81 (mixture of 2 distereoisomers)

411 (91% purity based on LC/MS) 61 Intermediate 85

386 54 Intermediate 87

410 72 Intermediate 89

410 64 Intermediate 91

130 (88% purity based on LC/MS) 20 Intermediate 93

650 99 Intermediate 95

544 91 Intermediate 95

260 44 Intermediate 104

440 (70% purity based on LC/MS) 59 Intermediate 106

537 (92% purity based on LC/MS) 86 Intermediate 108

2300  (62% purity based on LC/MS) 47 Intermediate 110

980 80 Intermediate 112

229 39 Intermediate 119

287 42 Intermediate 122

1000  78 Intermediate 124

653 — Intermediate 126

1310  Quant. Intermediate 128

370 60 Intermediate 130

325 53 Intermediate 132

1130  92 Intermediate 136

540 (88% purity based on LC/MS) 72 Intermediate 139

395 53 Intermediate 143

600 92 Intermediate 146

227 35 Intermediate 148

300 46 Intermediate 150

586 91 Intermediate 152

320 21 Intermediate 154

107 16 Intermediate 157

410 94 Intermediate 160

618 96 Intermediate 164

830 63 Intermediate 167

814 62 Intermediate 168

350 (47% purity based on LC/MS) 31 Intermediate 172

545 (63% purity based on LC/MS) 91 Intermediate 174

275 25 Intermediate 178

375 (76% purity based on LC/MS) 25 Intermediate 180

455 (44% purity based on LC/MS) 31 Intermediate 193 Mixture of 2 diastereoisomers

680 53 Intermediate 201 Mixture of 2 diastereoisomers

1170  (66% purity based on LC/MS) 52 Intermediate 203

365 63 Intermediate 215

288 55 Intermediate 217

380 (89% purity based on LC/MS) 63 Intermediate 230 Mixture of 2 diastereoisomers

1050  (77% purity based on LC/MS) 80 Intermediate 257

 75 15 Intermediate 259

195 38 mixture of Intermediate 265 and intermediate 266

340 62

Intermediate 271

880 98 Intermediate 294

790 61 Intermediate 297

430 (75% purity based on LC/MS) 50 Intermediate 353

245 39 Intermediate 356

290 63 Intermediate 392

630 51 Intermediate 396

1050  brown residue 71 Intermediate 411

135 31 Intermediate 415

711 88 Intermediate 437

382 86 Intermediate 440

335 75 Intermediate 454

266 (73% purity based on LC/MS) 85 Intermediate 473

517 61 Intermediate 493

900 (78% purity based on LC/MS) 98 Intermediate 497

120 64 Intermediate 510

343 59 Intermediate 515

675 Quant. Intermediate 519

565 77 Intermediate 523

247 34 Intermediate 527

270 34 Intermediate 531

258 25 Intermediate 535

170 50 Intermediate 539

479 64 Intermediate 543

870 Quant. Intermediate 547

368 53 Intermediate 570

3800  81 Intermediate 571

235 59 Intermediate 575

215 41 Intermediate 586

142 62 Intermediate 589

170 (80% purity based on LC/MS) 66 Intermediate 593

810 83 Intermediate 599

680 (86% purity based on LC/MS) 100  Intermediate 603

440 66 Intermediate 608

350 63 Intermediate 614

280 43 Intermediate 618

293 89 Intermediate 622

230 31 Intermediate 626

 80 16 Intermediate 630

720 90 Intermediate 638

233 (92% purity based on LC/MS) 87 Intermediate 648

819 (53% purity based on LC/MS) 100  Intermediate 653

182 (72% purity based on LC/MS) 93 Intermediate 660

540 83 Intermediate 664

420 68 Intermediate 670

240 (85% purity based on LC/MS) 17 Intermediate 676

510 75 Intermediate 682

816 (81% purity based on LC/MS) 90 Intermediate 688

227 76 Intermediate 690

600 70 Intermediate 694

440 76 Intermediate 705

405 47 Intermediate 710

180 18 Intermediate 716

103 24 Intermediate 719

550 100  Intermediate 727

266 53 Intermediate 765

260 (74% purity based on LC/MS) 92

Example A7 Preparation of Intermediate 306

In a sealed tube, a solution of intermediate 305 (350.00 mg, 0.84 mmol), intermediate 304 (275.12 mg, 1.52 mmol) and Cs₂CO₃ (686.90 mg, 2.11 mmol) in dry Me-THF (8.40 mL) was purged with N₂. Pd(OAc)₂ (18.90 mg, 84.30 μmol) and BINAP (52.50 mg, 84.30 μmol) were added. The mixture was purged with N₂ and heated at 85° C. for 3 h. After cooling down to rt, the mixture was filtered over a pad of Celite®. The cake was washed with EtOAc and the filtrate was evaporated in vacuo. The residue (752 mg, brown oil) was purified by column chromatography on silica gel (irregular SiOH, 15-40 m, 30 g, mobile phase: DCM/EtOAc, gradient from 100:0 to 50:50). The pure fractions were combined and evaporated to dryness to give 387 mg of intermediate 306 as an orange oil used as it in the next step.

The intermediates in the Table below were prepared by using an analogous method starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’

Int. number Structure Mass (mg) Yield (%) Intermediate 470

 323 71 Intermediate 505

 364 38 with T = 90° C. Intermediate 581

 244     2410 (crude) With T = 120° C. 26 25 Intermediate 643

4000 54

Example A8 Preparation of Intermediate 343

In a sealed tube, a mixture of intermediate 6 (0.30 g, 0.58 mmol), 5-methyl-1,3,4-oxadiazol-2-ylamine (63.50 mg, 0.64 mmol) and Cs₂CO₃ (569.00 mg, 1.75 mmol) in THF (6 mL) was purged with N₂. Then, chloro[2-(dicyclohexylphosphino)-3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl][2-(2-aminoethyl)phenyl] palladium (II) (47.00 mg, 58.20 μmol) and BRETTPHOS (31.00 mg, 58.20 μmol) were added. The mixture was purged with N₂ and stirred at 95° C. for 5 h 30 min. Further chloro[2-(dicyclohexylphosphino)-3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl][2-(2-aminoethyl)phenyl] palladium (II) (47.00 mg, 58.20 μmol) and BRETTPHOS (31.00 mg, 58.20 μmol) were added and the mixture was purged again with N₂ and stirred at 95° C. for 20 h. The reaction mixture was diluted with EtOAc and water. The layers were separated and the aqueous layer was extracted twice with EtOAc. The combined organic layers were dried over MgSO₄, filtered and the solvent was removed under reduced pressure to give intermediate 343 as a brown solid used as it in the next step.

The intermediates in the Table below were prepared by using an analogous method starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 31

259 41 with T = 90° C.

Example A9 Preparation of Intermediate 8

A mixture of intermediate 7 (2.96 g, 3.86 mmol) in a mixture of TFA (7 mL) and DCM (40 mL) was stirred at rt for 1 h and 20 min. The mixture was basified with a saturated aqueous solution of NaHCO₃. An extraction was performed with DCM. The organic layer was washed with brine, dried over MgSO₄, evaporated and purified by column chromatography on silica gel (irregular SiOH 15-40 m, 120 g, liquid injection with DCM, mobile phase: heptane/EtOAc, gradient from 100:0 to 0:100 in 15 CV). The fractions containing the product were combined and concentrated under vacuum to give 1.09 g of intermediate 8 (59% yield, white solid).

The intermediates in the Table below were prepared by using an analogous method starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 14

 165 yellow solid 36 Procedure with DCM/TFA (5:1, v/v) Intermediate 22

 143 yellow solid 57 Procedure with DCM/TFA (6.5:1, v/v) Intermediate 34

 370 — Procedure with DCM/TFA (4:1, v/v) Mixture of Intermediate 37 and compound 14

 430 (64% purity based on LC/MS; int. 37/ comp. 14 34/66) — Procedure with DCM/TFA (5:2, v/v) Intermediate 41

 385 (72% purity based on LC/MS) 92 Procedure with DCM/TFA (5:1, v/v) Intermediate 43

 333 83 Procedure with DCM/TFA (4:1, v/v) Intermediate 47

 350 white solid 25 Procedure with DCM/TFA (5:1, v/v) Intermediate 49

 264 (88% purity based on LC/MS) 62 Procedure with DCM/TFA (4:1, v/v) Intermediate 51

 256 yellow solid 82 Procedure with DCM/TFA (3:1, v/v) Intermediate 55

 107 56 Procedure with DCM/TFA (6:1, v/v) Intermediate 59

 343 (87% purity based on LC/MS) 79 Procedure with DCM/TFA (5:1, v/v) Intermediate 61

 291 63 Intermediate 64

 123 47 Procedure with DCM/TFA (5:2, v/v) Intermediate 69

 225 74 Intermediate 72

 112 61 Procedure with DCM/TFA (7:1, v/v) Intermediate 74

 350 (82% purity based on LC/MS) 74 Procedure with DCM/TFA (4:1, v/v) Intermediate 76

 100 27 Procedure with DCM/TFA (4:1, v/v) Intermediate 78

 112 24 Intermediate 80

 270 73 Procedure with DCM/TFA (4:1, v/v) Intermediate 82

 177 50 Procedure with DCM/TFA (4:1, v/v) Intermediate 86

 237 71 Intermediate 88

 108 32 Procedure with DCM/TFA (5:1, v/v) Intermediate 90

 160 (86% purity based on LC/MS) 46 Procedure with DCM/TFA (4:1, v/v) Intermediate 91

 210 (47% purity based on LC/MS) — Procedure with DCM/TFA (4:1, v/v) Intermediate 94

 419 (82% purity based on LC/MS) 76 Procedure with DCM/TFA (4:1, v/v) Intermediate 96

 300 (73% purity based on LC/MS) 66 Procedure with DCM/TFA (4:1, v/v) Intermediate 98

 132 yellow oil 48 Procedure with DCM/TFA (9:2, v/v) Intermediate 100

 2720 58 Procedure with DCM/TFA (9:2, v/v) Intermediate 102

 220 Quant. Procedure with DCM/TFA (4:1, v/v) Intermediate 105

 210 81 Procedure with DCM/TFA (4:1, v/v) Intermediate 107

 349 77 Procedure with DCM/TFA (7:1, v/v) Intermediate 109

 1240 (80% purity based on LC/MS) 64 Procedure with DCM/TFA (4:1, v/v) Intermediate 111

 761 92 Procedure with DCM/TFA (4:1, v/v) Intermediate 113

 146 76 Procedure with DCM/TFA (7:1, v/v) Intermediate 117

24000 80 Procedure with DCM/TFA (4:1, v/v) Intermediate 120

 118 48 Procedure with DCM/TFA (5:1, v/v) Intermediate 123

 810 95 Procedure with DCM/TFA (4:1, v/v) Intermediate 125

 273 50 Procedure with DCM/TFA (8:1, v/v) Intermediate 127

 676 63 Procedure with DCM/TFA (4:1, v/v) Intermediate 129

 171 55 Procedure with DCM/TFA (4:1, v/v) Intermediate 131

  72 (71% purity based on LC/MS) 26 Intermediate 133

 634 89% purity based on LC/MS) 67 Procedure with DCM/TFA (4:1, v/v) Intermediate 137

 370 91 Procedure with DCM/TFA (4:1, v/v) Intermediate 140

 227 67 Procedure with DCM/TFA (4:1, v/v) Intermediate 144

 296 (64% purity based on LC/MS) 58 Procedure with DCM/TFA (4:1, v/v) Intermediate 147

 218 54 Procedure with DCM/TFA (4:1, v/v) Intermediate 149

 169 66 Procedure with DCM/TFA (4:1, v/v) Intermediate 151

 354 71 Procedure with DCM/TFA (4:1, v/v) Intermediate 153

 179 66 Procedure with DCM/TFA (13:2, v/v) Intermediate 155

  65 71 Procedure with DCM/TFA (8:1, v/v) Intermediate 158

 250 71 Procedure with DCM/TFA (9:1, v/v) Intermediate 161

 376 72 Procedure with DCM/TFA (4:1, v/v) Intermediate 165

  47 58 Procedure with DCM/TFA (4:1, v/v) Intermediate 167

 505 73 Procedure with DCM/TFA (4:1, v/v) Intermediate 169

 110 (74% purity based on LC/MS) 27 Procedure with DCM/TFA (4:1, v/v) Intermediate 173

 195 (88% purity based on LC/MS) 43 Intermediate 175

 140 60 Procedure with DCM/TFA (4:1, v/v) Intermediate 179

 205 64 Procedure with DCM/TFA (4:1, v/v) Intermediate 181

 190 49 Procedure with DCM/TFA (4:1, v/v) Intermediate 185 mixture of 2 diastereoisomers

 260 55 Procedure with DCM/TFA (4:1, v/v) Intermediate 188

 150 yellow oil 41 Procedure with DCM/TFA (5:1, v/v) Intermediate 190

 122 yellow oil 82 Procedure with DCM/TFA (5:1, v/v) Intermediate 194 Mixture of 2 disatereomers

 219 38 Procedure with DCM/TFA (4:1, v/v) Intermediate 198

 269 yellow oil 81 Procedure with DCM/TFA (10:1, v/v) Intermediate 202

 730 (69% purity based on LC/MS) 77 Procedure with DCM/TFA (4:1, v/v) Intermediate 204

 155 46 Procedure with DCM/TFA (5:1, v/v) Intermediate 206

 173 yellow oil 77 Procedure with DCM/TFA (5:1, v/v) Intermediate 208

 182 yellow oil 75 Procedure with DCM/TFA (5:1, v/v) Intermediate 210

 130 yellow oil 60 Procedure with DCM/TFA (5:1, v/v) Intermediate 216

 169 69 Procedure with DCM/TFA (7:1, v/v) Intermediate 218

 242 75 Procedure with DCM/TFA (12:1, v/v) Intermediate 222

 2000 72 Procedure with DCM/TFA (4:1, v/v) Intermediate 227

 1050 44 Procedure with DCM/TFA (4:1, v/v) Intermediate 231

 531 59 Procedure with DCM/TFA (4:1, v/v) Intermediate 235

 254 68 Procedure with DCM/TFA (5:1, v/v) Intermediate 238

 1530 61 Procedure with DCM/TFA (6:1, v/v) Intermediate 244

 2830 66 Procedure with DCM/TFA (4:1, v/v) Intermediate 249

 2050 59 Procedure with DCM/TFA (7:2, v/v) Intermediate 258

  30 47 Procedure with DCM/TFA (8:1, v/v) Intermediate 260

  52 32 Procedure with DCM/TFA (8:1, v/v) mixture of Intermediate 267 and intermediate 268

 189 65 Procedure with DCM/TFA (8:1, v/v)

Intermediate 278

 710 (30% purity based on LC/MS) 56 Procedure with DCM/TFA (4:1, v/v) Intermediate 281

 1073 (60% purity based on LC/MS) — Procedure with DCM/TFA (4:1, v/v) Intermediate 291

 2860 (75% purity based on LC/MS) yellow solid 75 Procedure with DCM/TFA (10:1, v/v) Intermediate 295

 308 46 Procedure with DCM/TFA (4:1, v/v) Intermediate 310

 530 71 Procedure with DCM/TFA (5:1, v/v) Intermediate 314

 425 yellow oil 66 Procedure with DCM/TFA (10:1, v/v) Intermediate 318

 511 orange oil 78 Procedure with DCM/TFA (5:1, v/v) Intermediate 322

 119 yellow oil 47 Procedure with DCM/TFA (5:1, v/v) Intermediate 326

 243 (85% purity based on LC/MS) white solid 55 Procedure with DCM/TFA (10:1, v/v) Intermediate 334

 209 orange foam Quant. Procedure with DCM/TFA (10:1, v/v) Intermediate 340

 114 pale yellow solid 75 Procedure with DCM/TFA (10:1, v/v) Intermediate 354

 168 81 Procedure with DCM/TFA (7:1, v/v) Intermediate 357

 116 47 Procedure with DCM/TFA (6:1, v/v) Intermediate 361

 160 yellow residue 75 Procedure with DCM/TFA (6:1, v/v) Intermediate 369

 293 yellow residue 72 Procedure with DCM/TFA (10:1, v/v) Intermediate 382

  86 white solid 58 Procedure with DCM/TFA (10:1, v/v) Intermediate 397

 582 (65% purity based on LC/MS) yellow residue 68 (over 2 steps) Procedure with DCM/TFA (5:1, v/v) Intermediate 403

 284 yellow residue 76 Procedure with DCM/TFA (10:1, v/v) Intermediate 406

 170 yellow solid 48 Procedure with DCM/TFA (4:1, v/v) Intermediate 422

 210 70 Procedure with DCM/TFA (5:1, v/v) Intermediate 438

 390 Quant. Procedure with DCM/TFA (9:1, v/v) Intermediate 441

 396 Quant. Intermediate 443

 138 yellow solid 60 Procedure with DCM/TFA (10:1, v/v) Intermediate 445

 245 foam 72 Procedure with DCM/TFA (10:1, v/v) Intermediate 447

 220 orange solid 95 Procedure with DCM/TFA (10:1, v/v) Intermediate 449

 195 white solid 56 Procedure with DCM/TFA (7:1, v/v) Intermediate 451

 394 Quant. Procedure with DCM/TFA (10:1, v/v) Intermediate 459

 454 68 Procedure with DCM/TFA (10:1, v/v) Intermediate 463

 243 yellow residue 74 Procedure with DCM/TFA (10:1, v/v) Intermediate 467

 233 white foam 63 Procedure with DCM/TFA (10:1, v/v) Intermediate 482

 400 yellow residue 81 Procedure with DCM/TFA (5:1, v/v) Intermediate 498

  75 73 Procedure with DCM/TFA (5:1, v/v) Intermediate 502

 310 54 Procedure with DCM/TFA (5:1, v/v) Intermediate 520

 277 58 Procedure with DCM/TFA (7:1, v/v) Intermediate 740

  62 (80% purity based on LC/MS) quant Procedure with DCM/TFA (9:1, v/v) 5° C. for 1 h

Example A10 Preparation of Intermediate 10

A mixture of intermediate 9 (335.00 mg, 0.58 mmol) and TBAF (1M in THF) (0.64 mL, 0.64 mmol) in THF (5 mL) was stirred at rt for 1 h. An extraction was performed with EtOAc and water. The organic layer was washed with brine, dried over MgSO₄ and evaporated to give 355 mg of intermediate 10 (quant. yield, yellow solid) which was used as it for the next step.

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 12

950 (48% purity based on LC/MS) yellow solid 99 From intermediate 11 Intermediate 17

161 56 Procedure with 1.2 equiv. of TBAF From intermediate 16 Intermediate 20

180 78 Procedure with 1.2 equiv. of TBAF From intermediate 19 Intermediate 24

171 77 Procedure with 1.9 equiv. of TBAF From intermediate 23 Intermediate 26

252 99 Procedure with 1.9 equiv. of TBAF From intermediate 25 Intermediate 28

219 53 Procedure with 1.2 equiv. of TBAF From intermediate 27 Intermediate 32

246 brown oil — Procedure with 2.2 equiv. of TBAF From intermediate 31 Intermediate 39

170 44 Procedure with 1.9 equiv. of TBAF From intermediate 39 Intermediate 66

74 90 Procedure with 1.9 equiv. of TBAF From intermediate 65 Intermediate 272

618 76 Procedure with 1.5 equiv of TBAF From intermediate 271 Intermediate 302

680 (80% purity based on ¹H NMR) 62 Procedure with 1.7 equiv of TBAF From intermediate 301 Intermediate 435

270 Quant. From intermediate 435 Intermediate 549

569 yellow powder 85 Procedure with 2 equiv. of TBAF From intermediate 552 Intermediate 553

544 yellow powder 85 Procedure with 2 equiv. of TBAF From intermediate 46 Intermediate 728

165 73 From intermediate 727

Example A11 Preparation of Intermediate 30

In a sealed glassware, a mixture of intermediate 29 (400.00 mg, 0.96 mmol), 2-(2-dimethylaminoethyl)-5-methyl-2H-pyrazole-3-ylamine (178.37 mg, 1.06 mmol) and Cs₂CO₃ (942.10 mg, 2.89 mmol) in dry 1,4-dioxane (20 mL) was purged with N₂. Then, Pd(OAc)₂ (21.64 mg, 96.40 mol) and BINAP (60.00 mg, 96.40 μmol) were added. The mixture was purged with N₂ and stirred at 95° C. for 2 h. The crude was combined with another batch (from 245 mg of intermediate 29) and an extraction was performed with EtOAc and water. The layers were separated and the organic layer was dried over MgSO₄, filtered and evaporated under reduced pressure. The residue (958 mg) was purified by column chromatography on silica gel (irregular SiOH 15-40 m, 80 g, dry loading on Celite®, mobile phase: DCM/(MeOH(+aq. 5% NH₃)) gradient from 100:0 to 90:10). The fractions containing the product were combined and concentrated to dryness to give 600 mg of intermediate 30 (quant. yield, brown solid) which was used as it in the next step.

The intermediates in the Table below were prepared by using an analogous method starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 35

255 yellow oil 72 with T = 100° C. From intermediate 29 and 1,5- dimethy1-1H-pyrazol-3-ylamine Intermediate 749

340 54 μw, 120° C., 30 min From intermediate 305 and 748 Intermediate 753

3380 40 120° C., 60 min From intermediate 305 and 752 Intermediate 761

112 59 μw, 120° C., 30 min From intermediate 305 and 760

Example A12 Preparation of Intermediate 186

In a sealed glassware, a mixture of intermediate 6R (2.00 g, 3.88 mmol), ethyl-(5-amino-3-methyl-1H-pyrazol-1-yl)acetate hydrochloride (938.20 mg, 4.27 mmol) and Cs₂CO₃ (5.10 g, 15.50 mmol) in dry 1,4-dioxane (80 mL) was purged with N₂. Then, Pd(OAc)₂ (87.20 mg, 0.39 mmol) and BINAP (241.80 mg, 0.39 mmol) were added. The mixture was purged with N₂ and stirred at 90° C. for 3 h. Then, lithium hydroxide monohydrate (244.40 mg, 5.82 mmol) and distilled water (11 mL) were added at room temperature for 2 h. The reaction mixture was combined with another batch (from 4 g of intermediate 6R) and the mixture was evaporated under reduced pressure to give a crude. The crude was purified by column chromatography on silica gel (irregular SiOH 15-40 μm, dry load on celiteR, mobile phase: DCM/(MeOH(+10% aq. AcOH)), gradient from 100:0 to 90:10). The fractions containing the product were combined and evaporated to dryness to give 5.98 g of intermediate 186 (81% yield, over 2 steps, brown solid).

Preparation of Intermediate 187

In a sealed tube, intermediate 186 (500.00 mg, 0.79 mmol) and N-isopropylmethylamine (0.14 mL, 1.34 mmol) were diluted in dry DMF (10 mL). Then, HATU (0.81 g, 2.13 mmol) and DIPEA (0.34 mL, 1.97 mmol) were added and the mixture was stirred at rt for 17 h. The reaction mixture was evaporated under reduced pressure and an extraction was performed with EtOAc. The organic layer was washed with brine and the layers were separated. The organic layer was dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel (irregular SiOH, 15-40 m, 30 g, dry load on Celite®, mobile phase: DCM/(MeOH(+10% aq. AcOH)), gradient from 100:0 to 90:10). The fractions containing the product were combined and evaporated to dryness to give 504 mg of intermediate 187 (93% yield, yellow residue).

The intermediates in the Table below were prepared by using an analogous method starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 189

173 31 From intermediate 186 and dicyclopropylamine hydrochloride Intermediate 205

260 brown residue 58 From intermediate 186 and 3,3- difluoroazetidine hydrochloride Intermediate 207

285 brown oil 66 From int. 186 and pyrrolidine Intermediate 209

255 yellow oil 59 From intermediate 186 and N- methylcyclopropanamine

Example A13 Preparation of Intermediate 298

SiO₂ (35-70 μm, 1.1 g) was added to a solution of intermediate 298 (400.00 mg, 0.45 mmol) in toluene (3.63 mL, 34.17 mmol) at rt. The resulting mixture was stirred at reflux for 2 h. After cooling down to rt, the reaction mixture was evaporated. The residue was purified by column chromatography on silica gel (Irregular SiOH, 40 m, 40 g, deposited solid, mobile phase gradient from 100% DCM to 96% DCM, 4% MeOH, 0.4% NH₄OH). The pure fractions were combined and the solvent was evaporated to give 275 mg of intermediate 298 (Quant. yield).

The intermediates in the Table below were prepared by using an analogous method starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 330

420 85 From intermediate 329 Intermediate 340

260 82 From intermediate 339 Intermediate 348

530 Quant. From intermediate 347 Intermediate 365

420 84 From intermediate 364 Intermediate 373

280 (51% purity based on LC/MS) 82 From intermediate 372 Intermediate 378

1620 (83% purity based on LC/MS) 53 From intermediate 377 Intermediate 385

517 (85% purity based on LC/MS) Quant. From intermediate 384 Intermediate 389

337 Quant. From intermediate 388 Intermediate 393

313 59 From intermediate 392 Intermediate 412

107 91 From intermediate 411 Intermediate 416

452 73 From intermediate 415 Intermediate 426

260 95 From intermediate 425 Intermediate 430

445 Quant. From intermediate 429 Intermediate 434

260 Quant. From intermediate 432 Intermediate 455

162 (30% purity based on LC/MS) 72 From intermediate 454 Intermediate 474

450 Quant. From intermediate 473 Intermediate 478

271 71 From intermediate 477 Intermediate 486

290 90 From intermediate 485 Intermediate 494

664 (74% purity based on LC/MS) 85 From intermediate 493 Intermediate 511

279 93 From intermediate 510 Intermediate 516

403 (100% purity based on LC/MS) 70 From intermediate 515 Intermediate 524

263 84 From intermediate 523 Intermediate 528

210 90 From intermediate 527 Intermediate 532

135 60 From intermediate 531 Intermediate 536

121 (45% purity based on LC/MS) 81 From intermediate 535 Intermediate 540

432 (57% purity based on LC/MS) Quant. From intermediate 539 Intermediate 544 (mixture of 2 distereoisomers)

684 92 From intermediate 543 Intermediate 548

253 80 From intermediate 547 Intermediate 572

3150 Quant. From intermediate 570 Intermediate 573

214 Quant. From intermediate 571 Intermediate 574

166 90 From intermediate 575 Intermediate 587

110 89 Reflux 2 h From intermediate 586 Intermediate 590

120 (80% purity based on LC/MS) 82 Reflux 2 h From intermediate 589 Intermediate 594

620 91 From intermediate 593 Intermediate 600

580 100 Reflux 4 h From intermediate 599 Intermediate 649

642 (90% purity based on LCMS) 92 Reflux 3 h From intermediate 648 Intermediate 604

375 100 Reflux 4 h From intermediate 603 Intermediate 609

370 100 Reflux 2 h From intermediate 608 Intermediate 615

224 95 Reflux 2 h From intermediate 614 Intermediate 619

251 100 Reflux 2 h From intermediate 618 Intermediate 623

202 100 From intermediate 622 Intermediate 627

68 100 Reflux 4 h From intermediate 626 Intermediate 631

620 Quant Reflux 4 h From intermediate 630 Intermediate 639

175 88 Reflux 1 h 30 mins From intermediate 638 Intermediate 655

118 86 90° C. 2 days From intermediate 654 Intermediate 661

410 89 Reflux (120° C.) 4 h From intermediate 660 Intermediate 665

420 68 Reflux 12 h From intermediate 664 Intermediate 671

220 (84% purity based on LC/MS) 88 With T = 120° C. 5 h From intermediate 670 Intermediate 677

510 75 Reflux 4 h From intermediate 676 Intermediate 683

605 87 With T = 120° C. 4 h From intermediate 682 Intermediate 689

86 45 With T = 120° C. 3 h From intermediate 688 Intermediate 691

231 45 With T = 120° C. 2 h From intermediate 690 Intermediate 695

380 82 Reflux 4 h From intermediate 694 Intermediate 698

172 100 Reflux 4 h From intermediate 697 Intermediate 706

300 87 Reflux 2 h From intermediate 705 Intermediate 711

154 100 With T = 120° C. 1 h 30 mins From intermediate 710 Intermediate 717

83 94 With T = 120° C. 4 h From intermediate 716 Intermediate 720

550 100 With T = 120° C. 3 h 20 mins From intermediate 719 Intermediate 724

170 68 With T = 90° C. 5 h From intermediate 723 Intermediate 737

45 (91% purity based on LC/MS) 66 With T = 90° C. 2 days From intermediate 736 Intermediate 745

4450 100 From intermediate 744 Intermediate 766

113 LCMS pure at 68% 51 From intermediate 765

Example A14 Preparation of Intermediate 550

In a dry 25 ml 3 neck round bottom flask, DCM (0.3 mL) was charged and cooled to −78° C., oxalyl chloride (0.92 mL, 1.85 mmol) was added followed by DMSO (0.26 mL, 3.70 mmol). After 1 h, a solution of intermediate 549 (0.57 g, 1.23 mmol) in solution in DCM (1.5 mL) was added dropwise. The mixture was stirred for 1 h at −78° C., before DIPEA (1.27 mL, 7.40 mmol) was added. Stirring was continued and then the mixture was allowed to warm to rt over 5 h. A diluted solution of NH₄Cl was added and the aqueous layer was extracted twice with DCM and the combined layers were dried over MgSO₄. After filtration and removal of the solvent in vacuo, 669 mg of intermediate 550 (Quant. yield, orange solid) were obtained and directly used in the next steps without any further treatment.

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials.

Int. number Structure Mass (mg) Yield (%) Intermediate 554

608 yellow solid Quant.

Preparation of Intermediate 551

A solution of intermediate 550 (0.30 g, 0.65 mmol), 2-[[(1,1-dimethylethyl) dimethylsilyl]oxy]-N-methyl-ethanamine (0.74 mg, 3.92 mmol), AcOH (224 μl, 3.92 mmol) and NaBH(OAc)₃ (1.38 g, 6.53 mmol) in dichloroethane (13.2 ml) was stirred at rt overnight. A saturated solution of NaHCO₃ was added and the aqueous layer was extracted with DCM. The organic layer was dried over MgSO₄ and evaporated to dryness. The residue (1240 mg, yellow oil) was purified by column chromatography on silica gel (irregular SiOH, 40 g, mobile phase: heptane/EtOAc, gradient from 100:0 to 50:50). The fractions containing the product were combined and evaporated to dryness to provide 152 mg of intermediate 551 (37% yield, yellow oil).

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials.

Int. number Structure Mass (mg) Yield (%) Intermediate 555

93 colorless oil 23 Intermediate 556

295 (57% purity based on LC/MS) yellow oil 79 Intermediate 557

201 (57% purity based on LC/MS) yellow oil 59

Example A15 Preparation of Intermediate 15 and intermediate 15′

Methylhydrazine (1.14 mL, 21.77 mmol) was added to a stirred solution of 3-methyl-β-oxo-3-oxetanepropanetrile (2.33 g, 16.74 mmol) and TEA (3.23 mL, 23.24 mmol) in toluene (12.22 mL, 115.03 mmol) at rt and stirred at 90° C. for 1 h. The reaction mixture was purified by column chromatography on silica gel (Irregular SiOH 40 μm, mobile phase: DCM/MeOH/NH₄OH, gradient from 100% DCM to 95% DCM, 5% MeOH, 0.1% NH₄OH. The residue (1.37 g) was purified by achiral SFC (Stationary phase: CHIRALCEL OJ-H, 5 μm, 250×20 mm, mobile phase: 90% CO₂, 10% MeOH) providing 355 mg of intermediate 15′ (13% yield) and 966 mg of intermediate 15 (35% yield).

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials.

Int. number Structure Mass (mg) Yield (%) Intermediate 18

310 26

Example A16 Preparation of Intermediate 44

In sealed glassware, dimethylamine (1.64 mL, 3.28 mmol) and triazabicyclo[4.4.0]des-5-ene (TBD) (62.02 mg, 0.44 mmol) were added to a solution of ((5-amino-3-methyl-pyrazol-1-yl)-acetic acid ethyl ester (200.00 mg, 1.09 mmol) in dry toluene (19.5 mL). The reaction mixture was stirred at 50° C. for 17 h. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel (irregular SiOH, 15-40 μm, 40 g, liquid loading, mobile phase: DCM/(MeOH(+5% aq NH₃)), gradient from 100:0 to 90:10). The fractions containing the product were combined and evaporated to dryness to give 102 mg of intermediate 44 (51% yield, yellow oil).

Example A17 Preparation of Intermediate 52 and intermediate 52′

A mixture of 1-methyl-3-nitro-1H-pyrazole-5-carboxylic acid (400.00 mg, 2.34 mmol) and 1-methyl-2-nitro-1H-pyrazole-4-carboxylic acid, 4,4-difluoropiperidine (440.00 mg, 2.79 mmol), HATU (1.25 g, 3.29 mmol) in DCM (10 mL) and DIPEA (2.10 mL, 12.19 mmol) was stirred at rt for a weekend. Water was added and this mixture was extracted with DCM. The organic layer was decanted with Chromabond®, the solvent was evaporated until dryness. The residue (773 mg) was purified by column chromatography on silica gel (Stationary phase: irregular bare silica 40 g, mobile phase: 70% heptane, 30% EtOAc). The pure fractions were collected and the solvent was evaporated until dryness to give 270 mg of intermediate 52′ (42% yield) and 244 mg of intermediate 52 (38% yield). These intermediates were used as it in the next step.

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials.

Int. number Structure Mass (mg) Yield (%) Intermediate 62 + intermediate 62′

295 (intermediate 62) 530 (intermediate 62′) 40   71 Intermediate 83

520 Quant.

Preparation of Intermediate 53

Intermediate 52 (0.24 g, 0.88 mmol) was hydrogenated at rt in MeOH (6 mL) with Pd/C (10 wt. %, 50.00 mg, 0.05 mmol) as a catalyst at atmospheric pressure. After overnight, the catalyst was filtered through a pad of Celite® and the solvent was evaporated until dryness to give 210 mg of intermediate 53 (98% yield) used as it in the next step.

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 63

 265 Quant. Procedure with a mixture of MeOH/EtOAc (3:1, v/v) as solvent Intermediate 70

 251 Quant. Intermediate 84

 32  72 Procedure with a mixture of MeOH/EtOAc (5:2, v/v) as solvent Intermediate 118

 524 Quant. Mixture of intermediate 177/intermediate 177′

 640 mixture of intermediates  177 and 177′  43 under 3 bars of H₂ Intermediate 196

2140 orange solid  99 Intermediate 214

 160  23 Procedure with a mixture of MeOH/EtOAc (5:3, v/v) as solvent Intermediate 233

 297 Quant. Procedure with a mixture of MeOH/EtOAc (2:1, v/v) as solvent Intermediate 236

1950 Quant. Procedure with a mixture of MeOH/EtOAc (3:1, v/v) as solvent Intermediate 242

1000  73 Intermediate 247

1610  97 Procedure with a mixture of MeOH/EtOAc (2:1, v/v) Mixture of Intermediate 255/ Intermediate 256

 200 (mixture of intermediate 255 and intermediate 256, 50:34)  98 Procedure with a mixture of MeOH/EtOAc (3:2, v/v) as solvent Mixture of Intermediate 263/ Intermediate 264

 200  50 Procedure with a mixture of MeOH/EtOAc (3:2, v/v) as solvent Intermediate 270

 338 Quant. Procedure with a mixture of MeOH/EtOAc (5:2, v/v) as solvent Intermediate 304

2000 off-white solid  73 Procedure with EtOH as solvent Intermediate 328

 700 Quant. Procedure with a mixture of MeOH/EtOAc (3:1, v/v) as solvent Intermediate 342

 407  77 Procedure with a mixture of MeOH/EtOAc (3:1, v/v) as solvent Intermediate 346

 360 Quant. Procedure with a mixture of MeOH/EtOAc (3:1, v/v) as solvent Intermediate 352

 220 Quant. Procedure with a mixture of MeOH/EtOAc (3:1, v/v) as solvent Intermediate 355

 160 Quant. Procedure with a mixture of MeOH/EtOAc (2:1, v/v) as solvent Intermediate 363

 380 Quant. Procedure with a mixture of MeOH/EtOAc (3:1, v/v) as solvent Intermediate 383

 490  71 Procedure with a mixture of MeOH/EtOAc (3:1, v/v) as solvent Intermediate 387

 270 Quant. Procedure with a mixture of MeOH/EtOAc (3:1, v/v) as solvent Intermediate 391

 720 Quant. with a mixture of MeOH/EtOAc (5:4, v/v) as solvent Intermediate 410

 187 Quant. Procedure with a mixture of MeOH/EtOAc (3:2, v/v) as solvent Intermediate 414

 440  95 Procedure with a mixture of MeOH/EtOAc (2:1, v/v) as solvent Intermediate 424

 495  88 Intermediate 428

 700  98 Intermediate 431

 760 Quant. Intermediate 469

 287  92 Procedure with EtOH as solvent Intermediate 472

 440  93 Procedure with a mixture of MeOH/EtOAc (2:1, v/v) as solvent Intermediate 484

 940 Quant. Intermediate 492

 370 Quant. Procedure with a mixture of MeOH/EtOAc (2:1, v/v) as solvent Intermediate 509

 260  34 Procedure with a mixture of MeOH/EtOAc (2:1, v/v) as solvent Intermediate 514

 293  96 Procedure with a mixture of MeOH/EtOAc (5:2, v/v) as solvent Intermediate 518

 750 Quant. Procedure with a mixture of MeOH/EtOAc (2:1, v/v) as solvent Intermediate 522

 243 Quant. Procedure with a mixture of MeOH/EtOAc (2:1, v/v) as solvent Intermediate 526

 310  93 Procedure with a mixture of MeOH/EtOAc (2:1, v/v) as solvent Intermediate 530

 430 Quant. Procedure with a mixture of MeOH/EtOAc (2:1, v/v) as solvent Intermediate 534

 148  86 Procedure with a mixture of MeOH/EtOAc (2:1, v/v) as solvent Intermediate 538

 523  92 Procedure with a mixture of MeOH/EtOAc (2:1, v/v) as solvent Intermediate 542

 377  47 Procedure with a mixture of MeOH/EtOAc (2:1, v/v) as solvent Intermediate 546

 532  88 Procedure with a mixture of MeOH/EtOAc (2:1, v/v) as solvent Intermediate 585

 97  38 Intermediate 588

 100  99 Intermediate 592

 266  83 Intermediate 598

 340  95 Intermediate 602

 305 100 Intermediate 621

 330  84 Intermediate 625

 199 100 Intermediate 629

 312  91 Intermediate 637

 135  74 Intermediate 642

3960 100 Intermediate 647

 562  96 Intermediate 652

 65  90 Intermediate 659

 249 100 Intermediate 667

 308 Quant. Intermediate 669

1010 100 Intermediate 675

 665 100 Intermediate 681

 430 100 Intermediate 687

 115 100 Intermediate 693

 220  63 Intermediate 704

 290  84 Intermediate 709

 283  96 Intermediate 715

 165  80 Intermediate 718

 252  94 Intermediate 726

 687  93 Intermediate 743

1440             1380  51 Procedure with a mixture of ^(i)PrOH/THF (2:1, v/v) as solvent, 1.5 bars H₂, 2days OR  49 With MeOH as solvent, atmospheric pressure H₂, 18 h Intermediate 748

 307  86 Procedure with a mixture of AcOEt/EtOH (4:1, v/v) as solvent, atmospheric pressure H₂, 12 h Intermediate 752

4150 quant Procedure with a mixture of MeOH/AcOEt (4:1, v/v) as solvent, atmospheric pressure H₂, 1 h 30 Intermediate 764

 120  20

Example A18 Preparation of Intermediate 56 and intermediate 56′

Bromo-3-methoxypropane (1.20 mL, 10.51 mmol) was added at rt to a mixture of 5-nitro-1H-pyrazole (1.00 g, 8.84 mmol), K₂CO₃ (2.35 g, 17.00 mmol) in DMF (10 mL). This reaction was stirred in a sealed tube at 120° C. using one single mode microwave (Biotage Initiator EXP 60) with a power output ranging from 0 to 400 W for 30 min. Then, water was added and this mixture was extracted twice with EtOAc. The organic layers were mixed, dried over MgSO₄, filtered and the solvent was evaporated until dryness. The residue was purified by column chromatography on silica gel (Irregular SiOH, 40 μm, 80 g, mobile phase: gradient from 70% heptane, 29% EtOAc, 1% MeOH (+10% NH₄OH) to 40% heptane, 52% EtOAc, 8% MeOH (+10% NH₄OH)). The pure fractions were collected and the solvent was evaporated until dryness to give 1.39 g of intermediate 56 (85% yield) and 267 mg of intermediate 56′ (16% yield). These intermediates were used as it in the next step.

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 114

20400 (intermediate 114) 22 without microwave activation Intermediate 134 + intermediate 134′

880 (intermediate 134) 493 (intermediate 134′) 24 14 without microwave activation Intermediate 141 + intermediate 141′

2240 (intermediate 141) 2140 (intermediate 141′) 25 24 Intermediate 162 + intermediate 162′

1280 (intermediate 162) 3900 (intermediate 162′) 12 37 Intermediate 170

435 (intermediate 170) 17 Mixture of Intermediate 176 + intermediate 176′

1190 (mixture of intermediates 176 and 176′ (44:56)) 67 Intermediate 191

1300 (intermediate 191) 24 Intermediate 199

750 11 without microwave activation Intermediate 219

1770 (intermediate 219) 24 Intermediate 223

2300 32 without microwave activation Intermediate 228

1670 (intermediate 228) 27 Intermediate 275 + Intermediate 275′

1050 (intermediate 275) 1900 (intermediate 275′) 24 43 Intermediate 292 + Intermediate 292′

1270 (intermediate 292) 1730 (intermediate 292′) 24 32 Intermediate 370

336 14 Intermediate 506

4810 23 Intermediate 513

356 (intermediate 513) 37 without microwave activation and T = 80° C. Intermediate 650

83 17 RT overnight Intermediate 651

391 80 RT overnight Intermediate 656

4400 44 without microwave activation T = 120° C., 2 h Intermediate 708

335 14 without microwave activation T = 120° C., 2 h 20 Intermediate 713

235 18 without microwave activation T = 120° C., 2 h 20 Intermediate 714

305 24 without microwave activation T = 120° C., 2 h 20 Intermediate 633

675 80 rt, overnight Intermediate 731

1220 63 Intermediate 750 + 751

3600 3850 32 120° C., 1 h 40 34

Example A19 Preparation of Intermediate 57

Intermediate 56 (1.30 g, 7.02 mmol) was hydrogenated in MeOH (25 mL) with RaNi (1.00 g, 17.04 mmol) as a catalyst in a pressure vessel reactor with 3 bars of H₂ at rt for 2 h. The reaction was filtered over Celite® and the solvent was evaporated until dryness to give 1.03 g of intermediate 57 (95% yield) used as it in the next step.

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 67

220 Quant. Intermediate 115

16200 95 Intermediate 135

760 Quant. Intermediate 138

390 92 Intermediate 142

1960 Quant. Intermediate 145

1930 Quant. intermediate 163

1000 90 intermediate 166

3300 98 intermediate 184

850 Quant. intermediate 192

1100 Quant. intermediate 200

650 Quant. intermediate 220

1400 98 intermediate 229

1530 Quant. intermediate 276

890 96 intermediate 279

1700 Quant. intermediate 293

1100 Quant. intermediate 296

1400 96 intermediate 371

350 84 intermediate 607

120 70 intermediate 613

176 72 intermediate 617

105 89

Example A20 Preparation of Intermediate 103

In a sealed glassware, (2-ethoxyethyl)-hydrazine (1.70 g, 9.60 mmol) was added to a solution of 3-aminocrotononitrile (394.12 mg, 4.80 mmol) in a mixture of AcOH (6.3 mL) and EtOH (20.8 mL). The mixture was stirred at 90° C. for 17 h. Water was added and the aqueous layer was extracted with Et₂O. The aqueous layer was basified with K₂CO₃ powder and extracted twice with DCM. The combined organic layers were dried over MgSO₄, filtered and evaporated. The residue (400 mg) was purified by column chromatography on silica gel (Irregular SiOH, 40 m, mobile phase DCM/MeOH/NH₄OH, gradient from 100% DCM to 95% DCM, 5% MeOH, 0.1% NH₄OH). The pure fractions were combined and the solvent was evaporated to give 194 mg of intermediate 103 (24% yield).

Example A21 Preparation of Intermediate 121

3-aminocrotononitrile (1.91 g, 23.27 mmol) and [(tetrahydro-2-furanyl)methyl]-hydrazine (4.40 g, 23.27 mmol) in EtOH (7.8 mL) were stirred at reflux for 5 h. EtOH was evaporated. The residue was taken up into water, extracted with Et₂O twice, basified with K₂CO₃ powder and extracted with DCM. The organic layer was dried over MgSO₄, filtered and evaporated. The residue was purified by column chromatography on silica gel (stationary phase: irregular SiOH 15-40 μm, 80 g, mobile phase: DCM/MeOH/NH₄OH, gradient from 100% DCM to 97% DCM, 3% MeOH, 0.1% NH₄OH). The fractions containing the product were combined and evaporated to dryness to give 1.6 g of intermediate 121 (38% yield).

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials.

Int. number Structure Mass (mg) Yield (%) Intermediate 156

209 28 Intermediate 159

260 25 Intermediate 239 + intermediate 239′

3730 (intermediate 239) 2230 (intermediate 239′) 22     13

Example A22 Preparation of Intermediate 171

A mixture of intermediate 170 (430.00 mg, 2.57 mmol), NH₄Cl (550.36 mg, 10.29 mmol) and Iron powder (718.31 mg, 12.86 mmol) in a mixture of EtOH (9.82 mL) and distilled water (3.93 mL) was heated at 75° C. for 2 h. The reaction mixture was cooled to rt, poured onto a mixture of 10% aqueous K₂CO₃ and DCM, then filtered through a pad of Celite®. The organic layer was decanted, washed with brine, dried over MgSO₄, filtered and evaporated to dryness to give 331 mg of intermediate 171 (94% yield, 81% purity based on LC/MS).

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 225

1460 Quant. Intermediate 308

505 off-white solid 81 with T = 85° C. Intermediate 324

284 colorless oil 67 with T = 85° C. Intermediate 332

209 colorless oil 70 with T = 85° C. Intermediate 420

559 brown residue 90 with T = 85° C. Intermediate 461

600 86 with T = 85° C. Intermediate 496

95 (86% purity based on LC/MS) colorless oil 61 with T = 85° C. Intermediate 500

462 69 with T = 85° C. Intermediate 504

930 (79% purity based on LC/MS) colorless oil 81 with T = 85° C. Intermediate 722

130 77 with T = 70° C., 30 min Intermediate 735

120 77 with T = 70° C., 30 min

Example A23 Preparation of Intermediate 182 and intermediate 182′

A mixture of 5-methyl-3-nitro-1H-pyrazole (7.00 g, 55.07 mmol) (+/−)-propylene oxide (7.71 mL, 110.15 mmol) in EtOH (64.31 mL) in a sealed tube was stirred at 140° C. for 4 h. The solvent was evaporated and the residue was purified by column chromatography on silica gel (stationary phase: irregular SiOH, 15-40 m, 120 g, mobile phase: heptane/EtOAc, gradient from 80:20 to 50:50). The fractions containing the product were combined to give 2.5 g of intermediate 182 (25% yield) and 7.5 g of intermediate 182′ (74% yield).

Preparation of Intermediate 183

Intermediate 182 (1.00 g, 5.40 mmol) and iodomethane (504.26 μL, 8.10 mmol) in THF (10 mL) were added at 0° C. under N₂. Then, NaH (60% dispersion in mineral oil) (259.18 mg, 6.48 mmol) was added and the resulting mixture was stirred at rt for 4 h, poured out onto water, extracted with EtOAc, dried over MgSO₄, filtered and evaporated. The residue was purified by column chromatography on silica gel (stationary phase: irregular SiOH, 15-40 μm 40 g, mobile phase: heptane/EtOAc, gradient from 80:20 to 60:40). The fractions containing the product were combined and evaporated to dryness to give 1.01 g of intermediate 183 (94% yield).

Example A24 Preparation of Intermediate 195

To a solution of 3-methyl-5-nitro-1H-pyrazole (2.46 g, 19.40 mmol) and 1-methyl-4-piperidinemethanol (5.00 g, 38.70 mmol) in dry Me-THF (190 mL). Di-tert-butyl azodicarboxylate (8.91 g, 38.70 mmol) and PPh₃ (10.20 g, 38.70 mmol) were added. The solution was heated at 55° C. over the weekend. The reaction mixture was diluted with EtOAc and water. The organic layer was separated and the aqueous layer was extracted thrice with EtOAc. The organic layers were combined, washed with brine, dried over MgSO₄, filtered and concentrated. The residue (yellow oil) was purified by column chromatography on silica gel (Irregular SiOH, 15-40 m, 330 g, liquid loading in DCM, mobile phase: DCM/MeOH, gradient from 100:0 to 90:10). The fractions containing the product were combined and evaporated to dryness to give 2.36 g of intermediate 195 (51% yield, yellow oil).

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 288

4360 yellow oil 63 with T = rt Intermediate 307

780 yellow oil 65 with T = rt Intermediate 311

780 colourless oil 62 with T = rt Intermediate 315

759 yellow oil 60 with T = rt Intermediate 319

718 yellow oil 71 with T = rt Intermediate 323

484 white solid 31 with T = rt Intermediate 331

847 white solid 27 with T = rt Intermediate 358

274 16 with T = rt Intermediate 366

1240 colorless oil 74 colorless oil with T = rt Intermediate 379 + intermediate 379′

1040 (intermediate 379) colorless oil 426 (intermediate 379′) yellow oil 66       27 with T = rt Intermediate 394 + intermediate 394′

1560 (intermediate 394) colorless oil 730 (intermediate 394′) colorless oil 93     43 with T = rt Intermediate 398

10600 yellow oil 75 with T = rt Intermediate 479

706 yellow oil 49 with T = rt Intermediate 495

174 yellow oil 13 with T = rt Intermediate 499

761 yellow oil 55 with T = rt Intermediate 503

1450 off-white solid 92 with T = rt

Example A25 Preparation of Intermediate 211 and intermediate 212

MsCl (0.36 mL, 4.65 mmol) was added slowly at 0° C. to a solution of 1-methyl-4-nitro-1H-pyrazole-3-methanol (0.62 g, 3.95 mmol) in a mixture of DCM (8 mL) and TEA (1 mL, 7.194 mmol). This reaction was stirred for 2 h at rt. Then, water and an aqueous solution of HCl 3N was added. The aqueous layer was extracted twice with DCM. The organic layer was decanted and the solvent was evaporated until dryness to give 526 mg of a mixture of intermediate 211 and 212 (50:50) which was used directly as it in the next step.

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials.

Mass Yield Int. number Structure (mg) (%) Intermediate 490

800 86 Intermediate 702

500 100

Example A26 Preparation of Intermediate 213

NaH (60% dispersed in mineral oil) (0.61 g, 15.38 mmol) was added at rt to a solution of pyrrolidinone (1.10 mL, 14.26 mmol) in DMF (35 mL). After 5 min at rt, a mixture of intermediate 211 and 212 (1.83 g, 7.78 mmol) was added and stirred at rt overnight. Then, water and an aqueous solution of NH₄Cl 10% were added and this mixture was extracted twice with EtOAc. The organic layer was decanted and the solvent was evaporated until dryness to give 810 mg of intermediate 213 (46% yield) used as it for the next step.

Example A27 Preparation of Intermediate 224

Intermediate 223 (2.30 g, 10.17 mmol) and CH₃CN (15.93 mL, 0.30 mol) in POCl₃ (3.78 mL, mL, 40.67 mmol) in a sealed tube were stirred at 140° C. using one single mode microwave (Biotage Initiator EXP 60) with a power output ranging from 0 to 400 W for 5 min. The resulting mixture was poured out onto ice and water, extracted with DCM, dried over MgSO₄, filtered and evaporated. The residue was purified by column chromatography on silica gel (stationary phase: irregular SiOH, 15-40 m, 80 g, liquid injection, mobile phase: heptane/EtOAc 90:10). The pure fractions were combined and the solvent was evaporated to give 1.71 g of intermediate 224 (81% yield).

Example A28 Preparation of Intermediate 232 and intermediate 232′

In a sealed tube, 2-(tributylphosphoranylidene)-acetonitrile (7.30 g, 30.25 mmol) was added to a solution of 5-Methyl-3-nitro-1H-pyrazole (2.00 g, 15.74 mmol) and 2-cyclopropylethanol (2.04 g, 23.68 mmol) in toluene (70 mL). The mixture was heated at 60° C. for 19 h. After cooling down to rt, the mixture was diluted with EtOAc and water. The organic layer was decanted and the solvent was evaporated in vacuo. The residue was purified by column chromatography on silica gel (Irregular SiOH, 20-45 m, 40 g, mobile phase: heptane/EtOAc, gradient from 60:40 EtOAc to 50:50). The pure fractions were combined and the solvent was evaporated until dryness to give 2.10 g of intermediate 232′ (68% yield) and 330 mg of intermediate 232 (11% yield).

Example A29 Preparation of Intermediate 240

LiOH (1.40 g, 58.46 mmol) was added to a mixture of intermediate 239 (3.73 g, 19.01 mmol) at rt in a mixture of EtOH (20.00 mL), distilled water (20.00 mL) and 1,4-dioxane (20.00 mL). This reaction was stirred at 40° C. for 3 h then at rt 2 nights. The reaction was poured onto water and Et₂O. The organic layer was decanted and the aqueous layer was acidified by an aqueous solution of HCl 3N until pH=4. The aqueous layer was extracted twice with EtOAc and the organic layer was decanted and evaporated until dryness to give 3.71 g of intermediate 240 (quant. yield) used as it in the next step.

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials.

Int. number Structure Mass (mg) Yield (%) Intermediate 245

1600 77

Preparation of Intermediate 241

This reaction has been made twice from 1 g of intermediate 240. At rt, diphenyl phosphoryl azide (2.40 mL, 11.16 mmol) followed by benzyl alcohol (2.40 mL, 23.19 mmol) was added to a mixture of intermediate 240 (1.00 g, 5.49 mmol) and TEA (1.60 mL, 11.51 mmol). This reaction was stirred under microwave 160° C. using one single mode microwave (Biotage Initiator EXP 60) with a power output ranging from 0 to 400 W for 15 min. The reaction was cooled down to rt. These reactions were combined with another batch (from 860 mg of intermediate 240) and the solvent was evaporated until dryness. This residue was purified by column chromatography on silica gel (stationary phase: irregular SiOH, 15-40 μm, 120 g, mobile phase: heptane/EtOAc, gradient from 80:20 to 60:40). The pure fractions were collected and the solvent was evaporated until dryness to give 2.58 g of intermediate 241 (57% over 3 batches) which was directly used as it in the next step.

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials.

Int. number Structure Mass (mg) Yield (%) Intermediate 246

3.1 Quant.

Example A30 Preparation of Intermediate 250

At −78° C. under N₂, BuLi (1.6 M in hexane) (8.30 mL, 13.28 mmol) was added over 15 min to a solution of 1-(-2-tetrahydropyranyl)-1H-pyrazole (2.00 g, 13.14 mmol) in THF (20.00 mL). This reaction was stirred at −78° C. for 30 min. 1-bromo-3-methylbutane (1.80 mL, 14.40 mmol) was added dropwise over 10 min to this mixture. After 3 h at −78° C., the reaction mixture was warmed to rt overnight then quenched with water and few drops of an aqueous solution of HCl 3N was added. This mixture was extracted twice with EtOAc and once with DCM. The organic layers were combined and the solvent was evaporated until dryness. The residue was purified by column chromatography on silica gel (stationary phase: irregular SiOH, 15-40 μm, 40 g, mobile phase gradient from: 95% heptane, 5% MeOH to 75% heptane, 25% EtOAc). The pure fractions were collected and the solvent was evaporated until dryness to give: 1.23 g of intermediate 250 (42% yield) (and 60 mg of intermediate 251).

Preparation of Intermediate 251

At 0° C., HCl (37% in H₂O) (2.50 mL, 29.94 mmol) was added to a mixture of intermediate 250 (1.23 g, 5.53 mmol) in EtOH (55 mL). This reaction was stirred at rt for 5 h. The solvent was evaporated until dryness. This crude was basified by an aqueous solution of NaHCO₃ until pH=8. This mixture was extracted twice with Et₂O and the organic layer was decanted and the solvent was evaporated until dryness to give 625 mg of intermediate 251 (82% yield) which was directly used as it in the next step. Alternative preparation of intermediate 251: 5-methyl-1-hexyne (10 mL, 76.11 mmol) and (trimethylsilyl)diazomethane (38.06 mL, 2 M, 76.11 mmol) in a sealed glassware were stirred at 135° C. for 2 h then at 100° C. for 12 h. The volatiles were evaporated. The residue was performed by column chromatography on silica gel (stationary phase: irregular SiOH, 15-40 μm, 80 g, mobile phase: gradient from 80% heptane, 20% EtOAc to 60% heptane, 40% EtOAc). The fractions containing the product were combined and evaporated to dryness to give 3.2 g of intermediate 251 (30% yield).

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 678

4000 53 135° C. 4 hours Intermediate 684

8400 quant 135° C. 4 hours

Preparation of Intermediate 252

HNO₃ (65%) (6.50 mL, 142.35 mmol) was added dropwise to a solution of intermediate 251 (0.62 g, 4.49 mmol) in H₂SO₄ (6.50 mL, 122.00 mmol) at 0° C. and the reaction was stirred at 0° C. for 3 h and 40 min. HNO₃ (65%) (1.50 mL, 32.85 mmol) was added and this reaction was stirred at 0° C. for 2 h. At 0° C., the reaction was poured out onto ice and water, extracted twice with EtOAc and the combined organic layers were washed with saturated NaHCO₃ aqueous solution. The organic layer was dried over MgSO₄, filtered and evaporated until dryness to give 764 mg of intermediate 252 (93% yield) which was directly used as it in the next step.

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 679

1410 25 Intermediate 685

4410 37

Preparation of Intermediate 261, 262, 253 and 254

A mixture of intermediate 252 (0.76 g, 4.17 mmol), K₂CO₃ (1.10 g, 7.96 mmol) and 2-bromo-N,N-dimethylethylamine hydrobromide (1.13 g, 4.61 mmol) in DMF (8 mL) was stirred in a sealed tube at 120° C. using one single mode microwave (Biotage Initiator EXP 60) with a power output ranging from 0 to 400 W for 60 min. [fixed hold time]. This reaction was performed at 150° C. for 15 min then K₂CO₃ added 150° C. for 70 min. Water was added and this mixture was extracted twice with EtOAc. The organic layer was decanted and the solvent was evaporated until dryness. This residue was purified by column chromatography on silica gel (Irregular SiOH, 40 m, 40 g, mobile phase: heptane/EtOAc, gradient from 80:20 to 60:40). The pure fractions were collected and the solvent was evaporated until dryness to give 240 mg of a mixture of intermediates 253 & 254 (29% yield) used as it in the next step. This purification was performed with 95% DCM, 5% MeOH (+10% NH₄OH) to 85% DCM, 15% MeOH (+10% NH₄OH). The pure fractions were collected and the solvent was evaporated until dryness to give 450 mg of a mixture of intermediates 261 & 262 (42% yield) directly used as it in the next step and a mixture of intermediates 253 & 254 also directly used in the next step.

Example A31 Preparation of Intermediate 269

A mixture of 2-isopropyl-5-nitro-2H-pyrazole-3-carboxylic acid (0.64 g, 3.21 mmol), HATU (1.70 g, 4.47 mmol), DIPEA (1.50 mL, 8.70 mmol) and methylamaine (2M in THF) (3.20 mL, 3.40 mmol) in Me-THF (6.50 mmol) was stirred at 70° C. for overnight. The reaction was cooled down to rt. Water was added and this mixture was extracted twice with DCM. The organic layer was decanted and dried over MgSO₄, filtered then the solvent was evaporated until dryness. The residue (1 g) was purified by column chromatography on silica gel (Irregular SiOH, 20-45 m, 40 g, mobile phase: 60% heptane, 40% EtOAc). The pure fractions were collected and the solvent was evaporated until dryness to give 385 mg of intermediate 269 (56% yield).

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number structure Mass (mg) Yield (%) Intermediate 635

10300 39 DCM RT, overnight Intermediate 636

4900 18 DCM RT, overnight

Example A33 Preparation of Intermediate 289

A mixture of intermediate 288 (3.69 g, 18.12 mmol), Zinc (11.85 g, 181.21 mmol) and AcOH (10.37 mL, 181.21 mmol) in MeOH (86 mL) was stirred at rt for 1 h. The mixture was filtered over a pad of Celite® and the filtrate was concentrated under reduced pressure. The resulting residue was diluted with EtOAc and water. The aqueous layer was basified with solid K₂CO₃ and the layers were separated. The aqueous layer was extracted twice with EtOAc. The combined organic layers were washed with brine, dried over MgSO₄, filtered and the solvent was removed under reduced pressure to give 3.44 g of intermediate 289 as a yellow residue (92% yield) directly used as it in the next step.

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 312

360 yellow solid 53 Intermediate 316

553 colorless oil 84 with T = 85° C. Intermediate 320

227 yellow oil 46 with T = 85° C. Intermediate 359

205 yellow solid 85 Intermediate 367

888 yellow solid 65 Intermediate 380

226 pale yellow solid 25 Intermediate 395

1010 yellow oil 74 Intermediate 401

625 yellow oil — Intermediate 696

106 10

Example A34 Preparation of Intermediate 299

A mixture of 3-cyano-2-oxo-propanoic acid ethyl ester (4.00 g, 22.30 mmol), 3-methylbutyl-hydrazine (2.28 g, 22.32 mmol) and HCl (37% in H₂O) (5.50 mL, 65.90 mmol) in EtOH (80 mL) was stirred at 60° C. for 18 h. The mixture was evaporated and an extraction was performed with NaOH (3N) and Et₂O. The organic layer was dried over MgSO₄, evaporated. The resulting residue was purified by column chromatography on silica gel (stationary phase: irregular SiOH, 15-40 μm, 120 g, mobile phase heptane/EtOAc, gradient from 100:0 to 40:60). The fractions containing the product were combined and evaporated to dryness to give 1.36 g of intermediate 299 (27% yield, yellow solid).

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials.

Int. number Structure Mass (mg) Yield (%) Intermediate 456

723 31 Intermediate 464

397 33 Intermediate 475

879 (80% purity based on LC/MS) pale yellow solid 25

Preparation of Intermediate 300

At 0° C., LiAlH₄ (230.00 mg, 6.06 mmol) was added slowly to a solution of intermediate 299 (1.36 g, 6.04 mmol) in Et₂O (60 mL). The mixture was stirred at rt for 18 h. Further, LiAlH₄ (230.00 mg, 6.06 mmol) was added and the mixture was stirred at rt for 2 h. The mixture was placed at 0° C., water (0.5 mL), NaOH (3N, 0.5 mL) and water (1.5 mL) were successively added. The resulting mixture was stirred at rt for 20 min. MgSO₄ was added and the mixture was stirred at rt for 1 h. The mixture was filtered and the filtrate was evaporated. The resulting residue was purified by column chromatography on silica gel (irregular SiOH, 15-40 m, 120 g, liquid loading with DCM, mobile phase heptane/EtOAc, gradient from 100:0 to 0:100 in 10 CV then EtOAc/MeOH gradient from 100:0 to 80:20 in 5 CV). The fractions containing the product were combined and evaporated to dryness to give 720 mg of intermediate 300 (65% yield, white solid).

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 457

400 (84% purity based on LC/MS) 69 with THF as solvent Intermediate 465

243 56 with THF as solvent Intermediate 476

500 72 with THF as solvent

Example A35 Preparation of Intermediate 303

The reaction was performed in 2 batches. In a sealed tube, cyanomethylenetributyl phosphorane (9.28 mL, 35.40 mmol) was added to a solution of 3-methyl-5-nitro-1H-pyrazole (1.50 g, 11.80 mmol) and 3-hydroxymethyl-3-methyloxethane (3.53 mL, 35.40 mmol) in toluene (100 mL). The solution was heated at 60° C. for 18 h. The 2 batches were combined and the solvent was evaporated in vacuo. The residue (black oil) was purified by column chromatography on silica gel (irregular SiOH, 15-40 m, 330 g, liquid loading on DCM, mobile phase: heptane/EtOAc, gradient from 90:10 to 50:50). The fractions containing the product were combined and evaporated to dryness to give 3.95 g of intermediate 303 (79% yield, orange oil) directly used as it in the next step.

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 327

750 24 Intermediate 341 + intermediate 341′

590 (intermediate 341) 900 (intermediate 341′) 19   30 Intermediate 345

407 13 Intermediate 362

540 17 Intermediate 374

2900  32 Intermediate 386

324 (intermediate 386) 21 Intermediate 390

856 41 Intermediate 407

11100  75 Intermediate 417

10600  yellow oil 75 with T = rt Intermediate 423

640 (intermediate 423) 38 with T = 90° C. Intermediate 427 + intermediate 427′

817 (intermediate 427) 870 (intermediate 427′) 22   23 with T = 50° C. Intermediate 468

361 92 Intermediate 483

1050  63 with T = 90° C. Intermediate 488

3320  47 Intermediate 517 + intermediate 517′

832 (intermediate 517) 405 (intermediate 517′) 63   31 with T = 90° C. Intermediate 533

192 (80% purity based on LC/MS) 22 Procedure with Me-THF Intermediate 537

647 11 with T = 90° C. Intermediate 541

911 76 Intermediate 583

720 19 Procedure with Me-THF 8 h Intermediate 583

282 6 60° C., 6 h Intermediate 591

372 50 110° C. μw 30 min Intermediate 605

1660  17 110° C. μw 30 min Intermediate 601

350 68 110° C. μw 30 min Intermediate 656

700 51 60° C., 36 h Intermediate 688

1100  67 90° C., 5 h Intermediate 680

490 50 60° C., 19 h Intermediate 686

600 38 60° C., 19 h Intermediate 692

390 52 RT, 18 h Intermediate 699

680 31 110° C. μw 30 min Intermediate 700

1200  55 110° C. μw 30 min Intermediate 742

6700  79 60° C., 12 h Intermediate 747

470 48 60° C., 12 h

Example A36 Preparation of Intermediate 335

A mixture of 5-bromo-1H-pyrazol-3-amine (790.00 mg, 4.88 mmol) and N,N-dimethyl formamide dimethyl acetal (1.17 mL, 8.78 mmol) in MeOH (12 mL) was refluxed for 2 h. The mixture was evaporated in vacuo. The residual gum was triturated in Et₂O and filtered on a glass-frit to give 617 mg of intermediate 335 (58%, off-white solid). The filtrate was evaporated in vacuo and the residue (380 mg, orange oil) was purified by column chromatography on silica gel (irregular SiOH, 15-40 μm, 10 g, dry loading on Celite®, mobile phase gradient: from heptane 80%, EtOAc 18%, MeOH 2% to heptane 30%, EtOAc 63%, EtOAc 7%). The fractions containing the product were combined and evaporated to dryness to give additional 253 mg of intermediate 335 (24%, white solid).

Preparation of Intermediate 336

To a solution of intermediate 335 (899.00 mg, 4.14 mmol) and 1-iodo-2-methylpropane (0.71 mL, 6.21 mmol) in DMF (42 mL), Cs₂CO₃ (2.70 g, 8.28 mmol) was added and stirred at rt overnight. Further 1-iodo-2-methylpropane (0.24 mL, 2.07 mmol) and Cs₂CO₃ (1.35 g, 4.14 mmol) were added and the mixture was stirred at rt for 1 h. EtOAc was added and the mixture was filtered off. The filtrate was evaporated in vacuo and the residual crude was taken-up in EtOAc and water. The organic layer was washed thrice with brine, dried over MgSO₄, filtered off and evaporated in vacuo. The residue (1.09 g, pale yellow liquid) was purified by column chromatography on silica gel (irregular SiOH, 15-40 m, 50 g, dry loading on Celite®, mobile phase gradient: from heptane 90%, EtOAc 9%, MeOH 1% to heptane 60%, EtOAc 36%, MeOH 4%). The fractions containing the product were combined and evaporated to dryness to give 707 mg of intermediate 336 (62% yield, colorless liquid).

Preparation of Intermediate 337

In a sealed tube, a mixture of intermediate 336 (707.00 mg, 2.59 mmol), dimethylphosphine oxide (0.24 g, 2.85 mmol) and K₃PO₄ (0.60 g, 2.85 mmol) in DMF was purged with N₂. Pd(OAc)₂ (58.10 mg, 0.26 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (149.70 mg, 0.26 mmol) were added. The mixture was purged with N₂ and stirred at 130° C. overnight. The mixture was warmed to rt and filtered on a pad of Celite®. The cake was washed with EtOAc and the filtrate was evaporated in vacuo. The residue (920 mg, red oil) was purified by column chromatography on silica gel (irregular SiOH, 15-40 μm, 50 g, dry loading on Celite®, mobile phase: DCM/MeOH, gradient from 100:0 to 95:5). The fractions containing the product were combined and evaporated to dryness to give 330 mg of intermediate 337 (47% yield, reddish solid).

Preparation of Intermediate 338

In a sealed tube, to a solution of intermediate 337 (330.00 mg, 1.22 mmol) in EtOH (6 mL) was added HCl (3M in cyclopentyl methyl ether) (6.10 mL, 18.30 mmol). The mixture was stirred at 90° C. overnight. The mixture was evaporated in vacuo to give 501 mg of intermediate 338 (Quant. yield, 77% purity based on NMR, yellow gum).

Example A37 Preparation of Intermediate 349: and intermediate 349′

A mixture of 3-methyl-4-nitro-1H-pyrazole (1.36 g, 10.71 mmol), tert-butyl-4-iodopiperidine-1-carboxylate (10.00 g, 32.14 mmol) and K₂CO₃ (2.96 g, 21.42 mmol) in DMF (16.6 mL) was stirred at reflux for 24 h. The reaction mixture was diluted with EtOAc and water and the layers were separated. The organic layer was washed with brine, dried over MgSO₄, filtered and was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (irregular SiOH 40 m, 80 g, mobile phase: heptane/DCM, gradient from 50:50 to 0:100). The pure fractions were combined and the solvent was evaporated to give a mixture of intermediate 349 and intermediate 349′ (540.00 mg, 16% yield).

Preparation of Intermediate 350 and intermediate 350′

At 0° C., HCl (4M in dioxane) (15.00 mL, 60.00 mmol) was added to a solution of a mixture of intermediates 349 and 349′ (0.54 g, 1.74 mmol) in 1,4-dioxane (4 mL). The reaction was stirred at rt overnight. The solvent was evaporated until dryness. The residue was taken up into DCM and basified with a 10% aqueous solution of K₂CO₃. The organic layer was dried over MgSO₄, filtered and the solvent was evaporated until dryness. The residue (817 mg) was purified by column chromatography on silica gel (stationary phase: irregular SiOH, 15-40 μm, 40 g, mobile phase: 98% DCM, 2% MeOH (+10% NH₄OH) to 95% DCM, 5% MeOH (+10% NH₄OH)). The pure fractions were collected and the solvent was evaporated until dryness to give 0.480 g of a mixture of intermediates 350 and 350′ used as it for the next step.

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials.

Int. number Structure Mass (mg) Yield (%) Intermediate 408

6550 85

Preparation of Intermediate 351 and intermediate 351′

A mixture of intermediates 350 and 350′ (0.48 g, 2.28 mmol), formaldehyde (0.21 mL, 2.80 mmol) in MeOH (2.70 mL) and AcOH (0.32 mL, 5.59 mmol) was stirred for 10 min. Then, sodium cyanoborohydride (0.17 g, 2.75 mmol) was added. The reaction was stirred at rt over the weekend. DCM and a 10% solution of K₂CO₃ were added. The organic layer was washed with water, dried over MgSO₄, filtered and evaporated. The residue (538 mg) was purified by achiral SFC (Stationary phase: CHIRALPAK IC 5 μm 250×20 mm, mobile phase: 75% CO₂, 25% MeOH). The pure fractions were collected and the solvent was evaporated until dryness to give: 248 mg of intermediate 351 (49% yield) and 184 mg of intermediate 351′ (36% yield).

Example A38 Preparation of Intermediate 375

To a solution of intermediate 374 (4.30 g, 19.18 mmol) in DMF (95.9 mL, 0.2 M) at rt was added SOCl₂ (2.09 mL, 28.77 mmol) and the resulting solution was stirred at rt overnight. Then, EtOAc was added and the reaction mixture was washed with saturated aqueous sodium bicarbonate solution and water. The combined organic layers were dried over Na₂SO₄, filtered and concentrated. The residue (3.1 g) was purified by column chromatography on silica gel (irregular SiOH, 40 μm, 120 g, mobile phase: heptane/EtOAc, gradient from 90:10 to 60:40). The pure fractions were combined and the solvent was evaporated to give 2.11 g of intermediate 375 (53% yield).

Preparation of Intermediate 376

To a solution of intermediate 375 (2.11 g, 10.23 mmol) in a mixture of 1,4-dioxane (30 mL) and distilled water (6 mL), were added iron powder (5.71 g, 102.33 mmol) and iron (II) sulfate heptahydrate (6.22 g, 40.93 mmol). The resulting solution was heated to reflux for 12 h. The reaction mixture was filtered over a pad of Celite®. DCM was added and the organic layer was decanted, dried over MgSO₄, filtered and evaporated. DCM was added. The insoluble was filtered and dried with DIPE to give 1.21 g of intermediate 376 (67% yield).

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials.

Int. number Structure Mass (mg) Yield (%) Intermediate 453

100 22 Intermediate 480

540 yellow oil 95

Example A39 Preparation of Intermediate 399

To a solution of intermediate 398 (1.00 g, 2.90 mmol) in DCM (25 mL), TFA (2.50 mL, 32.70 mmol) was added and the reaction mixture was stirred at rt for 16 h. The solvent was removed under reduced pressure. The residue (1.66 g, yellow oil) was triturated with Et₂O to give a white solid. The solid was filtered on a glass frit, washed with Et₂O to give 820 mg of intermediate 399 (79% yield, white solid, TFA salt).

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 418

2820 90 Intermediate 507

4880 Quant. Procedure with T = 0-5° C. and with DCM/TFA (4:1, v/v)

Preparation of Intermediate 400

In a sealed tube, a solution of intermediate 399 (1.00 g, 2.79 mmol) in CH₃CN (14 mL) was treated with 1-(4-methylbenzenesulfonate)-2-fluoro-ethanol (0.70 g, 3.21 mmol) and Cs₂CO₃ (2.73 g, 8.36 mmol). The reaction mixture was stirred at 80° C. for 70 h. The crude was diluted with water and a saturated aqueous solution of NaHCO₃ and extracted with EtOAc. The organic layer was dried over MgSO₄, filtered and evaporated in vacuo to give 790 mg of intermediate 400 (97% yield, yellow oil).

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials.

Int. number Structure Mass (mg) Yield (%) Intermediate 460

790 87

Example A40 Preparation of Intermediate 409

In a sealed tube a mixture of intermediate 408 (0.50 g, 2.23 mmol), 2-chloro-N,N-dimethylacetamide (0.25 mL, 2.43 mmol) and DIPEA (0.95 mL, 5.51 mmol) in DMF (15 mL) was stirred at 80° C. for overnight. The reaction was cooled down to rt. Water was added and this mixture was extracted twice with EtOAc and twice with DCM. These organic layers were combined and the solvent was evaporated until dryness. The residue was purified by column chromatography on silica gel (irregular SiOH, 40 μm, 40 g, mobile phase gradient from 98% DCM, 2% MeOH (+10% NH₄OH) to 94% DCM, 6% MeOH (+10% NH₄OH)). The pure fractions were collected and the solvent was evaporated until dryness to give 189 mg of intermediate 409 (27% yield) used directly as it in the next step.

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 413

537 79 under microwave activation with T = 70° C. Intermediate 419

710 (70% purity based on LC/MS) 84 Intermediate 471

530 84 Intermediate 508

840 (61% purity based on LC/MS) 91 under microwave activation with T = 70° C. Intermediate 529

122 15 Intermediate 545

683 81 Intermediate 725

824 89

Example A41 Preparation of Intermediate 452

Intermediate 211 (0.729 g, 3.10 mmol), morpholine (540.15 mg, 6.20 mmol) and TEA (1.29 mL, 9.30 mmol) in CH₃CN (8.10 mL, 155.00 mmol) were stirred at 60° C. for 1 h. The solvent was evaporated. The residue was purified by column chromatography on silica gel (stationary phase: irregular SiOH, 15-40 μm, 80 g, mobile phase: gradient from 100% DCM to 98% DCM, 2% MeOH, 0.1% NH₄OH). The fractions were combined and evaporated to dryness to give 520 mg of intermediate 452 (74% yield).

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials.

Int. number Structure Mass (mg) Yield (%) Intermediate 491

450 Quant. Intermediate 521

275 49 Intermediate 525 From Intermediate 490 and 1-methyl 390 91 piperazine Intermediate 703 From intermediate 702 and 1-methyl 396 98 piperazone

Example A42 Preparation of Intermediate 487

SOCl₂ (4.62 mL, 63.66 mmol) was added dropwise over 5 min approximately to a solution of 4-Nitro-1H-pyrazole-3-carboxylic acid (5.00 g, 31.83 mmol) in MeOH (50 mL) at 0° C. The resulting clear solution was stirred at 0° C. for 30 min, followed by rt for 16 h. Solvent was evaporated under reduced pressure to obtain 5.4 of intermediate 487 (99% yield, white solid).

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 730

4800 99 Reflux, 5 h

Example A43 Preparation of Intermediate 489

To a solution of intermediate 488 (2.26 g, 9.45 mmol) in dry DCM (25.4 mL) was added dropwise diisobutylaluminium hydride (3.62 mL, 20.31 mmol) at −50° C. The reaction mixture was stirred at −50° C. for 3 h then at rt for 2 h. The mixture was acidified at 0° C. with a 3N aqueous solution of HCl and diluted with Et₂O. The organic layer was separated, washed with a 1N aqueous solution of HCl, then twice with brine, dried over MgSO₄ and evaporated in vacuo. The residue (2.17 g) was purified by column chromatography on silica gel (irregular SiOH, 40 m, 40 g, mobile phase: heptane/EtOAc, gradient from 100:0 to 60:40). The pure fractions were combined and the solvent was evaporated to give 536 mg of intermediate 489 (27% yield).

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 701

266 25 −20° C. 18 h, then 0° C. 2 h

Example A44 Preparation of Intermediate 512

At 0° C., oxalyl chloride (9.5 mL, 19.00 mmol) was added to a solution of 5-nitro-1H-pyrazole-3-carboxylic acid (1.50 g, 9.55 mmol) in a mixture of DCM (30 mL) and Me-THF (0.85 mL). Then, one drop of DMF was added at 0° C. and this mixture was stirred at rt for 3 h. The solvent was evaporated until dryness. This product was taken up into DCM (45 mL) and a mixture of cyclopropylamine (13 mL), DCM (3 mL) and pyridine (1.50 mL) was added over a period of 10 min. This reaction was stirred over the weekend at rt. This mixture was concentrated in vacuo and purified by column chromatography on silica gel (irregular SiOH, 20-45 m, 80 g, mobile phase gradient from: 100% DCM to 90% DCM, 10% MeOH (+10% NH₄OH)). The fractions containing the product were combined and the solvent was evaporated until dryness. The residue (1.80 g) was purified by column chromatography on silica gel (irregular SiOH, 20-45 m, 24 g, mobile phase: heptane/EtOAc, gradient from 70:30 to 50:50). The pure fractions were collected and the solvent was evaporated until dryness to give 1.30 g of intermediate 512 (69% yield).

Example A45 Preparation of Intermediate 558

A mixture of intermediate 186 in dioxane (18 mL) was stirred with lithium hydroxide monohydrate (55 mg, 1.31 mmol) and distilled water (2.5 mL) at rt for 2 h. Then, TFA (3.0 mL, 39.3 mmol) was added and the mixture was stirred at rt for 30 min. The reaction mixture was evaporated under reduced pressure and a dry load on Celite® was prepared. The residue was purified by column chromatography on silica gel (irregular SiOH, 15-40 μm, 30 g, dry load on Celite®, mobile phase gradient: from DCM 100% to DCM 90%, MeOH (+AcOH 10%) 10%). The fractions containing the product were combined and evaporated to dryness to give 697 mg of intermediate 558 (67% purity based on LC/MS) as a yellow residue used as it in the next step.

Preparation of Intermediate 559

In a sealed tube, intermediate 558 (434.00 mg, 0.84 mmol) and piperidine (99.20 μL, 1.00 mmol) were diluted in dry DMF (10.6 mL). Then, HATU (698.90 mg, 1.84 mmol) and DIPEA (0.36 mL, 2.09 mmol) were added and the mixture was stirred at 70° C. for 17 h. The reaction mixture was evaporated under reduced pressure and purified by column chromatography on silica gel (irregular SiOH, 40 g, dry load on Celite®, mobile phase gradient: from DCM 100% to DCM 90%, MeOH (+aq. NH₃ 5%) 10%). The fractions containing the product were combined and evaporated to dryness. The residue (512 mg, yellow residue) was triturated in Et₂O and the solid was filtered on a glass frit to give two batches of intermediate 559 (batch 1, 85 mg, 17% yield, yellow solid; batch 2, 90 mg, 18% yield, yellow residue) directly used as it in the next step.

Example A 46 Preparation of Intermediate 560

DMA-DMF (10.00 mL; 74.69 mmol) was added dropwise to methyl 5-methoxy-3-oxopentanoate (10.00 mL; 68.68 mmol) in DCM (50.00 mL) at room temperature. This reaction was stirred at room temperature for overnight. The solvent was evaporated until dryness to give 15.54 g of intermediate 560 (quantitative) directly used in the next step without any further treatment.

The intermediates in the table below were prepared by using an analogous method starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 755

820 97 Neat, rt, overnight

Preparation of Intermediate 561

Hydrazine monohydrate (8.00 mL; 164.73 mmol) was added to a solution of intermediate 560 (15.54 g; 72.19 mmol) in EtOH (230 mL). This reaction was stirred at reflux for 6 hours (T=95° C.) then cooled down to room temperature. The solvent was evaporated until dryness. The crude was purified by silica gel chromatography (Irregular SiOH 15-40 m 220 g, mobile phase gradient from: 80% Heptane, 20% EtOAc to 45% Heptane, 55% EtOAc). The pure fractions were collected and the solvent was evaporated until dryness to give 2 fractions of intermediate 561: Fraction A: 3.54 g (27% yield); Fraction B: 7.34 g (55% yield).

These two fractions were directly used in the next step without any further treatment.

The intermediates in the table below were prepared by using an analogous method starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 756

438 62 95° C., 2 h then rt, overnight

Preparation of Intermediate 562 and intermediate 563

In a sealed tube, 2-(tributylphosphoranylidene)acetonitrile (8.70 mL; 33.16 mmol) was added to a solution of intermediate 561 (3.40 g; 18.46 mmol) and 2,2-difluoroethanol (1.40 mL; 22.11 mmol) in toluene (50.00 mL). This reaction was heated at 70° C. overnight. The reaction was cooled down to room temperature. Water was added and this mixture was extracted twice with EtOAc. The organic layer was decanted and the solvent was evaporated until dryness. This crude was purified by silica gel chromatography (Irregular SiOH 15-40 μm 120 g GraceResolv, mobile phase gradient from: 80% Heptane, 20% EtOAc to 60% Heptane, 40% EtOAc). The pure fractions were collected and the solvent was evaporated until dryness to give 3.26 g of impure intermediate 563 and 1.47 g of impure intermediate 562.

Impure intermediate 563 (3.26 g) was repurified by silica gel chromatography (Irregular SiOH 15-40 m 80 g, mobile phase Gradient from: 90% Heptane, 10% EtOAc to 60% Heptane, 40% EtOAc). The fractions containing the product were collected and the solvent was evaporated until dryness to give 1.2 g (26%) of intermediate 563 and 1 g (22%) of intermediate 562.

Impure intermediate 562 (1.47 g) was repurified by silica gel chromatography (Irregular SiOH 15-40 m 80 g GraceResolv, mobile phase Gradient from: 90% Heptane, 10% EtOAc to 60% Heptane, 40% EtOAc). The pure fractions were collected and the solvent was evaporated until dryness to give 0.53 g (11%) of intermediate 562.

In total 1.53 g of intermediate 562 were obtained.

The intermediates in the table below were prepared by using an analogous method starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 757

395 69

Preparation of Intermediate 564

Lithium hydroxide 98% (0.33 g; 13.49 mmol) was added to a solution of intermediate 562 (1.53 g; 6.16 mmol) in ethanol (9.00 mL), water (9.00 mL) and 1,4-dioxane (9.00 mL). The reaction was stirred for 60 minutes at 95° C., then was cooled down to room temperature. Water was added and the mixture was acidified with an aqueous solution of HCl 3N. The aqueous layer was extracted twice with EtOAc. The organic layers were mixed, dried over MgSO₄, filtered and the solvent was evaporated until dryness to give 1.41 g of intermediate 564 (98% yield) which was directly engaged in the next step without any further treatment The intermediates in the table below were prepared by using an analogous method starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Int. number Structure Mass (mg) Yield (%) Intermediate 565

273 91 45° C. for 3 hours then, room temperature overnight Intermediate 758

234 quant

Preparation of Intermediate 566

A mixture of intermediate 564 (1.42 g; 6.06 mmol), diphenylphosphoryl azide (2.40 mL), triethylamine (1.6 mL; 11.51 mmol) and benzyl alcohol (2.4 mL; 23.19) was stirred at 160° C. using one single mode microwave (Biotage Initiator EXP 60)® with a power output ranging from 0 to [400 W] for 15 minutes. The reaction was cooled down to room temperature and the solvent was evaporated until dryness. The crude was purified by silica gel chromatography (Irregular SiOH 20-45 m 80 g, mobile phase Gradient from: 90% Heptane, 10% EtOAc to 50% Heptane, 50% EtOAc). The pure fractions were collected and the solvent was evaporated until dryness to give:

Fraction A: 0.92 g of intermediate 566 (45% yield)

Fraction B: 0.88 g of impure intermediate 566. Fraction B was repurified by silica gel chromatography (Irregular SiOH, 20-45 m, 40 g, mobile phase gradient from: 90%

Heptane, 10% EtOAc to 50% Heptane, 50% EtOAc). The pure fractions were collected and the solvent was evaporated until dryness to give:

Fraction C: 0.64 g of intermediate 566 (31% yield).

Fraction A and fraction C were combined to give 1.56 g of intermediate 566 (76% yield) which was directly used in the next step.

The intermediates in the table below were prepared by using an analogous method starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Inter- mediate Mass Yield number Structure (mg) (%) Inter- mediate 567

285 72 Inter- mediate 759

200 61 Anton Parr μw

Preparation of Intermediate 568

Intermediate 566 (1.56 g; 4.60 mmol) was hydrogenated at room temperature in MeOH (25.00 mL) and EtOAc (20.00 mL) with Pd/C 10% (0.330 g; 0.31 mmol) as a catalyst for 2 hours at atmospheric pressure. The catalyst was filtered over Celite® and the solvent was evaporated until dryness to give 916 mg of intermediate 568 (97% yield) directly used in the next step.

The intermediates in the table below were prepared by using an analogous method starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Intermediate Mass Yield number Structure (mg) (%) Intermediate 569

 156  91 Intermediate 576

 187  53 Intermediate 580

4340 100

Example A48 Preparation of Intermediate 577

At 0° C. oxalyl chloride (2M in DCM) (70 mL; 140 mmol) was added slowly to mixture of 5-nitro-3-pyrazolecaboxilic acid (14.50 g, 92.31 mmol) and dimethylformamide (0.200 mL, 2.58 mmol) in DCM (100 mL). The reaction mixture was stirred at room temperature overnight. The precipitate was filtered and the filtrate was evaporated until dryness to give 7.5 g (47%) of intermediate 577 directly used in the next steps without any further purification.

Preparation of Intermediate 578

Intermediate 577 (7.52 g; 42.84 mmol) was dissolved in THF (110.00 mL) at room temperature. Then a solution of methylamine (2M in THF) (28.00 mL; 56.00 mmol) in THF (20.00 mL) and trimethylamine (17.00 mL; 122.30 mmol) was added slowly (temperature increased). This reaction mixture was stirred for 4 hours at room temperature, then poured onto a mixture of a 10% aqueous solution of NH₄Cl and EtOAc (100 mL). The aqueous layer was extracted three times with EtOAc (3*200 mL). The organic layers were combined and the solvent was evaporated.

The crude residue was taken up with DCM and triturated. The precipitate was filtered and dried until dryness to give 825 mg (11%) of intermediate 578.

The filtrate was purified via silica gel chromatography (Gradient: 98% DCM, 2% MeOH, 0.2% NH₄OH to 93% DCM, 7% MeOH, 0.7% NH₄OH).

The desired fractions were collected and the solvent was evaporated to give 0.126 g of intermediate 578 (impure).

The aqueous layer was acidified until pH 5 with a 10% aqueous solution of HCl and was extracted twice with EtOAc (2*200 mL). The organic layers were mixed and the solvent was evaporated to give 3.46 g (47%) of intermediate 578.

A total of 4.28 g (59%) of intermediate 578 was obtained and directly used in the next reaction step without further purification.

Preparation of Intermediate 579 and intermediate 269

In sealed tube, a mixture of intermediate 578 (4.28 g; 25.16 mmol), potassium carbonate (6.81 g; 50.03 mmol) and 2-iodopropane (3.00 mL) in DMF (50 mL) was stirred at 120° C. for 2 hours and 20 minutes. Additional 2-iodopropane (1.00 mL; 10.00 mmol) was added and this reaction was stirred for 2 more hours at 120° C. The mixture was poured onto a mixture of water and a saturated solution of NH₄Cl. Then, this mixture was extracted three times with DCM. The organic layer were mixed and the solvent was evaporated until dryness.

The residue (6.34 g) was purified via silica gel chromatography (Stationary phase: irregular SiOH 40 m 330 g, Mobile phase: Gradient from 70% heptane, 30% EtOAc to 60% heptane, 40% EtOAc). The pure fractions were collected and the solvent was evaporated until dryness to give:

-   -   1.30 g (24%) of intermediate 269     -   2.50 g (47%) of intermediate 579 which was combined with another         batch of 2.42 g, coming from another reaction, and engaged in         the next reaction step.

Example A49 Preparation of Intermediate 582

To a suspension of 4-nitro-3-pyrazole carboxylic acid (6 g, 38.196 mmol) and DMF (73.938 μL, 0.944 g/mL, 0.955 mmol) in DCM (48.93 mL) at 0° C. was added dropwise a solution of oxalyl chloride 2M in DCM (36 mL, 2 M, 72 mmol) and the reaction mixture was stirred at ambient temperature for 18 h. The reaction mixture was concentrated in vacuo and the residue was dissolved in 20 mL of DCM and 1-methylpiperazine (6.355 mL, 0.903 g/mL, 57.294 mmol) was added slowly at 0° C. The reaction mixture was then allowed to warm to rt and stirred at rt overnight. DCM was removed in vacuo and the resulting slurry was diluted with DCM and a little MeOH. The insoluble residue was filtered off to give 5 g (54%) of intermediate 582.

The filtrate was concentrated in vacuo and purified by Normal phase flash chromatography (Irregular SiOH 40 m 40 g GRACE). Mobile phase 98% DCM, 2% MeOH, 0.2% NH₄OH to 90% DCM, 10% MeOH, 1% NH₄OH. The pure fractions were combined and the solvent was evaporated to give a further 2.7 g (30%) of intermediate 582.

Example A50 Preparation of Intermediate 584

Borane tetrahydrofuran complex, 1.0M in THF (8.30 mL; 1 M, 8.31 mmol) was added dropwise over 1 h to a stirred suspension of intermediate 583 (630 mg, 2.08 mmol) in THF (4.40 mL, 0.886 g/mL, 54.01 mmol) at 0° C. The reaction mixture was stirred at 0° C. for 2 h and then at rt overnight. Then H₂O was added (2.077 mL), and the mixture extracted with DCM. The organic layers were decanted, dried over MgSO₄, filtered and evaporated. The crude product was purified by Normal phase flash chromatography (Irregular SiOH 40 m 80 g GRACE). Mobile phase 100% DCM to 90% DCM, 10% MeOH, 1% NH₄OH. The pure fractions were combined and the solvent was evaporated to give 337 mg of material. This material was further purified by Normal phase flash chromatography (Irregular SiOH 40 μm 40 g GRACE). Mobile phase 80% Heptane, 20% AcOEt to 40% Heptane, 50% AcOEt, 10% MeOH, 0.1% NH₄OH. The pure fractions were combined in 2 batches and the solvent was evaporated to give respectively 113 mg (19%) of intermediate 584 (19%) and 120 mg of intermediate 584 (20%).

Example A51 Preparation of Intermediate 632, intermediate 633 and intermediate 634

A mixture of intermediate 730 (800 mg, 4.68 mmol), cyclopentyl bromide (0.600 mL, 5.60 mmol) and K₂CO₃ (1.25 g, 9.04 mmol) in DMF (5.50 mL) was stirred in a sealed tube at 120° C. using one single mode microwave (Biotage Initiator EXP 60) with a power output ranging from 0 to 400 W for 30 min. [fixed hold time]. The reaction was cooled down to room temperature. The mixture was poured out onto water and DCM. The mixture was decanted and the solvent was evaporated until dryness. The crude was purified by Normal phase flash chromatography (Irregular SiOH 15-40 m 40 g GraceResolv®). Mobile phase 90% Heptane, 10% AcOEt to 60% Heptane, 40% AcOEt. The pure fractions were combined and the solvent was evaporated to give 142 mg (10%) of intermediate 634 and 670 mg of a mixture of the intermediates (60%), which was used directly in the next step.

Alternative Preparation of Intermediate 633

Cyclopentyl iodide (0.608 ml; 5.26 mmol) was added to a solution of intermediate 730 (600 mg; 3.506 mmol) in DMF (12 ml) under N₂ atmosphere. The mixture was stirred at rt for 15 minutes and K₂CO₃ (969.2 mg; 7.013 mmol) was added. The reaction was stirred at rt for overnight. The reaction mixture was diluted with ice water (5 mL). The precipitate was filtered off and washed with water and dried in vacuo. The product was taken forward directly in the next step.

Preparation of Intermediate 640 and intermediate 641

Lithium hydroxide monohydrate (5.80 g; 137.94 mmol) and water (35.4 mL) were added to a solution of the mixture of intermediates 632, 633 and 634 (30 g; 125.40 mmol) in THF (430 mL) and MeOH (430 mL). The reaction mixture was stirred at rt for overnight. The volume of the solution was reduced in vacuo and the solution was poured onto an aqueous solution HCl 3N (500 mL). The resultant precipitate was filtered, washed with aqueous solution of HCl 1M and dissolved in DCM (400 mL). The organic layer was dried over MgSO₄, filtered and the solvent was evaporated to give 25.16 g of a mixture of the intermediates 640 and 641. The product (675 mg; 80%) was used without purification for the next step.

Alternative Preparation of Intermediate 641

Intermediate 633 (650 mg; 2.717 mmol) was dissolved in a mixture of MeOH (7 ml) and THF (7 ml). To this solution, was added H₂O (0.5 ml) and Lithium hydroxide monohydrate (125.4 mg; 2.989 mmol) and the mixture was stirred until the starting material had disappeared on the TLC. The solution was concentrated in vacuo, the residue was then dissolved in H₂O and acidified with 1M HCl (aq). The resultant precipitate was filtered, washed with aq. 1M HCl and dried in vacuo. The product (250 mg; 41%) was taken forward directly in the next step.

Preparation of Intermediate 721

Intermediate 641 (210 mg, 0.933 mmol) was dissolved in DCM (10 mL) and TEA (0.26 mL, 1.865 mmol) was added. To the stirred solution, pyrrolidine (0.156 mL, 1.865 mmol), EDC hydrochloride (357.5 mg, 1.865 mmol) and HOBT (285.6 mg, 1.865 mmol) were added. The resulting suspension was stirred at rt overnight. The reaction mixture was quenched by addition of water (10 ml). The organic layer was washed with brine and the layers were separated. The organic layer was dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel (irregular SiOH, 15-40 μm, mobile phase: Heptane/EtOAc 50:50). The fractions containing the product were combined and evaporated to dryness to give 210 mg of intermediate 721 (81% yield).

Example A52

Preparation of Intermediate 595 and 596

Cyanomethylenetributylphosphorane (19.769 mL, 0.92 g/mL, 75.354 mmol) was added to a solution of intermediate 487 (7 g, 40.909 mmol) and 2,2-difluoroethanol, 97% (4.68 g, 57.034 mmol) in toluene (195.641 mL, 0.867 g/mL, 1840.895 mmol) in a sealed tube. The reaction mixture was stirred at 110° C. using one single mode microwave (Masterwave BTR Anton Paar) with a power output ranging from 0 to 1700 W for 30 min. [fixed hold time]. The reaction mixture was diluted with EtOAc washed with a solution 10% of K₂CO₃ (aq), water and a solution of saturated NaCl. The layers were separated and the organic layer was dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The crude was purified by Normal phase flash chromatography (Irregular SiOH 40 m 330 g GRACE). Mobile phase 90% Heptane, 10% AcOEt to 40% Heptane, 60% AcOEt. The pure fractions were combined and the solvent was evaporated to give 1.77 g of pre-purified intermediate 596 (18%) and 2.9 g of pre-purified intermediate 595 (30%).

The 1.77 g was further purified by Normal phase flash chromatography (Irregular SiOH 40 μm 80 g GRACE). Mobile phase 80% DCM, 20% Heptane to 99% DCM, 1% MeOH, 0.1% NH₄₀OH. The pure fractions were combined and the solvent was evaporated to give 1 μg of intermediate 596 (11%).

The 2.9 g was further purified by Normal phase flash chromatography (Irregular SiOH 40 μm 120 g GRACE). Mobile phase 80% DCM, 20% Heptane to 99% DCM, 1% MeOH, 0.1% NH₄OH. The pure fractions were combined and the solvent was evaporated to give 1.66 g of intermediate 595 (17%).

The intermediates in the table below were prepared by using an analogous method starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Mass Yield Int. number structure (mg) (%) Mixture of Intermediates 644 + 645

1270 40

Example A53 Preparation of Intermediate 597

Intermediate 595 (0.6 g, 2.55 mmol) in methyl amine 40% in THF (6.40 mL, 2 M, 12.76 mmol) and ^(i)PrOH (3.90 mL, 0.785 g/mL, 51.03 mmol) in a sealed tube were stirred at 120° C. using one single mode microwave (Biotage Initiator EXP 60) with a power output ranging from 0 to 400 W for 30 min. [fixed hold time]. The volatiles were evaporated. The crude residue was purified via preparative LC (Stationary phase: irregular SiOH 15-40 μm 40 g GraceResolv®, Mobile phase: gradient from 100% DCM to 97% DCM, 3% MeOH (2% NH₄OH))

The pure fractions were collected and the solvent was evaporated until dryness to give intermediate 597 (418 mg, 70%)

The intermediates in the table below were prepared by using an analogous method starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Mass Yield Int. number structure (mg) (%) Intermediate 606

192 34 Intermediate 612

293 59 Intermediate 616

136 22 Procedure in MeOH 80° C. 10 min Intermediate 635

210 31 Intermediate 636

131 20 Intermediate 646

670 53 Intermediate 666

359 99 Neat Procedure in methyl- amine RT 30 min

Example A54 Preparation of Intermediate 654

A mixture of intermediate 653 and methylamine solution (33 wt % in EtOH) was stirred at rt for 1 h. The volatiles were removed under reduced pressure, without heating, to afford intermediate 654 (161 mg, 88%). The material was used directly in the next step.

Example A55 Preparation of Intermediate 620

A solution of 4-nitro-3-pyrazole carboxylic acid (5 g, 31.83 mmol), iodomethane (3.963 mL, 2.28 g/mL, 63.66 mmol) and K₂CO₃ (8.798 g, 63.66 mmol) in DMF (60 mL) was stirred rt overnight. Ethyl acetate and water were added to the mixture. The organic layer was dried over MgSO₄, filtered and concentrated. A purification was performed via preparative LC (Stationary phase: irregular SiOH 15-40 μm 220 g grace, Mobile phase: gradient from 90% Heptane, 10% AcOEt to 40% Heptane, 60% AcOEt. The pure fractions were combined and the solvent was evaporated to give 1.43 g of intermediate 610 (24%) and 2.5 g of intermediate 611 (42%).

Example A56 Preparation of Intermediate 620

KO^(t)Bu (938 mg, 8.36 mmol) was added to a stirred solution of 5-chloro-1-methyl-4-nitro-1H-pyrazole (900 mg, 5.57 mmol) and cyclopropanol (970.713 mg, 16.713 mmol) in MeCN (7.27 mL) at rt. Addition was done portionwise. The mixture was stirred at rt for 3 hours. Water was added and the mixture acidified with 3N HCl(aq). The reaction mixture was extracted with DCM, dried over MgSO₄, filtered and evaporated. A purification was performed via preparative LC (Stationary phase: irregular SiOH 15-40 μm 80 g GraceResolv®, Mobile phase: gradient from 100% DCM to 98% DCM, 2% MeOH, 0.1% NH₄OH) to afford intermediate 620 (470 mg, yield 46%).

The intermediates in the table below were prepared by using an analogous method starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Mass Int. number structure (mg) Yield (%) Intermediate 624

 235 19 140° C. 20 min Intermediate 628

 407 58 Procedure in ^(i)PrOH, reflux, 12 h Intermediate 741

3300 65

Example A57 Preparation of Intermediate 657

Lithium bis(trimethylsilyl)amide (3.713 mL, 1 M, 3.713 mmol) was added dropwise to a stirred solution of intermediate 656 (700 mg, 3.094 mmol) in THF (9.282 mL, 0.886 g/mL, 114.055 mmol) at −70° C. under nitrogen. The reaction mixture was stirred at −70° C. for 2 hours then hexachloroethane (878.997 mg, 3.713 mmol) in THF (1.856 mL, 0.886 g/mL, 22.811 mmol) was added dropwise. The resulting mixture was allowed to stir at rt and stirred for 1 hour. A diluted solution of NH₄Cl was added and the aqueous layer was extracted with DCM and the combined layers were dried over MgSO₄. After filtration and removal of the solvent in vacuo, 550 mg of intermediate 657 (68%. yield) were obtained and directly used in the next steps without any further treatment.

Preparation of Intermediate 658

Intermediate 657 (420 mg, 1.611 mmol) in ^(i)PrOH (2.965 mL, 0.785 g/mL, 38.726 mmol) in a sealed tube were stirred at 165° C. using one single mode microwave (Biotage Initiator EXP 60) with a power output ranging from 0 to 400 W for 10 min. [fixed hold time]. Sodium Isopropoxide (396.724 mg, 4.834 mmol) was added. Then the resulting mixture was stirred at 165° C. using one single mode microwave (Biotage Initiator EXP 60) with a power output ranging from 0 to 400 W for 5 min. [fixed hold time]. The reaction mixture was poured onto water and an extraction was performed with DCM. The organic layer was washed with brine and the layers were separated. The organic layer was dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel (irregular SiOH, 15-40 m, 40 g, GraceResolv®), mobile phase: DCM/(MeOH(+10% aq. NH₄OH)), gradient from 100:0 to 96:4). The fractions containing the product were combined and evaporated to dryness to give 285 mg of intermediate 658 (79% yield).

Example A58 Preparation of Intermediate 662

Intermediate 657 (990 mg, 3.798 mmol) was stirred in ^(i)PrOH for 20 minutes at 165° C. in a sealed tube. ^(i)PrOH was evaporated to give the nitro pre-cursor to the targeted amino pyrazole. The residue was taken up into MeOH (18.045 mL, 0.791 g/mL, 445.47 mmol). AcOH (2.143 mL, 1.049 g/mL, 37.432 mmol) then zinc (2.483 g, 37.978 mmol) were added and the reaction mixture was stirred at rt for 1 hour.

The resulting mixture was filtered on a pad of Celite® and the solvent was concentrated under reduced pressure. A diluted solution of 10% K₂CO₃ (aq) was added and the aqueous layer was extracted with DCM and the combined layers were dried over MgSO₄. After filtration and removal of the solvent in vacuo, 437 mg of intermediate 662 (50%) were obtained and directly used in the next steps without any further treatment.

Preparation of Intermediate 663

Intermediate 662 (384 mg, 1.665 mmol) and hexahydro-1H-furo[3,4-C]pyrrole (470.891 mg, 4.161 mmol) in ^(i)PrOH (3.063 mL, 0.785 g/mL, 40.009 mmol) in a sealed tube were stirred at 165° C. using one single mode microwave (Biotage Initiator EXP 60) with a power output ranging from 0 to 400 W for 10 min. [fixed hold time]. The residue was purified by column chromatography on silica gel (irregular SiOH 15-40 m, 40 g GraceResolv®, mobile phase: DCM/(MeOH(+2% aq. NH₄OH)), gradient from 100:0 to 90:10). The fractions containing the product were combined and evaporated to dryness to give 371 mg of intermediate 663 (73% yield).

Example A59 Preparation of Intermediate 672

Methyl alpha-chloroacrylate (25 g, 1.189 g/mL, 207.408 mmol) in THF (70 mL) and methylhydrazine (22.083 mL, 0.86 g/mL, 412.217 mmol) in THF (70 mL) were added dropwise at the same rate to THF (10 mL) at rt. The reaction mixture was stirred at rt for 16 h then was heated at 50° C. for 1 hour. The resulting mixture was diluted with water. The aqueous layer was extracted with EtOAc (4×) and the layers were separated. The organic layer was dried over MgSO₄, filtered and the solvent was removed under reduced pressure to give 15.7 g intermediate 672 (77%, yield) which was used directly for the next step>yligny_4508_1

Preparation of Intermediate 673

H₂SO₄ (39.369 mL, 1.84 g/mL, 738.569 mmol) was cooled down to −5° C. Intermediate 672 (3 g, 30.58 mmol) was added and the solution was stirred for 15 minutes at 0° C. HNO₃ (43.306 mL, 1.38 g/mL, 948.406 mmol) was added dropwise. The reaction was stirred at 0-5° C. for 2 hours. The reaction mixture was poured out onto ice and water, stirred for 20 min and the precipitate was filtered off and dried, affording intermediate 673 (2.3 g, yield 52.6%).

Preparation of Intermediate 674

Cyanomethylenetributyl phosphorane (3.483 mL, 0.92 g/mL, 13.277 mmol) was added to a solution of intermediate 673 (1 g, 6.988 mmol) and 4-(2-hydroxyethyl)morpholine (1.273 mL, 1.08 g/mL, 10.482 mmol) in toluene (30.449 mL) at rt. The mixture was stirred at rt for 18 hours. The solvent was evaporated and the residue was purified by preparative LC (Irregular SiOH 20-45 m 40 g GraceResolv®, mobile phase Gradient from 80% Heptane, 20% AcOEt to 40% Heptane, 50% AcOEt, 10% MeOH (2% NH₄OH)). The pure fractions were combined and the solvent was evaporated to afford intermediate 674 (1.52 g, yield 84.9%).

Example A60 Preparation of Intermediate 707

Intermediate 577 (2.00 g; 11.39 mmol) was dissolved in THF (30.00 mL). Then a solution of pyrrolidine (15.00 mL; 13.00 mmol), triethylamine (4.50 mL; 32.37 mmol) in THF (10.00 mL) was added slowly to this mixture and the reaction was stirred overnight at room temperature. Water was added and this mixture was extracted twice with EtOAc. The organic layer was decanted and the solvent was evaporated until dryness to give 1.10 g (46%) of intermediate 707. The aqueous layer was acidified with 3N HCl(aq) and extracted twice with EtOAc. The organic layer was decanted and the solvent was evaporated until dryness to give a further 0.90 g (38%) of intermediate 707. The two fractions were combined to give 2.00 g (84%) of intermediate 707 which was used directly in the next step.

The intermediates in the table below were prepared by using an analogous method starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Intermediate Mass Yield number Structure (mg) (%) Intermediate 712

2140 89 Procedure in Et₃N, THF RT, o/n

Example A61 Preparation of Intermediate 729

A mixture of intermediate 728 (0.165 g; 0.26 mmol), SiO₂ 35-70 m (0.500 g) in toluene (4.00 mL) was stirred at 120° C. for 2 hours. The reaction was cooled down to room temperature. SiO₂ was filtered off and washed four times with a mixture of EtOAc/MeOH (85%/15%). The solvent was evaporated until dryness. The crude was purified by preparative LC (Irregular SiOH 20-45 m 40 g GraceResolv®, mobile phase: 98% DCM, 2% MeOH to 94% DCM 6% MeOH). The pure fractions were collected and the solvent was evaporated until dryness to afford intermediate 729 (0.066 g; 48%) which was used directly for the next step.

Example A62 Preparation of Intermediate 732

A solution of intermediate 731 (1.22 g, 6.59 mmol) in dry DCM (30 mL) was cooled to −78° C. The reaction mixture was purged with N₂, then DIBAL-H (1M solution in DCM) (7.25 mL, 7.249 mmol) was added dropwise. The resulting mixture was stirred at −78° C. for 1.5 h. A saturated NH₄Cl solution (1 mL) was added, followed by 1 M HCl (1 mL). The mixture was extracted with DCM. The organic layer was washed with brine and the layers were separated. The organic layer was dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel (irregular SiOH, 15-40 μm, mobile phase: Heptane/EtOAc 70:30). The fractions containing the product were combined and evaporated to dryness to give intermediate 732 (530 mg; 52% yield).

Preparation of Intermediate 733

To a solution of SnAP reagent (2-[(tributylstannyl)methoxy]-ethanamine) (0.995 mL, 3.417 mmol) in DCM (15 mL) at rt was added intermediate 732 (530 mg, 3.417 mmol) and Molecular Sieves 4A (100 mg/mmol, 341 mg). The resulting suspension was stirred at rt for 2 hours, filtered and concentrated under reduced pressure to afford the imine. Separately, 2,6-lutidine (0.398 mmol, 3.417 mmol) was added in one portion to a suspension of HFIP (10 mL) and Cu(OTf)₂ (1.236 g, 3.417 mmol). A solution of the imine in DCM (6 mL) was added in one portion and the resulting mixture was stirred at rt overnight. The reaction was quenched by addition of 10% aq NH₄OH (5 ML) and was extracted with DCM. The organic layer was washed with brine and the layers were separated. The organic layer was dried over MgSO₄, filtered and the solvent was removed under reduced pressure to give. The crude was purified by column chromatography on silica gel (irregular SiOH 15-40 m, mobile phase: DCM/(MeOH), gradient from 100:0 to 98:2). The fractions containing the product were combined and evaporated to dryness to give 270 mg of intermediate 733 (37% yield).

Preparation of Intermediate 734

To a solution of intermediate 733 (250 mg, 1.178 mmol) in MeOH (10 mL) were added formaldehyde (0.191 mL, 2.356 mmol) and then formic acid (0.444 μL, 0.0118 mmol). The reaction mixture was stirred at rt 1 hour. Then, sodium triacetoxyborohydride (312.1 mg, 1.473 mmol) was added and the reaction mixture was stirred for 1 hour. Then, the reaction mixture was carefully quenched by addition of saturated NaHCO₃ (aq) (2 mL). The organic layer was washed with brine and the layers were separated. The organic layer was dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel (irregular SiOH, 15-40 μm, mobile phase: EtOAc 100%). The fractions containing the product were combined and evaporated to dryness to give 180 mg of intermediate 734 (68% yield).

Example A63 Preparation of Intermediate 738

DIPEA (0.385 mL; 2.24 mmol) was added to a solution of 1-methyl-1H-pyrazol-3-amine (0.159 mL; 2 mmol) and 2,4-dichloro, 1,3,5-triazine (0.3 g; 2 mmol) in acetone (9 mL) at 0° C. The reaction mixture was allowed to warm up to rt, was purged with N₂ and was stirred for 3 h. A diluted solution of NH₄Cl was added and the aqueous layer was extracted twice with EtOAc and the combined layers were dried over MgSO₄. After filtration and removal of the solvent in vacuo, 660 mg of intermediate 738 (quantitative recovery, purity 57%) were obtained and used directly in the next step without any further treatment.

Preparation of Intermediate 739

To a solution of intermediate 5 (0.6 g; 0.772 mmol), intermediate 738 (0.285 g; 0.772 mmol) and cesium carbonate (0.755 g; 2.32 mmol) in 1,4-dioxane (3.9 mL) and distilled water (0.4 mL) was added tetrakis(triphenylphosphine)palladium(0) (0.045 g; 0.0386 mmol). The reaction mixture was heated at 95° C. overnight. The reaction mixture was poured into ice and extracted with EtOAc. The organic layer was washed with brine and the layers were separated. The organic layer was dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The crude residue was purified by column chromatography on silica gel (irregular SiOH, 15-40 m, 40 g, mobile phase: Heptane/EtOAc gradient from 100:0 to 0:100). The fractions containing the product were combined and evaporated to dryness to give 60 mg of intermediate 739 (13% yield).

Example A64

Preparation of Intermediate 746

At 0° C. and under nitrogen flux, NaH (60% dispersion in mineral oil) (0.510 g; 12.8 mmol) was added portionwise to a solution of cyclopropanol (0.64 mL, 12.74 mmol) in Me-THF (24 mL). The reaction was stirred at room temperature for 10 minutes.

At −78° C., the above described suspension was added dropwise to a solution of 1,4-dinitro-1H-pyrazole (3.00 g; 18.98 mmol) in Me-THF (6.50 mL, 64.9 mmol). The reaction mixture was stirred at −78° C. for 1 h then allowed to stir at rt for 5 hours. The reaction mixture was poured out onto water, made acidic with 3N HCl(aq), extracted with DCM, dried over MgSO₄, filtered and evaporated. The crude was purified via preparative LC (Stationary phase irregular SiOH 15-40 m 24 g GraceResolv®, Mobile phase: gradient from 80% Heptane, 20% EtOAc to 40% heptane, 60% EtOAc). The pure fractions were collected and the solvent was evaporated to give 466 mg of intermediate 746 (22%).

Example A65 Preparation of Intermediate 754

NaH (60% dispersion in mineral oil) (0.340 g; 8.5 mmol) was added to a solution of dimethyl carbonate (0.83 mL; 9.85 mmol) in 1,4-dioxane (4.00 mL) The mixture was heated at 90° C. and 1-(tetrahydro-2H-pyran-4-yl) ethanone (0.5 g; 3.90 mmol) in 1,4-dioxane (1.00 mL) was added to the suspension. The reaction mixture was stirred at reflux for 3 hours. Water was added and few drops of an aqueous solution of 3N HCl.

The mixture was extracted twice with ethylic ether. The organic layer was decanted and the solvent was evaporated until dryness to give 0.65 g of intermediate 754 (89%).

Example A66 Preparation of Intermediate 762

In a sealed tube, 4-nitro-1H-pyrazole (1.9 g, 16.5 mmol), (R)-glycidyl methyl ether (1.6 g, 18.2 mmol) and K₂CO₃ (3.4 g, 24.8 mmol) in DMF (17.9 mL, 231 mmol) were stirred at 130° C. using one single mode microwave (Masterwave BTR Anton Paar) with a power output ranging from 0 to 1700 W for 5 min. [fixed hold time]. The reaction mixture was poured out onto water, made acidic with 3N HCl(aq), extracted twice with AcOEt and the combined organic layers were washed with water, dried over MgSO₄, filtered and evaporated. The residue was purified by Normal phase on (Irregular SiOH 40 μm 40 g GraceResolv®). Mobile phase gradient from 80% heptane, 20% AcOEt to 60% heptane, 40% AcOEt. The pure fractions were combined and the solvent was evaporated to give 1.52 g of intermediate 762 (46%).

Preparation of Intermediate 763

Lithium bis(trimethylsilyl)amide (1M in THF) (18 mL, 1 M, 18 mmol) was added dropwise to a stirred solution of intermediate E5 (1.5 g, 7.5 mmol) in THF (22 mL) at −70° C. under nitrogen. The reactive mixture was stirred at −70° C. for 1 hour and hexachloroethane (2.1 g, 8.9 mmol) in THF (4.5 mL) was added dropwise. The reactive mixture was allowed to stir at rt for 2 h. Water and 3N HCl(aq) were added and the solution was extracted with DCM. The organic layer was dried over MgSO₄, filtered and evaporated. The crude residue was purified via silica gel chromatography (Stationary phase: irregular SiOH 15-40 μm, 80 g, mobile phase: gradient from 80% heptane, 20% AcOEt to 60% heptane, 40% AcOEt) to give 700 mg of intermediate 763 (47% yield).

Example A67 Preparation of Intermediate 767

A solution of intermediate 4S (3.85 g; 8 mmol) in dry THF (50 mL) was treated with TBAF (1M in THF) (9 mL; 9 mmol) and allowed to stir at room temperature. The reaction mixture was stirred for 30 min, diluted with EtOAc and washed with brine (3×). The organic layer was dried over MgSO₄, filtered, concentrated, and dried overnight under high-vacuum to yield 3.36 g of intermediate 767 (greater than quantitative recovery, pure at 67%).

Preparation of Intermediate 768

A solution of intermediate 767 (3.36 g; 6.12 mmol) and DIPEA (3 mL; 17.4 mmol) in CH₂Cl₂ (50 mL) was cooled down to 0° C. and treated with mesyl chloride (1 mL; 12.9 mmol). The reaction mixture was allowed to warm to room temperature and stirred for 30 minutes. The volatiles were evaporated. The residue was redissolved in CH₂Cl₂ and purified via Flash column chromatography (330 g SiO₂, 25-75% EtOAc/Hex over 5 Column Volumes). The desired fractions were combined, concentrated, and dried under high-vac to yield 2.56 g of intermediate 768 (93% yield, 92% purity) as a pale yellow/off-white solid.

Preparation of Intermediate 769 and 769′

A heterogeneous solution of intermediate 768 (2.48 g; 5.13 mmol) and sodium azide (0.74 g; 11.2 mmol) in dry DMF (20 mL) was heated overnight at 115° C. while stirring under N₂. The reaction mixture was cooled to room temperature, diluted with EtOAc and washed with water followed by brine (2×). The organic layer was dried (MgSO₄), filtered, concentrated, and dried under high-vacuum to give 1.68 g of a mixture of intermediate 769 and intermediate 769′ (in a ratio of 3/1).

Preparation of Intermediate 770 and 770′

A homogeneous solution of the mixture of intermediate 769 and intermediate 769′ (1.68 g; 4.3 mmol) in dry THF (25 mL) was treated with triphenylphosphine (1.68 g; 6.4 mmol) and allowed to stir overnight at room temperature. Next day, Water (5 mL; 277 mmol) was added and the reaction mixture was stirred at 50° C. for 18 hours. Next day, the reaction mixture was cooled down to room temperature, diluted with EtOAc and washed with brine (3×). The organic layer was dried (MgSO₄), filtered, concentrated, and dried under high-vacuum. The crude residue was re-dissolved in a minimal amount of CH₂Cl₂ and purified via Flash Column Chromatography (120 g SiO₂, 0-10% 2N NH₃/MeOH/EtOAc over 10 Column Volumes, flushing with MeOH). The desired fractions were combined, concentrated, and dried under high-vacuum to give 2.03 g of intermediate 770 (129%, pure at 38%) and 0.38 g of intermediate 770′ (32%).

Preparation of Intermediate 771

A homogeneous solution of intermediate 770 (2.03 g, 2.1 mmol) in CH₂Cl₂ (20 mL) was treated with di-tert-butyl dicarbonate (1 mL; 4.7 mmol) at room temperature. The reaction mixture was stirred for 1 hour. The volatiles were evaporated. The residue was re-dissolved in a minimal amount of CH₂Cl₂ and purified via Flash Column Chromatography (40 g SiO₂, 0-50% EtOAc/Hex over 10 Column Volumes). The desired fractions were combined, concentrated, and dried under high-vacuum to yield 1 g of intermediate 771 (quant, based on purity of starting material) as a white solid.

Preparation of Intermediate 772

In a 20 mL vial, intermediate 771 (0.395 g; 0.847 mmol), bis(pinacolato)diboron (0.326 g; 1.284 mmol), potassium acetate (0.262 g; 2.67 mmol) and 2nd generation Xphos precatalyst (chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl) [2-(2′-amino-1,1′-biphenyl)]palladium(II)) (0.035 g; 0.0445 mmol) together with a stirbar were added and the vessel capped. The atmosphere was evacuated and purged with N₂ (3×) and then the vial was charged with dry, freshly degassed 1,4-dioxane (5 ml). Heating was started directly at 80° C. After 30 min, the reaction mixture had turned heterogeneous black and HPLC indicated complete consumption of intermediate 771. The filtrate was concentrated and dried under high-vacuum to yield crude intermediate 772 as a dark yellow oil. The material used directly in the next step (quantitative conversion assumed).

The intermediate in the table below was prepared by using an analogous 6 step sequence as applied for intermediate 772, but starting from the enantiomeric starting material, 4R.

Inter- mediate Yield number Structure Mass (mg) (%) Inter- mediate 773

218 (used without further purification)

Example A68 Preparation of Intermediate 774

1-Methyl-1H-pyrazol-3-amine (70.0 g, 721 mmol) and 2-(methylthio)pyrimidin-4(3H)-one (63.0 g, 443 mmol) were added to a 250 mL round-bottomed flask. The resulting mixture was then stirred and heated at 180° C. for 2 hours before a yellow solid was formed. The resulting mixture was cooled to room-temperature. The residue was triturated with ethanol (300 mL), filtered, to afford intermediate 774 (80 g, 94.3%) as a white solid, which was used in the next step without further purification.

Preparation of Intermediate 775

Intermediate 774 (80.0 g, 418 mmol) and phosphoryl trichloride (256.6 g, 1674 mmol) were added to a 500 mL flask. The reaction mixture was stirred at 100° C. for 2 hours. After cooling to r.t., the mixture was concentrated to dryness under reduced pressure. The residue was redissolved in dichloromethane (500 mL) and H₂O (500 mL), neutralised cautiously with saturated aqueous NaHCO₃ to pH=7.0. The mixture was extracted with dichloromethane (500 mL×3). The combined organic extracts were dried over anhydrous Na₂SO₄, filtered and concentrated to dryness under reduced pressure to afford intermediate 775 (81 g, 89%) as a yellow solid.

Example A69 Preparation of Intermediate 776

In a 25 mL round bottomed flask were added intermediate 773 (0.218 g; 0.425 mmol), intermediate 775 (0.189 g; 0.902 mmol), potassium phosphate (tribasic) (0.482 g; 2.203 mmol), 2nd generation Xphos precatalyst (chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II)) (0.022 g; 0.028 mmol) together with a stirbar. The vessel was sealed and the atmosphere evacuated and purged with N₂ (3×). The vessel was then charged with freshly degassed solvents: dioxane (5 mL) and de-ionized H₂O (1 mL). Heating was started directly at 80° C. After 1 hour 30 min the reaction was cooled to room temp, diluted with EtOAc, and washed with de-ionized H₂O (3×). The organic layer was dried (MgSO₄), filtered, concentrated, and dried under high-vacuum to yield a dark yellow oil. The crude material was dissolved in a minimal amount of CH₂Cl₂ and purified via Flash Column Chromatography (40 g, 0-100% EtOAc/CH₂Cl₂ over 10 Column Volumes). The desired fractions were combined, concentrated, and dried under high-vacuum to yield 172 mg of intermediate 776 (63% yield; 88% purity) as a yellow solid.

The intermediate in the table below was prepared by using an analogous method starting from the respective R enantiomer, intermediate 772. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Intermediate Mass Yield number Structure (mg) (%) Intermediate 777

240 95

Example A70 Preparation of Intermediate 778 and 778′

Methanesulfonyl chloride (6.683 mL, 1.48 g/mL, 86.338 mmol) was added to a solution of 3-methoxy-3-methylbutanol (5 g, 42.31 mmol) and Et₃N (17.661 mL, 0.728 g/mL, 127.059 mmol) in DCM (477.33 mL, 1.326 g/mL, 7452.28 mmol) at rt and the reaction mixture was stirred for 18 h. Water was added. The organic layer was separated, washed with 1N HCl(aq) then with brine before drying over MgSO₄. The organic layer was filtered and evaporated to afford a mixture on intermediate 778 and 778′ (10.3 g, quantitative yield) that was used directly in the next step.

Example A71 Preparation of Intermediate 779

To a solution of 2-Amino-3-bromobenzonitrile (30.0 g) in THF (240 mL) was added sodium tert-butoxide (1.1 eq.) and the mixture was stirred at −5 to 50° C. for 1 hour. A solution of intermediate 3a in THF (85.0 g) was then added dropwise and the mixture was stirred for 2-4 hours monitoring the conversion by HPLC. Water (210 mL) was then added dropwise and the mixture was concentrated to remove most of THF. Heptane (300 mL) was then added and the mixture was stirred for 30 min. After phase separation, the organic layer was washed with water (210 mL), concentrated to 2-3 volumes and filtered through a pad of silica gel (60 g), washing the pad with heptane (300 mL), affording 63.3 g of intermediate 779.

Preparation of Intermediate 780

To a solution of intermediate 779 (50.0 g) in dry THF (500 mL) was added dimethylaminopyridine (0.5 eq.) and the temperature was adjusted to 65-70° C. Di-tert-butyldicarbonate (2.2 eq.) was then added and the mixture was stirred for 2 hours (monitoring by HPLC). Water (350 mL) was added and the mixture was concentrated to 350-400 mL. Heptane (500 mL) was added and the pH was adjusted by addition of 20% aqueous AcOH to 4-6. The layers were separated and water (350 mL) was added. After pH adjustment to 7-8 with aqueous 8% NaHCO₃, the layers were separated and the organic layer was washed with water (350 mL) and concentrated to afford 64 g (quantitative) of intermediate 780.

B. Preparation of the Final Compounds Example B 1

Preparation of Compound 1

A mixture of intermediate 8 (1.09 g, 2.29 mmol) and TBAF (1M in THF) (2.50 mL, 2.50 mmol) in Me-THF (20 mL) was stirred at rt for 18 h. The reaction mixture was directly purified by column chromatography on silica gel (irregular SiOH 15-40 m, 120 g, liquid injection with a mixture of Me-THF/DCM, mobile phase: DCM/(MeOH(10% aq NH₃)), gradient from 100:0 to 90:10 in 10 CV). The fractions containing the product were combined and concentrated under vacuum to give 650 mg of compound 1 (78% yield, yellow solid). 255 mg of compound 1 was solubilized in a mixture of CH₃CN/H₂O (1:1) and freeze-dried overnight then dried at 50° C. under reduced pressure to give 255 mg of compound 1 (31%, yellow fluffy solid).

Preparation of Compound 19

A mixture of intermediate 47 (0.35 g, 0.74 mmol) and TBAF (1M in THF) (0.80 mL, 0.80 mmol) in THF (6 mL) was stirred at rt for 18 h. The reaction mixture was directly (without evaporation) purified by column chromatography on silica gel (irregular SiOH, 15-40 m, 120 g, liquid injection (THF/DCM), mobile phase gradient: DCM/(MeOH(10% aq. NH₃)) from 100:0 to 90:10 in 15 CV). The fractions containing the product were combined and evaporated to dryness to give 231 mg of compound 19 (87% yield, yellow solid).

Preparation of Compound 42

At rt, intermediate 100 (7.60 mL, 7.60 mmol) was added to a solution of TBAF (1M in THF) (2.72 g, 5.10 mmol) in Me-THF (50 mL) and stirred at rt overnight. Water was added and this mixture was extracted twice with EtOAc. The organic layer was decanted and the solvent was evaporated until dryness. The residue was taken up into EtOH and this precipitate was triturated and filtered. The product was dried until dryness to give 1.27 g of compound 42 (56% yield).

Preparation of Compound 49

This reaction was done twice on the same quantities of intermediate 117 (12 g, 21.91 mmol). A mixture of intermediate 117 (12.00 g, 21.9 mmol) and TBAF (1M in THF) (48.19 mL, 48.19 mmol) in Me-THF (231.5 mL) was stirred at rt for 12 h. The reaction mixtures were mixed and diluted with EtOAc and water and the layers were separated. The organic layer was washed with brine, dried over MgSO₄, filtered and was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (irregular SiOH, 40 m, 330 g mobile phase from 99% DCM, 1% MeOH, 0.1% NH₄OH to 97% DCM, 3% MeOH, 0.3% NH₄OH). The pure fractions were combined and the solvent was evaporated. The residue (12.900 g) was crystallized with CH₃CN to give 11.565 g of compound 49 (60% yield). M.P=164° C. (K).

Preparation of Compound 107

To a solution of intermediate 291 (2.86 g, 5.18 mmol) in Me-THF (60 mL) was added TBAF (1M in THF) (5.95 mL, 5.95 mmol) and the mixture was stirred at rt overnight and combined with another batch (from 270 mg of intermediate 291). The residue was purified by column chromatography on silica gel (irregular SiOH, 15-40 m, 120 g, dry load on Celite®, mobile phase: DCM/MeOH (aq. NH₃ 5%), gradient from 100:0 to 90:10). The fractions containing the product were combined and evaporated to dryness. The residue (1480 mg) was taken up with water, triturated and sonicated at 45° C. for 1 h. The mixture was then filtered on a glass frit and the resulting solid was then washed twice with Et₂O, collected and dried under reduced pressure at 50° C. for 16 h to give 1.23 g of compound 107 (54% yield, white solid).

Preparation of Compound 113

A mixture of intermediate 314 (425.00 mg, 0.73 mmol) and TBAF (1M in THF) (0.81 mL, 0.81 mmol) in dry Me-THF (10 mL) was stirred at rt for 17 h. The reaction mixture was diluted with EtOAc and washed with water. The organic layer was dried over MgSO₄, filtered and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (irregular SiOH, 15-40 m, 24 g, liquid injection in DCM, mobile phase: DCM/iPrOH, gradient from 100:0 to 90:10). The fractions containing the product were combined and evaporated to dryness. The residue (247 mg, yellow solid) was dried at 50° C. under reduced pressure for 17 h to give 205 mg of a yellow powder. This residue was dried again at 50° C. under reduced pressure for 72 h. Then, it was solubilized in MeOH (1 mL), extended with water (8 mL) and freeze-dried to afford 164 mg of compound 113 (48% yield, white fluffy solid).

Preparation of Compound 114

A mixture of intermediate 318 (511.00 mg, 0.88 mmol) and TBAF (1M in THF) (0.97 mL, 0.97 mmol) in Me-THF (12.5 mL) was stirred at rt for 17 h. The reaction mixture was diluted with DCM and washed with water. The organic layer was dried over MgSO₄, filtered, and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel (irregular SiOH, 15-40 m, 24 g, liquid injection in DCM, mobile phase: DCM/MeOH, gradient from 100:0 to 90:10). The fractions containing the product were combined and evaporated to dryness. The residue (275 mg, yellow oil) was purified by reverse phase (stationary phase: X-Bridge-C18, 10 m, 30×150 mm, mobile phase gradient: from 65% aq. NH₄HCO₃ (0.2%), 35% CH₃CN to 25% aq. NH₄HCO₃ (0.2%), 75% CH₃CN). The fractions containing the product were combined and evaporated to dryness. The residue (173 mg, pale yellow residue) was solubilized in MeOH (1 mL), extended with water (8 mL) and freeze-dried to afford 153 mg of compound 114 (37% yield, white fluffy solid).

Preparation of Compound 118

A solution of intermediate 334 (209.00 mg, 0.34 mmol) in Me-THF (4 mL) was treated with TBAF (1M in THF) (0.38 mL, 0.38 mmol) and stirred at rt for 17 h. Celite® was added and the crude mixture was evaporated in vacuo to give a dry load which was purified by column chromatography on silica gel (irregular SiOH, 15-40 m, 40 g, mobile phase gradient: from DCM 98%, MeOH (+5% aq. NH₃) 2% to DCM 90%, MeOH (+5% aq. NH₃) 10%). The fractions containing the product were combined and evaporated to dryness. The residue was recrystallized from EtOH. After cooling down to rt, the mixture was filtered on a glass frit and the solid was washed with Et₂O, collected and dried in vacuo. This residue (102 mg, white solid) was warmed in EtOH (mainly insoluble) and sonicated during 15 min. The mixture was evaporated in vacuo to give a solid which was dried in vacuo to afford 90 mg of compound 118 (53% yield, off-white solid).

Preparation of Compound 120

A mixture of intermediate 344 (260.00 mg, 0.41 mmol) and TBAF (1M in THF) (0.62 mL, 0.62 mmol) in Me-THF (6.7 mL) was stirred for 12 h. The resulting mixture was directly purified (injection of the solution) by column chromatography on silica gel (stationary phase: irregular SiOH, 15-40 μm, 80 g, mobile phase: gradient from 100% DCM to 91% DCM, 9% MeOH, 0.1% NH₄OH). The fractions containing the product were combined and the solvent was evaporated. The residue was crystallized from CH₃CN to give 143 mg of compound 120 (67% yield).

Preparation of Compound 132

A mixture of intermediate 393 (582.00 mg, 0.98 mmol) and TBAF (1M in THF) (1.07 mL, 1.07 mmol) in Me-THF (14 mL) was stirred at rt for 17 h. The reaction mixture was diluted with DCM and washed with water. The organic layer was dried over MgSO₄, filtered, and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel (irregular SiOH, 15-40 m, 40 g, liquid injection in DCM, mobile phase gradient: from DCM 100% to 90%, MeOH (+aq. NH₃ 5%) 10%). The fractions containing the product were combined and evaporated to dryness. The residue (318 mg, brown residue) was purified by reverse phase (stationary phase: YMC-actus Triart-C18, 10 m, 30×150 mm, mobile phase gradient: from 75% aq. NH₄HCO₃ (0.2%), 25% CH₃CN to 35% aq. NH₄HCO₃ (0.2%), 65% CH₃CN). The fractions containing the product were combined and evaporated to dryness. The residue (275 mg, yellow oil) was solubilized in MeOH (1 mL), extended with water (8 mL) and freeze-dried to afford 246 mg of compound 132 (52% yield, white fluffy solid).

Preparation of Compound 145

A solution of intermediate 443 (138.00 mg, 0.28 mmol) in Me-THF (5 mL) was treated with TBAF (1M in THF) (0.308 mL, 0.31 mmol) and stirred at rt for 17 h. Celite® was added and the crude mixture was evaporated in vacuo. The residue was purified by column chromatography on silica gel (irregular SiOH, 15-40 m, 40 g, mobile phase gradient: from DCM 98%, MeOH (+5% aq. NH₃) 2% to DCM 90%, MeOH (+5% aq. NH3) 10%). The fractions containing the product were combined and evaporated to dryness. The solid was recrystallized from EtOH. After cooling down to rt, the superrnatent was removed with a pipette. The solid was triturated in Et₂O. The supernatent was removed with a pipette and the solid was dried in vacuo to afford 53 mg of compound 145 (50% yield, pale yellow solid).

Preparation of Compound 156

A mixture of intermediate 478 (271.00 mg, 0.51 mmol) and TBAF (1 M in THF) (1.00 mL, 1 mmol) in Me-THF (7 mL) was stirred at rt for 4 h. The reaction mixture was concentrated then directly purified by column chromatography on silica gel (irregular SiOH, 15-40 μm, 120 g, liquid injection (Me-THF/DCM), mobile phase gradient: DCM/(MeOH/10% aq. NH₃) from 100:0 to 90:10 in 10 CV). The fractions containing the product were combined and evaporated to dryness to give 192 mg of compound 156 (90% yield, white solid).

Preparation of Compound 164

TBAF (1M in THF) (1.00 mL, 1.00 mmol) was added to a solution of intermediate 516 (0.40 g, 0.69 mmol) in Me-THF (5 mL) and this reaction was stirred overnight at rt. This mixture was poured onto water and a 10% aqueous solution of K₂CO₃. This mixture was extracted twice with EtOAc. The organic layer was decanted and the solvent was evaporated until dryness. The residue was purified by column chromatography on silica gel (irregular SiOH, 45 μm, 40 g, mobile phase gradient from: 98% DCM, 2% MeOH (+10% NH₄OH) to 92% DCM, 8% MeOH (+10% NH₄OH)). The pure fractions were collected and the solvent was evaporated until dryness. The residue was taken up into CH₃CN, triturated and the precipitate was filtered and dried until dryness to give: 224 mg of compound 164 (69% yield).

Preparation of Compound 180

At room temperature, TBAF (1M in THF) (9.00 mL; 9.00 mmol) was added to a solution of intermediate 572 (3.15 g; 5.40 mmol) in THF (50 mL). This reaction was stirred at room temperature for 1 hour. Water and a 10% aqueous solution of K₂CO₃ were added and this mixture was extracted twice with EtOAc. The organic layer was mixed, dried over MgSO₄, filtered and the solvent was evaporated until dryness. The crude was purified by silica gel chromatography (Irregular SiOH 15-40 m 120 g, mobile phase Gradient from: 99% DCM, 1% MeOH, 0.1% NH₄OH to 93% DCM, 7% MeOH, 0.7% NH₄OH). The pure fractions were collected and the solvent was evaporated until dryness to give 1.71 g of compound 180 (67% yield). This quantity of compound 180 was mixed with 510 mg of another batch (obtained from a reaction performed on 710 mg of intermediate 572), taken up into a small amount of ACN, totally dissolved with a hot bath (60° C.) and then, triturated. The solution was cooled to room temperature and a crystalline product appeared after 1 night. This solid was triturated, filtered, washed once with cold ACN and dried until dryness (1 h and 20 min) under vacuum (70° C.) to give 1.22 g of fraction A of compound 180 (MP: 131° C., DSC).

The filtrate was evaporated until dryness and the resulting product was taken up into ACN, totally dissolved, and triturated (initiating crystallization with some crystal coming from fraction A). After several minutes the product crystallized. A small amount of cold isopropylic ether was added and this cristal product was filtered, washed once with cold isopropylic ether then dried until dryness (70° C. under vacuum) to give after 40 minutes 0.67 g of fraction B of compound 180. Fraction B was taken up into ACN, totally solubilized with a hot bath (60° C.) then cooled to room temperature overnight. The cristal product was filtered, washed once with cold isopropylic ether and dried until dryness (70° C. under vacuum) to give 501 mg of fraction B of compound 180 (MP: 150° C., DSC).

Preparation of Compound 183

TBAF (1M in THF) (8.00 mL 8.00 mmol) was added slowly to a solution of intermediate 581 (2.44 g; 4.35 mmol) in tetrahydrofurane (40.00 mL) This reaction was stirred at room temperature for 3 hours and 40 minutes and was purified (without treatment) by silica gel chromatography (Irregular SiOH 15-40 m 220 g, mobile phase Gradient from: 100% DCM to 93% DCM, 7% MeOH, 0.7% NH₄OH). The pure fractions were collected and the solvent was evaporated until dryness to give 1.7 g (88%) of compound 183.

This material was combined with another batch (1.74 g) of compound 183 obtained from a reaction performed on 2.41 g of intermediate 581 to give 3.44 g of compound 183 which were totally dissolved in ACN (57 mL) and MeOH (34 mL) at 90° C.

This solution was cooled down to room temperature and let for crystallization overnight. The precipitate was filtered and dried C under vacuum until dryness at 900 during 3 hours to give 1.25 g (36%) of compound 183. M.P.=256° C. (DSC).

The filtrate was evaporated until dryness and the residue (1.72 g) was dissolved totally in MeOH (38 mL) at 70° C. (bath oil). The solution was cooled down to room temperature overnight. The precipitate was filtered and dried for 2 hours and 30 minutes at 90° C. under vacuum to give 0.77 g (22%) of compound 183 (not crystalline). This material (0.77 g) was dissolved in a mixture of ACN (12 mL) and MeOH (7 mL) at 95° C. (bath oil). The solution was cooled down to room temperature and let for crystallization overnight. The precipitate was filtered to give 303 mg (9%) of compound 183. M.P.=255° C. (DSC).

The compounds in the Table below were prepared by using an analogous method than the one used for the preparation of compound 1 starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Compound number Structure Mass (mg) Yield (%) Compound 4 

 99 79 Procedure with 1.1 equiv. of TBAF Compound 7 

 74 white solid 67 Procedure with 1.1 equiv. of TBAF Compound 11 

 128 off-white solid 19 Procedure with 2.2 equiv. of TBAF Compound 12 

 70 28 Procedure with 3 equiv. of TBAF Compound 13 

 67 pale yellow solid 34 Procedure with 1.1 equiv. of TBAF Compound 14 

 34 off-white solid 10 Procedure with 1.3 equiv. of TBAF Compound 16 

 161 54 Procedure with 1.9 equiv. of TBAF Compound 17 

 140 53 Procedure with 2 equiv. of TBAF Compound 18 

 72 yellow solid 43 Procedure with 2.2 equiv. of TBAF Compound 20 

 174 97 Procedure with 1.5 equiv. of TBAF Compound 21 

 45 pale yellow solid 23 Procedure with 1.1 equiv. of TBAF Compound 22 

 37 42 Procedure with 1.5 equiv. of TBAF Compound 23 

 89 33 Procedure with 1.5 equiv. of TBAF Compound 24 

 107 48 Procedure with 1.5 equiv. of TBAF Compound 25 

 62 62 Procedure with 1.5 equiv. of TBAF Compound 27 

 114 65 Procedure with 1.7 equiv. of TBAF Compound 28 

 42 46 Procedure with 1.5 equiv. of TBAF Compound 29 

 123 45 Procedure with 1.5 equiv. of TBAF Compound 30 

 12 37 Procedure with 1.5 equiv. of TBAF Compound 31 

 45 52 Procedure with 1.5 equiv. of TBAF Compound 32 

 94 45 Procedure with 1.1 equiv. of TBAF Compound 33  (obtained as a mixture of 2 diastereoisomers)

 69 48 Procedure with 1.5 equiv. of TBAF Compound 34 

1250 63 Procedure with 1.1 equiv. of TBAF Compound 35 

 55 28 Procedure with 1.5 equiv. of TBAF Compound 36 

 27 33 Procedure with 1.5 equiv. of TBAF Compound 37 

 59 44 Procedure with 1.1 equiv. of TBAF Compound 38 

 43 26 Procedure with 1.1 equiv. of TBAF Compound 39 

 186 55 Procedure with 1.1 equiv. of TBAF Compound 40 

 160 69 Procedure with 1.1 equiv. of TBAF Compound 41 

 44 orange solid 43 Procedure with 1.1 equiv. of TBAF Compound 43 

 128 75 Procedure with 1.5 equiv. of TBAF Compound 44 

 45 27 Procedure with 1.5 equiv. of TBAF Compound 45 

 185 67 Procedure with 1.5 equiv. of TBAF Compound 46 

 490 38 Procedure with 1.5 equiv. of TBAF Compound 47 

 243 41 Procedure with 2.2 equiv. of TBAF Compound 48 

 51 45 Procedure with 1.5 equiv. of TBAF Compound 50 

 35 37 Procedure with 1.5 equiv. of TBAF Compound 51 

 100 16 Procedure with 1.5 equiv. of TBAF Compound 52 

 97 15 Procedure with 1.5 equiv. of TBAF Compound 53 

 145 68 Procedure with 1.5 equiv. of TBAF Compound 54 

 153 32 Procedure with 2.2 equiv. of TBAF Compound 55 

 54 40 Procedure with 2.2 equiv. of TBAF Compound 56 

  9 16 Procedure with 1 equiv. of TBAF Compound 57 

 150 30 Procedure with 1.5 equiv. of TBAF Compound 58 

 150 51 Procedure with 1.5 equiv. of TBAF Compound 59 

 130 71 Procedure with 1.5 equiv. of TBAF Compound 60 

 81 34 Procedure with 2.2 equiv. of TBAF Compound 61 

 113 65 Procedure with 2.2 equiv. of TBAF Compound 62 

 58 43 Procedure with 2.2 equiv. of TBAF Compound 63 

 131 46 Procedure with 2.2 equiv. of TBAF Compound 64 

 71 50 Procedure with 1.5 equiv. of TBAF Compound 65 

 25 48 Procedure with 1.5 equiv. of TBAF Compound 66 

 111 white foam 55 Procedure with 1.5 equiv. of TBAF Compound 67 

 203 68 Procedure with 1.6 equiv. of TBAF Compound 68 

 78 24 Procedure with 2.2 equiv. of TBAF Compound 69 

 77 24 Procedure with 2.2 equiv. of TBAF Compound 70 

 95 28 Procedure with 2.2 equiv. of TBAF Compound 71 

 106 31 Procedure with 2.2 equiv. of TBAF Compound 72 

 31 35 Procedure with 1.5 equiv. of TBAF Compound 73 

 59 39 Procedure with 1.5 equiv. of TBAF Compound 74 

 65 58 Procedure with 1.5 equiv. of TBAF Compound 75 

 92 56 Procedure with 1.5 equiv. of TBAF Compound 76 

 42 29 Procedure with 1.5 equiv. of TBAF Compound 77 

 57 28 Procedure with 1.5 equiv. of TBAF Compound 78 

 58 28 Procedure with 1.5 equiv. of TBAF Compound 79 

 58 48 Procedure with 1.1 equiv. of TBAF Compound 80 

 52 52 Procedure with 1.1 equiv. of TBAF Compound 81 

 58 33 Procedure with 2.2 equiv. of TBAF Compound 82 

 55 32 Procedure with 2.2 equiv. of TBAF Compound 83 

 77 orange powder 36 Procedure with 1.1 equiv. of TBAF Compound 84 

 66 11 Procedure with 1.5 equiv. of TBAF Compound 85 

 66 11 Procedure with 1.5 equiv. of TBAF Compound 86 

 110 90 Procedure with 1.8 equiv. of TBAF Compound 87 

 26 pink solid 19 Procedure with 1.1 equiv. of TBAF Compound 88 

 105 beige solid 72 Procedure with 1.1 equiv. of TBAF Compound 89 

 85 pink solid 63 Procedure with 1.1 equiv. of TBAF Compound 90 

 49 36 Procedure with 1.5 equiv. of TBAF Compound 91 

 68 35 Procedure with 1.5 equiv. of TBAF Compound 92 

1230 78 Procedure with 1.5 equiv. of TBAF Compound 93 

 321 38 Procedure with 1.5 equiv. of TBAF Compound 94  (obtained as a mixture of 2 diastereoisomers)

 60 17 Procedure with 2.2 equiv. of TBAF Compound 95 

 124 62 Procedure with 1.5 equiv. of TBAF Compound 96 

 813 67 Procedure with 1.6 equiv. of TBAF Compound 97 

1500 68 Procedure with 1.5 equiv. of TBAF Compound 98 

1000 62 Procedure with 1.6 equiv. of TBAF Compound 99 

 15 63 Procedure with 1.6 equiv. of TBAF Compound 100

 36 88 Procedure with 2.5 equiv. of TBAF Compound 101

 50 32 Procedure with 1.7 equiv of TBAF Compound 102

 20 13 Procedure with 1.7 equiv of TBAF Compound 104

 327 57 Procedure with 2.2 equiv. of TBAF Compound 105

 312 36 Procedure with 2.2 equiv. of TBAF Compound 108

 137 56 Procedure with 2.2 equiv. of TBAF Compound 109

 103 54 Procedure with 2.2 equiv. of TBAF Compound 111

 127 34 (over 2 steps) Procedure with 1 equiv. of TBAF Compound 112

 218 51 Procedure with 1.1 equiv. of TBAF Compound 115

 12 off-white solid 13 Procedure with 1.1 equiv. of TBAF Compound 116

 112 off-white solid 57 Procedure 1.1 equiv. of TBAF Compound 117

 205 60 Procedure with 1.5 equiv. of TBAF Compound 119

 40 white fluffy solid 43 Procedure with 1.1 equiv. of TBAF Compound 121

 85 20 Procedure with 1.5 equiv. of TBAF Compound 122

 106 79 Procedure with 1.5 equiv. of TBAF Compound 123

 19 20 Procedure with 1.5 equiv. of TBAF Compound 124

 56 white fluffy solid 43 Procedure with 1.1 equiv. of TBAF Compound 125

 114 33 Procedure with 2 equiv. of TBAF Compound 126

 85 white fluffy solid 36 Procedure with 1.1 equiv. of TBAF Compound 127

 75 33 Procedure with 2 equiv. of TBAF Compound 128

 592 46 Procedure with 2 equiv. of TBAF Compound 129

 61 white solid 88 Procedure with 2 equiv. of TBAF Compound 130

 246 58 Procedure with 2 equiv. of TBAF Compound 131

 144 53 Procedure with 2 equiv. of TBAF Compound 133

 246 white fluffy solid 52 Procedure with 1.1 equiv. of TBAF Compound 134

 134 yellow solid 57 Procedure with 1.1 equiv. of TBAF Compound 135

 88 yellow fluffy solid 62 with 2.2 equiv. of TBAF Compound 136

 50 57 Procedure with 1.5 equiv. of TBAF Compound 137

 210 56 Procedure with 1.6 equiv. of TBAF Compound 138

 114 white fluffy solid 66 Procedure with 1.1 equiv. of TBAF Compound 139

 152 73 Procedure with 2 equiv. of TBAF Compound 140

 271 76 Procedure with 2 equiv. of TBAF Compound 141

 163 79 Procedure with 2 equiv. of TBAF Compound 143

 78 32 Procedure with 1.5 equiv. of TBAF Compound 144

 130 61 Procedure with 1.5 equiv. of TBAF Compound 146

 138 pinkish solid 73 Procedure with 1.1 equiv. of TBAF Compound 147

 17 off-white solid 10 Procedure with 1.7 equiv. of TBAF and a mixture of DCM/THF (3:2, v/v) as solvent Compound 148

 73 yellow solid 48 Procedure with 1.8 equiv. of TBAF Compound 149

 172 off-white solid 54 Procedure with 1.1 equiv. of TBAF Compound 150

 53 41 Procedure with 2 equiv. of TBAF Compound 151

 274 76 Procedure with 2 equiv. of TBAF Compound 152

 157 78 Procedure with 1.1 equiv. of TBAF Compound 153

 176 white solid 95 Procedure with 2.1 equiv. of TBAF Compound 154

 164 off-white solid 45 (over 2 steps) Procedure with 1.1 equiv. of TBAF Compound 155

 70 19 Procedure with 1.5 equiv. of TBAF Compound 156

 47 15 Procedure with 1.1 equiv. of TBAF Compound 157

 172 74 Procedure with 2.5 equiv. of TBAF Compound 158

 179 33 Procedure with 2 equiv. of TBAF Compound 160

 29 yellow fluffy solid 47 Procedure with 1.1 equiv. of TBAF Compound 161

 132 white solid 53 Procedure with 2.1 equiv. of TBAF Compound 162

 70 white fluffy- solid 24 Procedure with 1.1 equiv. of TBAF Compound 163

 64 27 Procedure with 2 equiv. of TBAF Compound 165

 154 69 Procedure with 1.5 equiv. of TBAF Compound 166

 137 65 Procedure with 2 equiv. of TBAF Compound 167

 84 49 Procedure with 2 equiv. of TBAF Compound 168

 27 25 Procedure with 2 equiv. of TBAF Compound 169

 21 21 Procedure with 2 equiv. of TBAF Compound 170

 119 34 Procedure with 2 equiv. of TBAF Compound 171 (obtained as a mixture of 2 diastereoisomers)

 274 49 Procedure with 1.5 equiv. of TBAF Compound 172

 37 18 Procedure with 1.5 equiv. of TBAF Compound 181

 106 61 Compound 182

 72 54 Procedure with 1.5 eq. of TBAF Compound 184

 68 75 Procedure with 2 eq of TBAF Me—THF 3 h Compound 185

 63 64 Procedure with 2 eq. of TBAF Compound 186

 228 47 Procedure with 2 eq. of TBAF Compound 187

 740 63 Procedure with 2 eq. of TBAF Compound 188

 70 23 Procedure with 2 eq. of TBAF Compound 189

 140 46 Procedure with 2 eq. of TBAF Me—THF 12 h Compound 190

 114 65 Procedure with 2 eq. of TBAF Compound 191

 119 60 Procedure with 2 eq of TBAF Me—THF 4 h Compound 192

 90 57 Procedure with 2 eq of TBAF Me—THF 12 h Compound 193

 22 41 Procedure with 2 eq of TBAF Me—THF 8 h Compound 194

 217 44 Procedure with 2 eq of TBAF Me—THF 8 h Compound 195

 73 51 Procedure with 1.6 eq of TBAF THF 2 h Compound 196

1850 55 Procedure with 2 eq of TBAF THF Compound 197

 166 32 Procedure with 1.54 eq of TBAF Me—THF Compound 198

 55 58 Procedure with 1.2 eq of TBAF Me—THF 18 h Compound 199

 114 35 Procedure with 2 eq of TBAF Me—THF 8 h Compound 200

 75 26 Procedure with 2 eq of TBAF Me—THF 2 h Compound 202

 45 25 Procedure with 1.55 eq of TBAF THF 5 h Compound 203

 164 53 Procedure with 2 eq of TBAF Me—THF 4 h Compound 204

 328 68 Procedure with 1.5 eq of TBAF THF 12 h Compound 205

 30 44 Procedure with 1.51 eq of TBAF Me—THF 12 h Compound 206

 96 52 Procedure with 1.5 eq of TBAF THF 5 h Compound 207

 129 41 Procedure with 2 eq of TBAF Me—THF 8 h Compound 208

 21 15 Procedure with 2 eq of TBAF Me—THF 8 h Compound 209

 159 66 Procedure with 2 eq. of TBAF Compound 210

 104 83 Procedure with 1.6 eq of TBAF THF 12 h Compound 211

 25 37 Procedure with 1.45 eq of TBAF THF 12 h Compound 212

 176 54 Procedure with 1.5 eq of TBAF THF 2 h Compound 213

 87 63 Procedure with 1.2 eq of TBAF Me—THF 3 h Compound 215

 23 64 Procedure with 1.2 eq of TBAF Me—THF 3 h Compound 216

 17 35 Procedure with 1.43 eq of TBAF THF 18 h Compound 217

2100 64 Procedure with 2 eq TBAF Compound 218

 65  28 27 11 Procedure with 1.5 eq TBAF Compound 219

2400 69 Procedure with 2 eq TBAF Compound 220

 37 41 Procedure with 1.6 eq TBAF Compound 221

 36 40 Procedure with 2 eq TBAF

Example B2 Preparation of Compound 2

A mixture of intermediate 10 (268.00 mg, 0.58 mmol) in a mixture of TFA (2 mL) and DCM (5 mL) was stirred at rt for 1 h. The mixture was basified with saturated aqueous solution of NaHCO₃. An extraction was performed with DCM. The organic layer was washed with brine, dried over MgSO₄, evaporated and purified by column chromatography on silica gel (irregular SiOH 15-40 m, 120 g, liquid injection with DCM, mobile phase: DCM/(MeOH(10% aq. NH₃)), gradient from 100:0 to 90:10 in 15 CV). The fractions containing the product were combined and concentrated to give 70 mg of compound 2 (33% yield over 3 steps, white solid).

Preparation of Compound 103

At 0° C., TFA (1.73 mL; 22.61 mmol) was added dropwise to a mixture of intermediate 272 (0.618 g; 1.13 mmol) in DCM (10.00 mL). This reaction was stirred for 1 hour at 0° C. Water and a 10% aqueous solution of K₂CO₃ were added. This mixture was extracted twice with DCM. The organic layer was decanted and the solvent was evaporated until dryness. The crude was purified (solid deposit) by silica gel chromatography (Irregular SiOH 20-45 m 40 g, mobile phase: gradient from 98% DCM, 2% MeOH to 92% DCM, 8% MeOH (+10% NH₄OH)). The fractions containing the product were collected and the solvent was evaporated until dryness. The product was taken up into ethylic ether and the precipitate was filtered to give 140 mg of compound 103 (23% yield)

The compounds in the Table below were prepared by using an analogous procedure than the one used for the preparation of compound 2 or 103 starting from the respective starting materials. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Compound number Structure Mass (mg) Yield (%) Compound 3

130 white solid 36% (over 3 step) Procedure with DCM/TFA (8:3, v/v) Compound 5

 66 41 Procedure with DCM/TFA (4:1, v/v) Compound 6

 54 37 Procedure with DCM/TFA (4:1, v/v) Compound 7

 53 38 Procedure with DCM/TFA (5:1, v/v) Compound 9

 65 32 Procedure with DCM/TFA (6:1, v/v) Compound 10

 69 39 Procedure with DCM/TFA (4:1, v/v) Compound 11

 18  9 Procedure with DCM/TFA (5:2, v/v) Compound 15

 15 11 Procedure with DCM/TFA (5:1, v/v) Compound 26

 8 13 Procedure with DCM/TFA (6:1, v/v) Compound 110

200 45 Procedure with DCM/TFA (10:1, v/v) Compound 142

 17 8 Procedure with DCM/TFA (5:1, v/v)

Example B3 Preparation of Compound 173

HCl (3M in H₂O) (0.80 mL, 2.40 mmol) was added to a solution of intermediate 551 (152.00 mg, 0.24 mmol) in MeOH (3.7 mL) and the reaction mixture was stirred at reflux overnight. The reaction mixture was cooled to rt, poured onto a 10% aqueous solution of K₂CO₃ and extracted with DCM. The organic layer was decanted, dried over MgSO₄, filtered and evaporated to dryness. The residue (75 mg, orange powder) was purified by column chromatography on silica gel (irregular SiOH, 12 g, mobile phase: gradient from 0% NH₄OH, 0% MeOH, 100% DCM to 0.8% NH₄OH, 8% MeOH, 92% DCM). The fractions containing the product were collected and evaporated to dryness. The residue (39 mg) was taken up with Et₂O to provide 15 mg of compound 173 (yellow powder).

The compounds in the Table below were prepared by using an analogous starting from the respective starting materials.

Compound number Structure Mass (mg) Yield (%) Compound 174

21 yellow oil 34

Example B4 Preparation of Compound 176

TFA (0.40 mL, 5.29 mmol) was added at 5° C. to a solution of intermediate 557 (201.00 mg, 0.35 mmol) in DCM (3.84 mL). The reaction mixture was stirred at 5° C. for 1 h and 30 min. The residue was diluted with DCM and poured onto a 10% aqueous solution of K₂CO₃, dried over MgSO₄, filtered, evaporated to dryness (500 m, yellow powder) and purified by column chromatography on silica gel (irregular SiOH, 24 g, mobile phase: gradient from 100% DCM to 90% DCM, 10% MeOH, 1% NH₄OH). The fractions containing the product were collected and evaporated to dryness. The residue (151 mg, light yellow powder) was purified by reverse phase (stationary phase: X-Bridge-C18, 5 m, 30×150 mm, mobile phase: gradient from 75% NH₄HCO₃ 0.2%, 25% CH₃CN to 35% NH₄HCO₃ 0.2%, 65% CH₃CN). The fractions containing the product were combined and evaporated. The residue (31 mg, colorless oil) was taken up with Et₂O to provide 27 mg of compound 176 (16% yield, white powder).

The compounds in the Table below were prepared by using an analogous starting from the respective starting materials.

Compound number Structure Mass (mg) Yield (%) Compound 175

57 white powder 23

Example B5 Preparation of Compound 179

In a sealed tube, a mixture of intermediate 559 (90.00 mg, 153 μmol) and TFA (583.00 μL, 7.62 mmol) in dry DCM (3 mL) was stirred at rt for 1 h. The reaction mixture was diluted with DCM and basified with a saturated aqueous solution of NaHCO₃. The layers were separated and the organic layer was combined with another batch (from 75 mg of intermediate 559), dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The residue (155 mg, yellow residue) was purified by column chromatography on silica gel (irregular SiOH, 15-40 μm, 10 g, liquid injection in DCM, mobile phase gradient: from DCM 100% to DCM 90%, MeOH (+aq. NH₃ 5%) 10%). The fractions containing the product were combined and evaporated to dryness. The residue (55 mg, yellow oil) was triturated in EtOH and the solvent was removed under reduced pressure. The residue (48 mg, yellow solid) was dried 17 h at 50° C. under reduced pressure to give 36 mg of compound 179 (26% yield, yellow powder).

Example B6 Preparation of Compound 214

Lithium hydroxide monohydrate (0.011 g; 0.26 mmol) was added slowly to a mixture of intermediate 729 (0.066 g; 0.12 mmol) in H₂O (0.250 mL) and 1,4-dioxane (0.500 mL). The reaction was stirred at 100° C. for 1 hour then room temperature overnight. Water was added and this mixture was acidified with an aqueous solution of HCl 3N. This mixture was extracted twice with EtOAc. The solvent was evaporated until dryness to give: 86 mg of crude product. Purification was performed via Reverse phase (Stationary phase: YMC-actus Triart-C18 10 μm 30*150 mm, Mobile phase: Gradient from 85% H₂O, 15% ACN to 45% H₂O, 55% ACN). The pure fractions were collected and the solvent was evaporated until dryness. The product was taken up into ACN/Water (2 mL/5 mL) and freeze-dried overnight to afford compound 214 (10 mg, 16%).

Example B7 Preparation of Compound 201

A mixture of intermediate 6R (415.5 mg; 0.81 mmol) and intermediate 667 (252 mg; 1.21 mmol) in 1,4-dioxane (4.40 mL) was added p-toluensulfonic acid monohydrate (236 mg; 1.37 mmol). The resulting mixture was stirred at 95° C. for 15 h. Then the reaction was quenched with a solution of 10% K₂CO₃ (aq), and extracted with a mixture of DCM-MeOH 9:1. The crude was purified using a silica gel column (DCM:MeOH 90:10) to afford compound 201 (60 mg, 16%).

Example B8 Preparation of Compound 222

To a homogeneous solution of intermediate 776 (0.172 g; 0.27 mmol) in dry toluene (10 ml) was added SiO₂ (0.5 g; 40-63 μm) and the reaction heated at reflux (˜120° C.) overnight (16 h). The reaction mixture was cooled to room temp and filtered through celite, rinsing the SiO₂ with THF followed by CH₂Cl₂. The filtrate was concentrated to dryness, redissolved in MeOH, and purified via acidic prep-HPLC (Shimadzu pumps with Gilson fraction collector, DAD. Column: Inertsil ODS-3 (5 uM, 30×50 mm). Mobile phase: A=0.05% TFA in H₂O, B=0.05% TFA in CH₃CN. Gradient: 5% B for 1 min to 95% B over 12 min, held at 95% B for 2 min. Flow: 80 mL/min. Run time: 15 min). Desired fractions were combined, frozen, and lyophilized to yield 23.6 mg (18% yield) of compound 222 as a yellow solid TFA salt.

The compound in the table below was prepared by using an analogous method starting from the respective R enantiomer, intermediate 777. The most relevant minor deviations to the referenced method are indicated as additional information in the column ‘Yield (%)’.

Compound number Structure Mass (mg) Yield (%) Compound 223

47 33

Example C1 Preparation of Compound 177

A mixture of compound 49 (50.00 mg, 0.11 mmol), AcOH (6.60 μL, 0.11 mmol), HATU (57.01 mg, 0.15 mmol), DIPEA (70.50 μL, 0.40 mmol) in DMF (2 mL) was stirred 12 h at rt. Water and DCM were added. The mixture was extracted with DCM. The organic layer was washed with brine, dried over MgSO₄, filtered and the solvent was evaporated. The residue (690 mg) was purified by column chromatography on silica gel (irregular SiOH, 40 m, 40 g, mobile phase 100% DCM to 98% DCM, 2% MeOH, 0.2% NH₄OH). The pure fractions were combined and the solvent was evaporated. The residue (237 mg) was purified again by column chromatography on silica gel (irregular SiOH, 40 μm, 40 g, mobile phase 100% DCM to 99% DCM, 1% MeOH, 0.1% NH₄OH). The pure fractions were combined and the solvent was evaporated. The residue (185 mg) was freeze-dried with CH₃CN and water. The residue (169 mg) was further purified by reverse phase (Stationary phase: X-Bridge-C18, 10 m, 30×150 mm, mobile phase: gradient from 75% H₂O, 25% CH₃CN to 35% H₂O, 65% CH₃CN). The fractions containing the product were combined and evaporated to dryness. The residue (122 mg) was freeze-dried with CH₃CN and water to give 101 mg of compound 177 (18% yield). M.P.=70° C. (K, gum).

The intermediates in the Table below were prepared by using an analogous starting from the respective starting materials.

Compound number Structure Mass (mg) Yield (%) Compound 178

45 24

Analytical Part

LCMS (Liquid Chromatography/Mass Spectrometry)

The High Performance Liquid Chromatography (HPLC) measurement was performed using a LC pump, a diode-array (DAD) or a UV detector and a column as specified in the respective methods. If necessary, additional detectors were included (see table of methods below).

Flow from the column was brought to the Mass Spectrometer (MS) which was configured with an atmospheric pressure ion source. It is within the knowledge of the skilled person to set the tune parameters (e.g. scanning range, dwell time . . . ) in order to obtain ions allowing the identification of the compound's nominal monoisotopic molecular weight (MW). Data acquisition was performed with appropriate software. Compounds are described by their experimental retention times (R_(t)) and ions. If not specified differently in the table of data, the reported molecular ion corresponds to the [M+H]⁺ (protonated molecule) and/or [M−H]⁻ (deprotonated molecule). In case the compound was not directly ionizable the type of adduct is specified (i.e. [M+NH₄]⁺, [M+HCOO]⁻, etc. . . . ). For molecules with multiple isotopic patterns (Br, Cl.), the reported value is the one obtained for the lowest isotope mass. All results were obtained with experimental uncertainties that are commonly associated with the method used. Hereinafter, “SQD” means Single Quadrupole Detector, “RT” room temperature, “BEH” bridged ethylsiloxane/silica hybrid, “HSS” High Strength Silica, “DAD” Diode Array Detector.

Table: LCMS Method codes (Flow expressed in mL/min; column temperature (T) in ° C.; Run time in minutes).

Method Flow Run code Instrument Column Mobile phase gradient Column T time Method Waters: Acquity Waters: A: 95% 84.2% A for 0.343 6.2 1 UPLC ® - DAD BEH C18 CH₃COONH₄ 0.49 min, to 10.5% 40 and Quattro (1.7 μm, 7 mM/5% A in 2.18 min, held Micro ™ 2.1 × 100 CH₃CN, B: for 1.94 min, back mm) CH₃CN to 84.2% A in 0.73 min, held for 0.73 min. Method Waters: Waters: A: 95% From 84.2% A to 0.343 6.1 2 Acquity BEH CH₃COONH₄ 10.5% A in 2.18 40 UPLC ® H - C18 7 mM/5% min, held for Class - (1.7 μm, CH₃CN, B: 1.94 min, back to DAD and 2.1 × 10 CH₃CN 84.2% A in SQD 2 0 mm) 0.73 min, held for 0.73 min. Method Agilent ACE A: 0.05% 1% B to 99% B 1.5 3.5 3 1260 Series - EXCEL TFA in over 2.5 min, held 50 DAD 3 C18- H₂O, B: at 99% for VL+ and AR 100% 0.5 min, then back Agilent (3 uM, CH₃CN to 10% B over G6120B 3.0 × 0.5 min ESI-SQD 50 mm) Quadrupole LC/MS Method Agilent YMC- A: 0.1% From 95% A to 2.6 6.2 4 1100 HPLC pack HCOOH in 5% A in 4.8 min, 35 DAD ODS- H₂O held for 1.0 min, LC/MS AQ B: CH₃CN to 95% A in 0.2 G1956A C18 min. (50 × 4.6 mm, 3 μm) Method Agilent YMC- A: 0.1% From 94.51% A 2.6 6.0 5 1290 pack HCOOH in to 5% A in 4.8 35 Infinity ODS- water min, held for 1.0 DAD TOF- AQ B: CH₃CN min, to 95% A in LC/MS C18 (3 0.2 min G6224A μm, 4.6 × 50 mm)

NMR

The NMR experiments were carried out using a Bruker Avance 500 III using internal deuterium lock and equipped with reverse triple-resonance (¹H, ¹³C, ¹⁵N TXI) probe head or using a Bruker Avance DRX 400 spectrometer at ambient temperature, using internal deuterium lock and equipped with reverse double-resonance (¹H, ¹³C, SEI) probe head with z gradients and operating at 400 MHz for the proton and 100 MHz for carbon. Chemical shifts (δ) are reported in parts per million (ppm). J value are expressed in Hertz (Hz).

Compound 19: ¹H NMR (400 MHz, DMSO-d₆): δ 9.56 (s, 1H), 8.36 (d, J=5.6 Hz, 1H), 8.08 (d, J=1.0 Hz, 1H), 7.98 (d, J=1.0H, 1H), 7.57 (d, J=2.0 Hz, 1H), 7.36 (s, 1H), 7.25 (d, J=5.0 Hz, 1H), 6.60 (d, J=2.0 Hz, 1H), 5.00 (t, J=5.3 Hz, 1H), 3.75 (s, 3H), 3.68 (d, J=10.1 Hz, 1H), 3.41-3.47 (m, 1H) 3.34-3.40 (m, 1H), 3.28 (m, 1H, partially obscured by solvent peak), 1.28 (s, 3H)

Compound 42: ¹H NMR (500 MHz, DMSO-d₆): δ 9.17 (s, 1H), 8.38 (d, J=5.4 Hz, 1H), 8.07 (d, J=1.6 Hz, 1H), 7.97 (d, J=1.6 Hz, 1H), 7.42 (s, 1H), 7.35 (d, J=5.4 Hz, 1H), 6.14 (s, 1H), 5.02 (t, J=5.4 Hz, 1H), 4.13 (t, J=5.6 Hz, 2H), 3.67 (d, J=9.8 Hz, 1H), 3.63 (t, J=9.8 Hz, 2H), 3.40-3.46 (m, 1H) 3.35-3.40 (m, 1H), 3.30 (d, J=9.8 Hz, 1H), 3.22 (s, 3H), 2.13 (s, 3H), 1.27 (s, 3H)

Compound 145: ¹H NMR (500 MHz, DMSO-d₆): δ 11.51 (br s, 1H), 8.53 (d, J=5.4 Hz, 1H), 8.23 (d, J=1.6 Hz, 1H), 8.15 (s, 1H), 7.45-7.53 (m, 2H), 6.71 (s, 1H), 5.02 (t, J=5.2 Hz, 1H), 3.70 (d, J=9.8 Hz, 1H), 3.43-3.49 (m, 1H) 3.37-3.42 (m, 1H), 3.31 (m, 1H, partially obscured by solvent peak), 2.26 (s, 3H), 1.30 (s, 3H)

Compound 49: ¹H NMR (500 MHz, DMSO-d₆): δ 9.14 (s, 1H), 8.36 (d, J=5.4 Hz, 1H), 8.06 (d, J=1.9 Hz, 1H), 7.95 (d, J=1.3 Hz, 1H), 7.39 (s, 1H), 7.32 (d, J=5.4 Hz, 1H), 6.07 (s, 1H), 4.99 (t, J=5.4 Hz, 1H), 3.98 (t, J=7.1 Hz, 2H), 3.67 (d, J=9.5 Hz, 1H), 3.40-3.45 (m, 1H) 3.34-3.39 (m, 1H) 3.31 (m, 1H, partially obscured by solvent peak), 3.27 (t, J=6.3 Hz, 2H), 3.16 (s, 3H), 2.13 (s, 3H), 1.92 (q, J=6.6 Hz, 2H), 1.27 (s, 3H)

Compound 107: ¹H NMR (400 MHz, DMSO-d₆): δ 9.54 (s, 1H), 8.41 (d, J=5.1 Hz, 1H), 8.07 (s, 1H), 7.93 (s, 1H), 7.41 (s, 1H), 7.38 (d, J=5.0 Hz, 1H), 6.40 (s, 1H), 4.98 (t, J=5.0 Hz, 1H), 3.87 (d, J=7.6 Hz, 2H), 3.69 (br d, J=10.1 Hz, 1H), 3.40-3.48 (m, 1H) 3.33-3.39 (m, 1H), 3.29 (m, 1H, partially obscured by solvent peak), 2.04-2.18 (m, 1H), 1.27 (s, 3H), 0.81 (d, J=6.6 Hz, 6H)

Compound 113: ¹H NMR (400 MHz, DMSO-d₆): δ 9.41 (s, 1H), 8.43 (d, J=5.6 Hz, 1H), 8.07 (s, 1H), 7.95 (s, 1H), 7.40-7.42 (m, 2H), 6.46 (s, 1H), 4.96 (t, J=5.3 Hz, 1H), 4.24-4.12 (m, 3H), 3.78-3.60 (m, 3H), 3.34-3.47 (m, 2H), 3.31 (m, 1H, partially obscured by solvent peak), 1.94-1.88 (m, 1H), 1.81-1.74 (m, 2H), 1.67-1.57 (m, 1H), 1.28 (s, 3H)

Compound 114: ¹H NMR (400 MHz, DMSO-d₆): δ 9.44 (s, 1H), 8.43 (d, J=5.0 Hz, 1H), 8.07 (d, J=2.0 Hz, 1H), 7.95 (d, J=1.5 Hz, 1H), 7.45-7.38 (m, 2H), 6.46 (s, 1H), 4.99 (t, J=5.0 Hz, 1H), 4.24-4.10 (m, 3H), 3.83-3.53 (m, 3H), 3.34-3.47 (m, 2H), 3.30 (m, 1H, partially obscured by solvent peak), 1.98-1.84 (m, 1H), 1.82-1.77 (m, 2H), 1.67-1.57 (m, 1H), 1.28 (s, 3H)

Compound 118: ¹H NMR (500 MHz, DMSO-d₆): δ 9.84 (s, 1H), 8.39 (d, J=5.4 Hz, 1H), 8.09 (d, J=1.6 Hz, 1H), 7.99 (d, J=1.3 Hz, 1H), 7.41 (s, 1H), 7.32 (d, J=5.4 Hz, 1H), 6.80 (s, 1H), 5.13 (s, 2H), 5.02 (s, 1H), 3.68 (d, J=9.7 Hz, 1H), 3.47-3.29 (m, 3H, partially obscured by solvent peak), 2.90-2.86 (m, 1H), 2.83 (s, 3H), 1.29 (m, 3H), 0.83-0.95 (s, 4H)

Compound 120: ¹H NMR (500 MHz, DMSO-d₆): δ 8.53 (s, 1H), 8.26 (d, J=5.0 Hz, 1H), 8.00 (s, 1H), 7.88 (s, 1H), 7.61-7.50 (m, 2H), 7.33 (s, 1H), 7.15 (d, J=5.0 Hz, 1H), 6.85 (s, 1H), 5.31 (s, 2H), 5.03 (t, J=5.4 Hz, 1H), 3.66 (d, J=9.5 Hz, 1H), 3.60 (s, 3H), 3.33-3.44 (m, 2H), 3.27 (d, J=9.5 Hz, 1H), 2.67 (t, J=8.2 Hz, 2H), 1.52-1.44 (m, 1H), 1.28-1.21 (m, 5H), 0.79 (d, J=6.6 Hz, 6H)

Compound 132: ¹H NMR (500 MHz, DMSO-d₆): δ 8.77 (s, 1H), 8.34 (d, J=5.4 Hz, 1H), 8.10-7.93 (m, 3H), 7.35 (s, 1H), 7.21 (d, J=5.4 Hz, 1H), 6.32 (tt, J=55.1, 3.7 Hz, 1H), 5.01 (t, J=5.4 Hz, 1H), 4.49 (td, J=15.0, 3.8 Hz, 2H), 3.67 (d, J=9.8 Hz, 1H), 3.35-3.35 (m, 2H), 3.29 (d, J=9.5 Hz, 1H), 2.17 (s, 3H), 1.28 (s, 3H)

Compound 156: ¹H NMR (400 MHz, DMSO-d₆): δ 9.15 (s, 1H), 8.34 (d, J=5.0 Hz, 1H), 8.05 (d, J=1.0 Hz, 1H), 7.93 (s, 1H), 7.38 (s, 1H), 7.32 (d, J=5.6 Hz, 1H), 6.14 (s, 1H), 4.98 (t, J=5.3 Hz, 1H), 4.93 (t, J=5.8 Hz, 1H), 4.49 (q, J=6.4 Hz, 1H), 4.37 (d, J=6.1 Hz, 2H), 3.68 (d, J=10.1 Hz, 1H), 3.32-3.46 (m, 2H), 3.28 (m, 1H, partially obscured by solvent peak), 1.31 (d, J=6.6 Hz, 6H), 1.26 (s, 3H)

Compound 164: ¹H NMR (500 MHz, DMSO-d₆): δ 9.75 (s, 1H), 8.52 (d, J=4.1 Hz, 1H), 8.37 (d, J=5.4 Hz, 1H), 8.10 (s, 1H), 7.98 (s, 1H), 7.38 (s, 1H), 7.29 (d, J=5.4 Hz, 1H), 7.12 (s, 1H), 5.41 (q, J=6.6 Hz, 1H), 4.98 (t, J=5.4 Hz, 1H), 3.70 (d, J=10.1 Hz, 1H), 3.34-3.48 (m, 2H), 3.29 (d, J=9.8 Hz, 1H), 2.78-2.85 (m, 1H), 1.38 (dd, J=6.6, 2.2 Hz, 6H), 1.28 (s, 3H), 0.70-0.64 (m, 2H), 0.63-0.58 (m, 2H)

Compound 177: ¹H NMR (500 MHz, DMSO-d₆): δ 9.16 (s, 1H), 8.38 (d, J=5.4 Hz, 1H), 8.11 (d, J=1.3 Hz, 1H), 8.04 (d, J=1.3 Hz, 1H), 7.51 (s, 1H), 7.35 (d, J=5.4 Hz, 1H), 6.07 (s, 1H), 4.12 (d, J=10.7 Hz, 1H), 4.04 (d, J=11.0 Hz, 1H), 3.98 (t, J=7.1 Hz, 2H), 3.63 (d, J=10.1 Hz, 1H), 3.40 (d, J=10.1 Hz, 1H), 3.26 (t, J=6.1 Hz, 2H), 3.15 (s, 3H), 2.13 (s, 3H), 1.98 (s, 3H), 1.91 (q, J=6.6 Hz, 2H), 1.34 (s, 3H)

Compound 103: ¹H NMR (500 MHz, DMSO-d₆) δ ppm 9.76 (s, 1H) 8.42 (q, J=4.4 Hz, 1H) 8.38 (d, J=5.4 Hz, 1H) 8.11 (d, J=1.9 Hz, 1H) 8.01 (d, J=1.6 Hz, 1H) 7.37 (s, 1H) 7.29 (d, J=5.4 Hz, 1H) 7.17 (s, 1H) 5.43 (quin, J=6.6 Hz, 1H) 5.00 (t, J=5.5 Hz, 1H) 3.70 (d, J=9.1 Hz, 1H) 3.42-3.48 (m, 1H) 3.35-3.40 (m, 1H) 3.29 (d, J=9.5 Hz, 1H) 2.75 (d, J=4.7 Hz, 3H) 1.38 (dd, J=6.6, 0.9 Hz, 6H) 1.28 (s, 3H)

Compound 180 (fraction B): ¹H NMR (500 MHz, DMSO-d₆) δ ppm 8.78 (s, 1H) 8.35 (d, J=5.0 Hz, 1H) 8.06 (br s, 2H) 7.96 (s, 1H) 7.37 (s, 1H) 7.23 (d, J=5.4 Hz, 1H) 6.09-6.48 (m, 1H) 5.02 (br t, J=5.0 Hz, 1H) 4.40-4.65 (m, 2H) 3.67 (br d, J=10.1 Hz, 1H) 3.57 (t, J=6.9 Hz, 2H) 3.41-3.48 (m, 1H) 3.35-3.41 (m, 1H) 3.29 (br d, J=10.1 Hz, 1H) 3.27 (s, 3H) 2.87 (br t, J=6.9 Hz, 2H) 1.28 (s, 3H)

Compound 183: ¹H NMR (500 MHz, DMSO-d₆) δ 9.35 (s, 1H), 8.38 (d, J=5.4 Hz, 1H), 8.05 (s, 1H), 7.94 (s, 1H), 7.88 (q, J=4.4 Hz, 1H), 7.42 (s, 1H), 7.36 (d, J=5.4 Hz, 1H), 6.58 (s, 1H), 5.00 (t, J=5.2 Hz, 1H), 4.57-4.66 (m, 1H), 3.68 (d, J=9.8 Hz, 1H), 3.40-3.46 (m, 1H), 3.34-3.38 (m, 1H), 3.29 (br d, J=10.1 Hz, 1H), 2.76 (d, J=4.7 Hz, 3H), 1.38 (d, J=6.6 Hz, 6H), 1.26 (s, 3H)

OR

Optical Rotation is measured with a polarimeter such as e.g. 341 Perkin Elmer, an Autopol IV automatic polarimeter (Rodolph research analytical) or a P-2000 (Jasco). Specific rotation(OR): [α]^(θ) _(λ)=(100*α)/(c*1)

α (measured rotation) is the angle through which plane polarized light is rotated by a solution of c (mass concentration) and 1 (path length). Concentration is in grams per 100 mL; path length is in decimeters and is 1.000 decimeter.

θ is the temperature (° C.) and a the wavelength of the light used.

Unless otherwise indicated, temperature is 20° C., and the sodium D line is used (589 nanometer).

Or Data:

Solvent: DMF (unless otherwise indicated); temperature: 20° C. (unless otherwise indicated); wavelength: 589 nm (unless otherwise indicated); ‘Conc.’ means concentration of the sample in grams per 100 mL; ‘OR’ means optical rotation (specific rotation); ‘N°’ means compound number

Concentration N° OR (°) (g/100 mL) 19 +19.82 0.202 31 −15.60 0.250 34 −19.41 0.232 37 +7.92 0.240 38 +9.52 0.210 39 +14.78 0.230 40 +17.14 0.210 41 +16.92 0.260 42 +11.20 0.250 43 +17.58 0.330 44 +12.96 0.270 45 +14.07 0.270 46 +14.21 0.218 47 −17.24 0.273 48 +16.94 0.310 49 +16.06 0.330 51 −11.00 0.264 52 +39.24 0.273 53 +31.17 0.231 54 −17.59 0.290 55 +14.83 0.290 57 −12.54 0.311 58 +15.29 0.340 59 +13.93 0.280 60 +13.87 0.310 61 +12.69 0.260 62 +14.80 0.250 63 +13.70 0.270 64 +4.46 0.269 65 +21.20 0.250 66 +16.45 0.274 67 +16.45 0.310 72 +10.88 0.340 73 +15.52 0.290 74 +4.62 0.238 75 +4.14 0.290 76 +14.62 0.260 79 +13.79 0.290 80 +10.40 0.250 83 +9.60 0.271 86 +19.66 0.290 87 +8.93 0.280 88 +12.50 0.280 89 +14.00 0.250 90 −4.52 0.310 91 +13.64 0.330 92 +14.07 0.270 93 +15.15 0.330 94 +48.33 0.300 95 +10.00 0.290 96 +8.30 0.253 97 −6.71 0.298 98 +11.48 0.248 101 +20.5 0.317 103 +9.00 0.300 104 +10.65 0.310 105 +31.90 0.210 107 +20.69 0.242 108 +12.52 0.192 109 +10.43 0.192 110 +14.40 0.250 111 +13.29 0.241 112 +17.42 0.258 113 +21.50 0.200 114 −7.86 0.242 115 +16.89 0.225 116 +14.71 0.258 117 +11.08 0.217 118 +14.48 0.242 119 −29.77 0.215 120 +4.80 0.250 122 −9.60 0.250 123 +18.58 0.258 124 +16.14 0.242 125 +14.83 0.283 126 +12.86 0.233 127 +11.46 0.148 128 +16.55 0.242 129 +20.80 0.250 130 +5.45 0.275 131 +14.48 0.242 132 +6.43 0.233 133 +15.31 0.242 134 +19.29 0.233 135 +11.67 0.300 136 +11.63 0.215 137 +9.55 0.262 138 +11.11 0.225 142 +24.22 0.244 145 +27.81 0.241 146 +8.85 0.260 147 +16.09 0.230 148 +29.33 0.150 149 +30.38 0.260 150 +22.91 0.183 151 +16.40 0.250 152 +11.58 0.242 153 +16.73 0.275 154 +15.74 0.235 155 +9.34 0.289 156 +13.82 0.275 157 +17.20 0.250 159 +17.50 0.200 160 +15.60 0.250 161 +18.08 0.260 162 +11.11 0.270 163 +8.50 0.200 164 +26.07 0.280 165 +18.48 0.330 166 +32.69 0.260 167 +9.62 0.260 168 +7.20 0.250 169 +9.58 0.240 170 +8.33 0.300 172 +9.06 0.309 173 −13.95 0.251 174 +18.48 0.233 175 −30.99 0.284 176 +39.18 0.268 177 +35.99 0.192 178 +29.12 0.364 179 +12.59 0.270 180 +8.26 0.363 181 +12.99 0.254 182 +14.52 0.31  183 +10.71 0.252 184 +11.72 0.290 185 +11.11 0.270 186 +10.91 0.330 187 +12.17 0.230 188 +9.58 0.240 189 +11.74 0.230 190 +15.71 0.210 192 +13.6 0.250 194 +16.94 0.366 195 +4.72 0.254 196 +8.97 0.290 197 +13.15 0.251 198 +18.60 0.07 (MeOH @ 23° C.) 199 +7.17 0.279 200 +10.29 0.272 201 +4.2 0.1 (MeOH @ 23° C.) 203 +4.36 0.390 204 +4.68 0.278 205 +30.0 0.220 206 +11.63 0.301 207 +5.18 0.251 208 +7.39 0.230 209 +13.48 0.230 210 +9.35 0.278 211 +5.65 0.230 212 +7.27 0.289 213 +12.4 0.06 (MeOH @ 23° C.) 217 +7.69 0.260 218 +5.81 0.241 219 +11.55 0.251 220 +9.13 0.230

Melting Point (DSC, MP50, or K)

For a number of compounds, melting points (MP) were determined with a DSC1 (Mettler-Toledo) (indicated with DSC in the analytical table). Melting points were measured with a temperature gradient of 10° C./minute. Maximum temperature was 350° C. Values are peak values.”

For a number of compounds, melting points were obtained with a Kofler hot bench, consisting of a heated plate with linear temperature gradient, a sliding pointer and a temperature scale in degrees Celsius (indicated with K in the analytical table).

For a number of compounds, melting points were obtained with a Mettler Toledo MP50 apparatus (indicated with MP50 in the analytical table). Melting points were measured with a temperature gradient of 10° C. per minute starting from 50° C. (waiting time 10 seconds) to a maximum value of 300° C.

Table: N° means compound number; MP means melting point (° C.); R_(t) means retention time (min)

MP MP LC/MS N° (° C.) method Rt [M + H]⁺ Method  1 212 DSC 2.15 362 1  2 208 DSC 2.08 362 1  3 232 DSC 2.15 376 1  4 252 DSC 2.10 362 1  5 — — 2.14 432 1  6 >260 K 2.74 444 1  7 227 DSC 2.04 376 2  8 — — 2.37 418 2  9 — — 1.91 434 2  10 — — 2.17 448 2  11 206 DSC 2.14 433 1  12 203 K 1.66 445 2  13 260 DSC 1.97 375 2  14 — — 2.01 420 1  15 — — 2.33 390 1  16 — — 2.21 406 1  17 — — 2.00 433 1  18 — — 2.08 447 1  19 199 DSC 2.15 362 1  20 215 DSC 2.45 390 1  21 233 DSC 2.02 348 1  22 — — 2.40 509 1  23 — — 2.30 420 1  24 — — 2.28 390 1  25 — — 2.05 489 1  26 — — 2.18 432 1  27 — — 2.24 420 1  28 — — 2.39 509 1  29 150 K 2.42 402 1 (gum)  30 — — 2.25 412 1  31 — — 2.45 390 1  32 163 K 2.19 396 1  33 250 K 2.33 480 1  34 200 DSC 2.14 362 1  35 <260 K 2.35 517 1  36 — — 2.04 376 1  37 >260 K 1.94 445 1  38 249 K 1.90 445 1  39 170 K 2.13 461 1  40 221 K 2.45 402 1  41 208 DSC 2.34 396 1  42 — — 2.30 420 1  43 240 K 2.44 396 1  44 — — 2.41 434 1  45 — — 2.03 433 1  46 166 K 2.18 420 1  47 174 K 2.18 420 1  48 — — 2.38 390 1  49 162 DSC 2.34 767 1  50 — — 2.14 489 1  51 192 K 2.47 446 1  52 173 K 2.46 446 1  53 260 K 2.33 419 1  54 159 K 2.32 434 1  55 200 K 2.50 418 1  56 — — 1.95 419 1  57 — — 2.29 420 1  58 228 K 2.60 462 1  59 — — 2.45 462 1  60 >260 K 2.39 460 1  61 138 K 2.24 460 1 (gum)  62 192 K 2.00 459 1  63 >250 K 2.21 446 1  64 — — 2.58 430 1  65 — — 2.07 468 1  66 — — 2.32 490 1  67 — — 2.17 446 1  68 142 K 2.64 460 1 (gum)  69 138 K 2.65 460 1 (gum)  70 214 K 2.63 460 1  71 150 K 2.63 460 1 (gum)  72 167 K 2.17 446 1 (gum)  73 — — 2.32 402 1  74 191 K 2.20 446 1  75 203 K 2.24 460 1  76 134 K 2.21 460 1 (gum)  77 123 K 2.44 434 1 (gum)  78 117 K 2.44 434 1 (gum)  79 — — 2.31 475 1  80 304 DSC 2.35 499 1  81 124 K 2.22 446 1 (gum)  82 140 K 2.22 446 (gum)  83 — — 2.00 473 1  84 140 K 2.28 462 1 (gum)  85 141 K 2.28 462 1 (gum)  86 152 K 2.03 433 1 (gum)  87 — — 2.26 495 1  88 — — 2.19 473 1  89 — — 2.25 473 1  90 118 K 2.00 459 1 (gum)  91 — — 2.40 474 1  92 — — 2.08 420 1  93 — — 2.89 443 1  94 — — 2.33 460 1  95 222 DSC 2.74 430 1  96 182 DSC 2.54 430 1  97 — — 2.52 418 1  98 248 DSC 2.48 418 1  99 — — 2.61 432 1 100 — — 2.66 432 1 101 — — 2.49 489 1 102 — — 2.44 489 1 103 — — 2.08 447 1 104 — — 2.74 490 1 105 150 K 2.80 490 1 107 202 DSC 2.80 438 1 108 186 K 2.21 448 1 109 230 K 2.30 448 1 110 — — 2.31 448 1 111 227 DSC 2.24 446 1 112 190 DSC 2.62 454 1 113 — — 2.75 466 1 114 — — 2.74 466 1 115 202 DSC 2.81 450 1 116 277 DSC 2.23 467 1 117 206 K 2.43 512 1 118 238 DSC 2.46 493 1 119 — — 2.16 480 1 120 189 K 2.37 512 1 121 189 K 2.63 518 1 122 — — 1.97 459 1 123 — — 1.93 459 1 124 — — 2.19 493 1 125 194 K 2.52 531 1 126 — — 2.54 482 1 127 178 K 2.37 462 1 128 184 K 2.76 441 1 129 — — 2.48 466 1 130 226 K 2.51 512 1 131 139 K 2.15 491 1 (gum) 132 — — 2.30 426 1 133 — — 2.54 482 1 134 — — 2.45 525 1 135 — — 1.69 420 1 136 — — 2.07 544 1 137 — — 2.64 541 1 138 — — 2.29 537 1 139 — — 2.21 475 1 140 — — 2.03 473 1 141 129 K 2.04 473 1 (gum) 142 — — 1.89 364 1 143 >250 K 2.31 380 1 144 >250 K 2.31 380 1 145 — — 2.40 379 1 146 222 DSC 2.43 379 1 147 — — 2.10 363 1 148 285 DSC 2.55 393 1 149 — — 2.14 450 1 150 >260 K 2.21 461 1 151 227 DSC 2.19 434 1 152 257 DSC 2.93 561 1 153 199 DSC 1.98 436 1 154 — — 2.24 460 1 155 197 DSC 2.07 517 1 156 219 DSC 2.05 420 1 157 — — 2.18 479 1 158 141 K 2.21 475 1 (gum) 159 183 K 2.63 515 1 160 — — 2.36 511 1 161 243 DSC 2.18 479 1 162 211 DSC 2.49 466 1 163 191 K 3.17 597 1 164 262 DSC 2.50 473 1 165 — — 2.35 475 1 166 245 K 1.96 474 1 167 165 K 2.33 528 1 168 126 K 2.21 559 1 169 147 K 2.95 579 1 (gum) 170 177 K 2.08 475 1 171 — — 2.12 487 1 172 — — 1.95 503 1 173 110 K 2.22 419 1 (gum) 174 110 K 2.22 419 1 (gum) 175 260 K 2.67 470 1 176 264 K 2.67 470 1 177 70 K 2.63 476 1 (gum) 178 — — 2.28 515 1 179 — — 2.34 487 1 180 131 DSC 2.43 470 1 170 DSC 181 182 DSC 2.41 470 1 182 271 DSC 2.23 475 1 183 255- DSC 2.24 447 1 256 184 148 K 2.38 538 1 (gum) 185 154 K 2.00 524 2 (gum) 186 240 K 2.36 426 1 187 267 DSC 2.47 469 1 188 107 K 2.74 470 1 (gum) 189 238 K 2.81 509 1 190 250 K 2.03 419 1 191 192 K 2.15 459 1 192 204 K 2.27 418 1 193 128 K 1.98 434 1 (gum) 194 250 K 2.34 420 1 195 292 DSC 2.47 473 2 196 217 DSC 2.49 473 1 197 304 DSC 2.33 469 1 198 158 MP50 2.86 473 4 199 226 K 2.25 461 1 200 138 K 2.06 572 1 (gum) 201 290 MP50 2.32 473 5 202 158 K 2.12 496 1 (gum) 203 112 K 2.15 491 1 (gum) 204 — — 2.60 454 1 205 — — 2.53 452 1 206 212 DSC 2.11 447 1 207 126 K 2.45 519 1 208 129 K 2.25 495 1 (gum) 209 254 K 1.78 474 2 210 179 DSC 2.54 487 1 211     2.44 487 1 212 275 DSC 2.53 487 1 213 299 MP50 2.08 513 4 214 — — 1.88 517 1 215 230 MP50 1.99 461 4 216 — — 2.06 363 1 217 156 DSC 2.46 486 1 218 183 DSC 2.56 468 1 219 173 DSC 2.37 461 1 220 — — 2.36 496 1 221 — — 2.03 466 1 222 — — 1.61 361 3 223 — — 1.61 361 3

SFC-MS Method

The SFC measurement was performed using an Analytical Supercritical fluid chromatography (SFC) system composed by a binary pump for delivering carbon dioxide (CO₂) and modifier, an autosampler, a column oven, a diode array detector equipped with a high-pressure flow cell standing up to 400 bars. If configured with a Mass Spectrometer (MS) the flow from the column was brought to the (MS). It is within the knowledge of the skilled person to set the tune parameters (e.g. scanning range, dwell time . . . ) in order to obtain ions allowing the identification of the compound's nominal monoisotopic molecular weight (MW). Data acquisition was performed with appropriate software.

Table: Analytical SFC-MS Methods (flow expressed in mL/min; column temperature (T) expressed in ° C.; run time expressed in minutes, backpressure (BPR) expressed in bars.

Flow Run time Method column mobile phase gradient Col T BPR Method 1 Chiralpak ® AD-H A: CO₂ 30% B 3 7 column (5 μm, 150 × B: iPrOH hold 7 min, 35 100 4.6 mm) (0.3% iPrNH₂) Method 2 Chiralcel ® OJ-H A: CO₂ 40% B 3 7 column (5 μm, 150 × B: MeOH hold 7 min, 35 100 4.6 mm) (0.3% iPrNH₂) Method 3 Chiralpak ® AD-3 A: CO₂ 30% B 3.5 3 column (3 μm, 100 × B: EtOH (0.3% hold 3 min, 35 103 4.6 mm) iPrNH₂) Method 4 Chiralcel ® OJ-H A: CO₂ 15% B 3.5 6 column (5 μm, 150 × B: MeOH hold 6 min, 35 103 4.6 mm) (0.3% iPrNH₂) Method 5 Chiralpak ® AD-3 A: CO₂ 40% B 3.5 3 column (3 μm, 100 × B: EtOH (0.3% hold 3 min, 35 103 4.6 mm) iPrNH₂) Method 6 Chiralpak ® AD-3 A: CO₂ 35% B 3.5 3 column (3 μm, 100 × B: iPrOH hold 3 min, 35 103 4.6 mm) (0.3% iPrNH₂) Method 7 Chiralpak ® IC3 A: CO₂ 35% B 3.5 3 column (3 μm, 100 × B: iPrOH hold 3 min, 35 103 4.6 mm) (0.3% iPrNH₂) Method 8 Lux cellulose 4 A: CO₂ 40% B 3.5 3 column (3 μm, 100 × B: EtOH (0.3% hold 3 min, 35 103 4.6 mm) iPrNH₂)

Table: Analytical SFC data (R_(t) means retention time (in minutes), [M+H]⁺ means the protonated mass of the compound, method refers to the method used for SFC-MS analysis of enantiomerically pure compounds; N° means compound number).

Chiral purity UV N° Rt [M + H]⁺ Area % Method  68 2.96 460 100 1  69 3.54 460 99.10 1  70 4.16 460 100 2  71 2.31 460 100 2  77 1.01 434 100 3  78 1.14 434 99.12 3  81 2.31 446 99.39 4  82 2.70 446 98.12 4  84 1.00 462 100 5  85 1.56 462 100 5 121 0.99 518 97.2 6 139 1.69 475 100 7 140 1.52 473 100 8 141 2.05 473 98.63 8 158 2.31 475 100 7

Pharmacological Part

Biological Assay a

Inhibition of auto-phosphorylation of recombinant human NF-kappaB-inducing kinase (NIK/MAP3K14) activity (AlphaScreen®)

NIK/MAP3K14 auto-phosphorylation activity was measured using the AlphaScreen® (αscreen) format (Perkin Elmer). All compounds tested were dissolved in dimethyl sulfoxide (DMSO) and further dilutions were made in assay buffer. Final DMSO concentration was 1% (v/v) in assays. Assay buffer was 50 mM Tris pH 7.5 containing 1 mM EGTA (ethylene glycol tetraacetic acid), 1 mM DTT (dithiothreitol), 0.1 mM Na₃VO₄, 5 mM MgCl₂, 0.01% Tween® 20. Assays were carried out in 384 well Alphaplates (Perkin Elmer). Incubations consisted of compound, 25 microM Adenosine-5′-triphosphate (ATP), and 0.2 nM NIK/MAP3K14. Incubations were initiated by addition of GST-tagged NIK/MAP3K14 enzyme, carried out for 1 h at 25° C. and terminated by addition of stop buffer containing anti-phospho-IKK Ser176/180 antibody. Protein A Acceptor and Glutathione-Donor beads were added before reading using an EnVision® Multilabel Plate Reader (Perkin Elmer). Signal obtained in the wells containing blank samples was subtracted from all other wells and IC₅₀'s were determined by fitting a sigmoidal curve to % inhibition of control versus Log₁₀ compound concentration.

Biological assay B

Effect of compounds on P-IKKα levels in L363 (NIK translocated multiple myeloma) cells

All compounds tested were dissolved in DMSO and further dilutions were made in culture medium. Final DMSO concentration was 1% (v/v) in cell assays. The human L363 cells (ATCC) were cultured in RPMI 1640 medium supplemented with GlutaMax and 10% fetal calf serum (PAA). Cells were routinely maintained at densities of 0.2×10⁶ cells per ml-1×10⁶ cells per ml at 37° C. in a humidified 5% CO₂ atmosphere. Cells were passaged twice a week splitting back to obtain the low density. Cells were seeded in 96 well plates (Nunc 167008) at 2×10⁶ per ml media in a volume of 75 μl per well plus 25 μl 1 μg/ml recombinant human B-cell activating factor (BAFF/BLyS/TNFSF13B). Seeded cells were incubated at 37° C. in a humidified 5% CO₂ atmosphere for 24 hr. Drugs and/or solvents were added (20 μl) to a final volume of 120 μl. Following 2 hr treatment plates were removed from the incubator and cell lysis was achieved by the addition of 30 μl 5× lysis buffer followed by shaking on a plate shaker at 4° C. for 10 min. At the end of this incubation lysed cells were centrifuged at 800×g for 20 min at 4° C. and the lysate was assessed for P-IKKα levels by sandwich immuno-assay carried out in anti-rabbit antibody coated Mesoscale plates. Within an experiment, the results for each treatment were the mean of 2 replicate wells. For initial screening purposes, compounds were tested using an 8 point dilution curve (serial 1:3 dilutions). For each experiment, controls (containing MG132 and BAFF but no test drug) and a blank incubation (containing MG132 and BAFF and 10 μM ADS125117, a test concentration known to give full inhibition) were run in parallel. The blank incubation value was subtracted from all control and sample values. To determine the IC₅₀ a sigmoidal curve was fitted to the plot of % inhibition of control P-IKKα levels versus Log₁₀ compound concentration.

Biological assay C

Determination of antiproliferative activity on JJN-3 (NIK translocated) and KMS12-BM (NIK WT) multiple myeloma cells

All compounds tested were dissolved in DMSO and further dilutions were made in culture medium. Final DMSO concentration was 0.3% (v/v) in cell proliferation assays. Viability was assessed using CellTiter-Glo cell viability assay kit (Promega). The human JJN-3 and KMS12-BM cells (DSMZ) were cultured in RPMI 1640 medium supplemented with 2 mM L-glutamine, and 10% fetal calf serum (PAA). Cells were routinely kept as suspension cells at 37° C. in a humidified 5% CO₂ atmosphere. Cells were passaged at a seeding density of 0.2×10⁶/ml twice a week. Cells were seeded in black tissue culture treated 96-well plates (Perkin Elmer). Densities used for plating ranged from 15000 (JJN3) to 20000 (KMS12BM) cells per well in a total volume of 135 μl medium. Drugs and/or solvents were added (15 μl) to a final volume of 150 μl. Following 96 hr of treatment, plates were removed from the incubator and allowed to equilibrate to room temperature for approx 10 min. 75 μl CellTiter-Glo reagent was added to each well that was then covered (Perkin Elmer Topseal) and shaken on plate shaker for 10 min. Luminescence was measured on a HTS Topcount (Perkin Elmer). Within an experiment, the results for each treatment were the mean of 2 replicate wells. For initial screening purposes, compounds were tested using a 9 point dilution curve (serial 1:3 dilutions). For each experiment, controls (containing no drug) and a blank incubation (containing cells read at the time of compound addition) were run in parallel. The blank value was subtracted from all control and sample values. For each sample, the mean value for cell growth (in relative light units) was expressed as a percentage of the mean value for cell growth of the control.

Data for the compounds of the invention in the above assays are provided in Table A (the values in Table are averaged values over all measurements on all batches of a compound). (‘n.c.’ means not calculated)

TABLE A Auto- Inhibition phosphorylation of KMS-12 JJN-3 inhibition of pIKKα_L- Proliferation Proliferation Com- NIK 363 inhibition inhibition pound (IC50 (nM)) (IC50 (nM)) (IC50 (nM)) (IC50 (nM)) 1 4.0 n.c. 2434 250 2 6.9 n.c. 794 141 3 4.2 n.c. ~1230 407 4 2.5 n.c. 162 ~55 5 5.4 n.c. >10000 708 6 7.6 n.c. >10000 347 7 3.2 2 ~1738 112 8 5.5 n.c. 7943 129 9 5.1 n.c. >10000 832 10 13 n.c. >10000 724 11 21 n.c. 3702 576 12 3.6 n.c. ~213.8 ~45 13 3.4 n.c. ~2512 162 14 7.1 n.c. ~7244 234 15 5.4 n.c. 437 191 16 2.8 n.c. 7079 525 17 10 n.c. 4169 4365 18 11 n.c. >10000 1862 19 2.2 n.c. 2717 163 20 3.4 n.c. 2512 229 21 2.9 n.c. 1023 813 22 18 n.c. >10000 2344 23 4.9 n.c. 3890 295 24 10 n.c. >10000 646 25 8.1 n.c. 1514 1905 26 10 n.c. ~2951 457 27 13 n.c. ~4571 389 28 ~17 n.c. >10000 2570 29 4.4 n.c. 1445 ~603 30 3.2 n.c. ~170 47 31 14 n.c. >10000 589 32 27 n.c. >10000 7762 33 9.1 n.c. ~6166 1259 34 10 n.c. ~10000 1175 35 7.9 4 >10000 209 36 2.6 n.c. 7586 174 37 2.0 n.c. 182 162 38 47 n.c. 3890 3981 39 32 n.c. >10000 1445 40 2.2 n.c. 562 295 41 2.1 n.c. ~479 78 42 4.2 68 5976 398 43 2.6 n.c. 933 234 44 4.5 n.c. 8710 324 45 7.6 n.c. 4169 1318 46 6.6 n.c. 2399 158 47 44 n.c. >10000 1549 48 5.1 n.c. 263 89 49 4.0 11 2089 134 50 3.8 n.c. >10000 316 51 4.1 n.c. ~1905 ~59 52 6.9 n.c. >10000 115 53 3.5 n.c. ~5012 851 54 11 n.c. >10000 525 55 4.4 n.c. ~2041.74 59 56 3.1 n.c. ~1412.54 ~363 57 28 n.c. >10000 ~933 58 1.5 n.c. 468 69 59 5.0 n.c. 1950 68 60 2.0 5 ~501.19 72 61 4.4 n.c. 355 162 62 23 n.c. 269 204 63 9.8 n.c. 6310 692 64 1.9 n.c. 3236 240 65 10 n.c. >10000 ~1412 66 13 n.c. >10000 324 67 1.6 n.c. 912 141 68 5.3 n.c. >10000 38 69 5.8 n.c. >10000 78 70 3.8 6 1862 209 71 2.8 4 813 102 72 2.9 3 724 102 73 1.9 2 1318 195 74 3.0 n.c. ~3890 324 75 13 n.c. ~6026 2089 76 1.2 2 741 141 77 13 n.c. 1585 309 78 9.8 n.c. 9120 457 79 8.3 n.c. >10000 2239 80 3.9 n.c. 6166 1096 81 4.3 11 851 195 82 ~5.0 13 380 182 83 10 514 148 111 84 11 11 >10000 437 85 9.8 31 ~4898 380 86 2.6 15 ~3715 871 87 ~6.5 34 >10000 3236 88 6.8 9 >10000 2138 89 3.7 ~85 >10000 427 90 5.7 n.c. 5129 1549 91 5.5 13 >10000 324 92 3.5 7 1514 ~224 93 11 37 457 182 94 5.6 7 4169 178 95 1.6 4 871 100 96 1.6 12 3802 76 97 2.0 2 >10000 309 98 2.0 5 >10000 1023 99 2.9 3 9772 288 100 2.1 ~15 >10000 54 101 6.0 234 5248 1513 102 2.2 12 ~6457 112 103 2.6 4 3020 71 104 3.4 15 >10000 117 105 5.5 20 >10000 447 107 3.8 9 1349 55 108 4.1 14 ~3162 ~724 109 3.6 11 468 50 110 3.0 4 2042 138 111 9.3 ~331 5129 355 112 2.9 13 8913 69 113 6.2 42 3020 69 114 6.0 30 1072 151 115 4.6 10 4266 62 116 9.3 269 n.c. n.c. 117 6.0 11 >10000 269 118 4.0 33 >10000 447 119 9.6 43 >10000 3162 120 ~29 3 5012 126 121 5.0 25 >10000 282 122 6.8 1023 ~1660 479 123 1.6 20 ~447 195 124 6.8 219 832 49 125 3.5 1 >10000 120 126 4.8 170 >10000 468 127 2.0 25 >10000 617 128 3.7 ~41 1905 417 129 3.8 28 2042 251 130 6.0 115 >10000 1000 131 5.9 166 >10000 224 132 1.0 2 ~1862 58 133 6.9 65 6607 389 134 4.8 107 2239 47 135 5.1 229 >10000 >10000 136 7.2 562 >10000 724 137 6.3 36 >10000 676 138 8.3 178 2570 44 139 13 182 >10000 1122 140 8.3 145 6457 174 141 42 813 >10000 79 142 42 n.c. ~9772 >10000 143 1.3 n.c. 204 ~81 144 2.0 n.c. 44 36 145 1.5 n.c. ~3388 71 146 1.3 n.c. 589 102 147 9.6 n.c. ~5012 ~436 148 0.8 n.c. 282 93 149 0.7 8 ~741 50 150 15 170 >10000 2399 151 2.0 13 7079 871 152 17 135 7943 646 153 4.3 28 >10000 1445 154 4.9 15 2291 646 155 9.3 126 >10000 59 156 3.6 14 ~7244 1259 157 12 182 141 45 158 10 123 >10000 339 159 10 91 >10000 1514 160 3.6 34 ~5012 69 161 4.3 83 2239 204 162 7.2 35 2630 832 163 12 5 >10000 309 164 2.6 <0.66 4677 132 165 8.5 48 >10000 1622 166 13 151 >10000 37 167 13 62 >10000 83 168 2.3 3 7586 631 169 3.9 16 ~7079 389 170 2.2 7 ~1778 417 171 6.2 1445 n.c. n.c. 172 4.6 ~10000 n.c. n.c. 173 162 n.c. ~6310 6026 174 35 n.c. 3162 1549 175 n.c. n.c. >10000 4074 176 32 76 ~3311.31 65 177 10 28 >10000 81 178 20 141 2344 98 179 6.2 n.c. ~10000 832 180 4.7 2 ~6719 46 181 3.3 11 ~9120 87 182 1.7 1 1380 151 183 22 35 ~9772 1412 184 5.4 17 >10000 224 185 6.0 20 >10000 91 186 6.5 3 617 151 187 7.2 11 >10000 ~1380 188 2.9 4 ~8128 138 189 17.0 51 n.c. n.c. 190 11.7 110 n.c. n.c. 191 107 4467 n.c. n.c. 192 8.1 6 >10000 91 193 25.1 91 n.c. n.c. 194 3.1 29 >10000 407 195 4.9 1 >10000 158 196 8.3 36 5248 554 197 2.1 4 ~2239 204 198 6.8 20 >10000 112 199 3.5 25 >10000 1905 200 5.9 20 >10000 3548 201 3.4 2 >10000 100 202 7.2 1950 n.c. n.c. 203 4.0 25 >10000 339 204 1.1 2 ~6026 16 205 2.2 1 ~4898 5 206 2.9 31 n.c. n.c. 207 15.5 93 n.c. n.c. 208 2.0 4 ~4786 48 209 28.2 141 n.c. n.c. 210 6.3 71 >10000 1585 211 14.8 204 n.c. n.c. 212 11.7 98 >10000 257 213 5.6 27 >10000 95 214 18.6 2630 n.c. n.c. 215 168 3490 n.c. n.c. 216 7.8 n.c. 2630 537 217 4.6 11 ~7623 154 218 2.8 7 ~7431 38 219 9.5 100 n.c. 214 220 5.6 11 >10000 195 221 14.8 ~105 >10000 2291 222 12.0 15 n.c. n.c. 223 224 269 n.c. n.c.

Prophetic Composition Examples

“Active ingredient” (a.i.) as used throughout these examples relates to a compound of Formula (I), including any tautomer or stereoisomeric form thereof, or a pharmaceutically acceptable addition salt, or a solvate thereof; in particular to any one of the exemplified compounds.

Typical examples of recipes for the formulation of the invention are as follows:

1. Tablets

Active ingredient 5 to 50 mg Di-calcium phosphate 20 mg Lactose 30 mg Talcum 10 mg Magnesium stearate 5 mg Potato starch ad 200 mg

2. Suspension

An aqueous suspension is prepared for oral administration so that each milliliter contains 1 to 5 mg of active ingredient, 50 mg of sodium carboxymethyl cellulose, 1 mg of sodium benzoate, 500 mg of sorbitol and water ad 1 ml.

3. Injectable

A parenteral composition is prepared by stirring 1.5% (weight/volume) of active ingredient in 0.9% NaCl solution or in 10% by volume propylene glycol in water.

4. Ointment

Active ingredient 5 to 1000 mg Stearyl alcohol 3 g Lanoline 5 g White petroleum 15 g Water ad 100 g

In this Example, active ingredient can be replaced with the same amount of any of the compounds according to the present invention, in particular by the same amount of any of the exemplified compounds. 

The invention claimed is:
 1. A compound of Formula (I):

a tautomer or a stereoisomeric form thereof, wherein R¹ represents C₁₋₄alkyl; R² represents C₁₋₆alkyl, C₁₋₆alkyl substituted with one R⁵, or C₁₋₆alkyl substituted with one, two or three fluoro atoms; Y represents CR⁴; R⁴ represents hydrogen or halo; R⁵ represents Het^(3a), —NR^(6a)R^(6b), or —OR⁷; R^(6a) represents hydrogen or C₁₋₄alkyl; R^(6b) represents hydrogen; C₁₋₄alkyl; C₃₋₆cycloalkyl; —C(═O)—C₁₋₄alkyl; —C(═O)—Het⁴; —S(═O)₂—C₁₋₄alkyl; —C(═O)—C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH and —NR^(16a)R^(16b); or C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH and —S(═O)₂—C₁₋₄alkyl; R⁷ represents hydrogen, C₁₋₄alkyl, —C₁₋₄alkyl-NR^(8a)R^(8b), —C(═O)—R⁹, —S(═O)₂—OH, —P(═O)₂—OH, —(C═O)—CH(NH₂)—₁₋₄alkyl-Ar¹, or —C₁₋₄alkyl-Het^(3b); R^(8a) represents hydrogen or C₁₋₄alkyl; R^(8b) represents hydrogen, C₁₋₄alkyl, or C₃₋₆cycloalkyl; R⁹ represents C₁₋₆alkyl, or C₁₋₆alkyl substituted with one substituent selected from the group consisting of —NH₂, —COOH, and Het⁶; R^(16a) and R^(16b) each independently represents hydrogen, C₁₋₄alkyl or C₃₋₆cycloalkyl; R³ represents a 5-membered heteroaromatic ring containing one, two or three heteroatoms each independently selected from O, S, and N; wherein said 5-membered heteroaromatic ring may optionally be substituted, where possible, on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; C₃₋₆cycloalkyl; Het^(1a); R¹⁸; R²¹; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₅alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; —C₁₋₄alkyl-O—C₁₋₄alkyl substituted with one or two —OH substituents; C₁₋₄alkyl substituted with one R¹⁸; C₂₋₆alkenyl; and C₂₋₆alkenyl substituted with one R¹³; provided that when Het^(1a) or R¹⁸ are directly attached to the N-atom of the 5-membered heteroaromatic ring, said Het^(1a) or R¹⁸ are attached to the N-atom via a ring carbon atom; and wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; cyano; C₁₋₆alkyl; —O—C₁₋₄alkyl; —C(═O)—R¹⁰; —S(═O)₂—C₁₋₄alkyl; —S(═O)(═N—R^(20a))—C₁₋₄alkyl; —O—C₁₋₄alkyl substituted with one, two or three halo atoms; —O—C₁₋₄alkyl-R¹²; C₃₋₆cycloalkyl; —O—C₃₋₆cycloalkyl; Het^(1a); —O—Het^(1b); R¹⁸; R²¹; —P(═O)—(C₁₋₄alkyl)₂; —NH—C(═O)—C₁₋₄alkyl; —NH—C(═O)-Het^(1g); —NR^(17a)R^(17b); C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; C₁₋₄alkyl substituted with one R¹⁸; C₂₋₆alkenyl; and C₂₋₆alkenyl substituted with one R¹³; R¹⁰ represents —OH, —O—C₁₋₄alkyl, —NR^(11a)R^(11b) or Het²; R¹⁸ represents a 5-membered aromatic ring containing one, two or three N-atoms; wherein said 5-membered aromatic ring may optionally be substituted with one substituent selected from the group consisting of C₁₋₄alkyl and C₃₋₆cycloalkyl; R²¹ represents 3,6-dihydro-2H-pyran-4-yl or 1,2,3,6-tetrahydro-4-pyridinyl, wherein 1,2,3,6-tetrahydro-4-pyridinyl may optionally be substituted on the N-atom with C₁₋₄alkyl or C₃₋₆cycloalkyl; Het^(1a), Het^(1c) and Het^(1d) each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N; or a 6- to 11-membered bicyclic saturated heterocyclyl, including fused, spiro and bridged cycles, containing one, two or three heteroatoms each independently selected from O, S, S(═O)_(p) and N; wherein said 4- to 7-membered monocyclic saturated heterocyclyl or said 6- to 11-membered bicyclic saturated heterocyclyl may optionally be substituted, where possible, on one, two or three ring N-atoms with a substituent each independently selected from the group consisting of C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkyl substituted with one, two or three halo atoms, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH, —C(═O)—OH, —C(═O)—NR^(22a)R^(22b) and —O—C₁₋₄alkyl; and wherein said 4- to 7-membered monocyclic saturated heterocyclyl or said 6- to 11-membered bicyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of —OH, oxo, halo, C₁₋₄alkyl, cyano, —C(═O)—C₁₋₄alkyl, —NH₂, —NH(C₁₋₄alkyl), and —N(C₁₋₄alkyl)₂; Het^(1b), Het^(1e), Het^(1g) and Het⁴ each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl, attached to the remainder of the molecule of Formula (I) through any available ring carbon atom, said Het^(1b), Het^(1e), Het^(1g) and Het⁴ containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N; wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted, where possible, on one or two ring N-atoms with a substituent each independently selected from the group consisting of C₁₋₄alkyl, C₃₋₆cyloalkyl, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH and —O—C₁₋₄alkyl; and wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of —OH, halo, C₁₋₄alkyl, cyano, —C(═O)—C₁₋₄alkyl, —O—C₁₋₄alkyl, —NH₂, —NH(C₁₋₄alkyl), and —N(C₁₋₄alkyl)₂; Het² represents a heterocyclyl of formula (b-1):

(b-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional heteroatom selected from O, S, S(═O)_(p) and N, or a N-linked 6- to 11-membered bicyclic saturated heterocyclyl, including fused, spiro and bridged cycles, optionally containing one or two additional heteroatoms each independently selected from O, S, S(═O)_(p) and N; wherein in case (b-1) contains one or two additional N-atoms, said one or two N-atoms may optionally be substituted with C₁₋₄alkyl; and wherein (b-1) may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of halo, —OH, cyano, C₁₋₄alkyl, —O—C₁₋₄alkyl, —NH₂, —NH(C₁₋₄alkyl), —N(C₁₋₄alkyl)₂, and C₁₋₄alkyl-OH; R^(11b) represents hydrogen; Het^(1e); C₁₋₄alkyl; C₁₋₄alkyl-Het⁵; C₁₋₄alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and —O—C₁₋₄alkyl; C₃₋₆cycloalkyl; or C₃₋₆cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and —O—C₁₋₄alkyl; R¹³ represents —O—C₁₋₄alkyl, —C(═O)OH, —C(═O)NR^(15a)R^(15b), —NR^(19a)R^(19b), C₃₋₆cycloalkyl, Het^(1d), Het⁷, —S(═O)₂—C₁₋₄alkyl, —S(═O)(═N—R^(20c))—C₁₋₄alkyl, or —C(═O)—Het^(1f); R¹² represents —OH, —O—C₁₋₄alkyl, —NR^(14a)R^(14b), —C(═O)NR^(14c)R^(14d), —S(═O)₂—C₁₋₄alkyl, —S(═O)(═N—R^(20b))—C₁₋₄alkyl, C₃₋₆cycloalkyl, Ar², or Het^(1c); A¹ represents phenyl optionally substituted with one hydroxy; Ar² represents phenyl optionally substituted with one C₁₋₄alkyl; Het^(3a), Het^(3b), Het⁵, Het⁶ and Het^(1f) each independently represents a heterocyclyl of formula (c-1):

(c-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional heteroatom selected from O, S, S(═O)_(p) and N; wherein in case (c-1) contains one additional N-atom, said additional N-atom may optionally be substituted with C₁₋₄alkyl or C₃₋₆cycloalkyl; and wherein (c-1) may optionally be substituted on one or two ring C-atoms atoms with one or two substituents each independently selected from the group consisting of halo, C₁₋₄alkyl, and C₃₋₆cycloalkyl; Het⁷ represents 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridinyl; R^(11a), R^(14a), R^(14c), R^(15a), R^(17a), R^(19a) and R^(22a)each independently represents hydrogen, C₁₋₄alkyl, or C₃₋₆cycloalkyl; R^(14b), R^(14d), R^(15b), R^(17b), R^(19b) and R^(22b) each independently represents hydrogen; C₁₋₄alkyl; C₃₋₆cycloalkyl; or C₁₋₄alkyl substituted with one substituent selected from the group consisting of halo, —OH and —O—C₁₋₄alkyl; R^(20a), R^(20b) and R^(20c) each independently represents hydrogen; C₁₋₄alkyl; C₃₋₆cycloalkyl; or C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH and —O—C₁₋₄alkyl; p represents 1 or 2; or a pharmaceutically acceptable addition salt, or a solvate thereof.
 2. The compound according to claim 1, wherein R² represents C₁₋₆alkyl, or C₁₋₆alkyl substituted with one R⁵; Y represents CR⁴; R³ represents a 5-membered heteroaromatic ring containing one, two or three heteroatoms each independently selected from O, S, and N; wherein said 5-membered heteroaromatic ring may optionally be substituted, where possible, on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; C₃₋₆cycloalkyl; Het^(1a); R¹⁸; R²¹; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; C₁₋₄alkyl substituted with one R¹⁸; C₂₋₆alkenyl; and C₂₋₆alkenyl substituted with one R¹³; provided that when Het^(1a) or R¹⁸ are directly attached to the N-atom of the 5-membered heteroaromatic ring, said Het^(1a) or R¹⁸ are attached to the N-atom via a ring carbon atom; and wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; cyano; C₁₋₆alkyl; —O—C₁₋₄alkyl; —C(═O)—R¹⁰; —S(═O)₂—C₁₋₄alkyl; —S(═O)(═N—R^(20a))—C₁₋₄alkyl; —O—C₁₋₄alkyl substituted with one, two or three halo atoms; —O—C₁₋₄alkyl-R¹²; C₃₋₆cycloalkyl; —O—C₃₋₆cycloalkyl; Het^(1a); —O-Het^(1b); R¹⁸; R²¹; —P(═O)—(C₁₋₄alkyl)₂; —NH—C(═O)—C₁₋₄alkyl; —NH—C(═O)-Het^(1g); —NR^(17a)R^(17b); C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; C₁₋₄alkyl substituted with one R¹⁸; C₂₋₆alkenyl; and C₂₋₆alkenyl substituted with one R¹³; R¹³ represents —O—C₁₋₄alkyl, —C(═O)OH, —C(═O)NR^(15a)R^(15b); —NR^(19a)R^(19b), C₃₋₆cycloalkyl, Het^(1d), —S(═O)₂—C₁₋₄alkyl, —S(═O)(═N—R^(20c))—C₁₋₄alkyl, or —C(═O)—Het^(1f).
 3. The compound according to claim 1, wherein R² represents C₁₋₆alkyl substituted with one R⁵; R^(6b) represents hydrogen; or C₁₋₄alkyl substituted with one —OH substituent; R⁷ represents hydrogen or —C(═O)—R⁹; R⁹ represents C₁₋₆alkyl; R³ represents a 5-membered heteroaromatic ring containing one, two or three heteroatoms each independently selected from O, S, and N; wherein said 5-membered heteroaromatic ring may optionally be substituted, where possible, on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; C₃₋₆cycloalkyl; Het^(1a); C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₅alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; —C₁₋₄alkyl-O—C₁₋₄alkyl substituted with one or two —OH substituents; C₁₋₄alkyl substituted with one R¹⁸; and C₂₋₆alkenyl; provided that when Het^(1a) is directly attached to the N-atom of the 5-membered heteroaromatic ring, said Het^(1a) is attached to the N-atom via a ring carbon atom; and wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; cyano; C₁₋₆alkyl; —O—C₁₋₄alkyl; —C(═O)—R¹²; C₃₋₆cycloalkyl; —O—C₃₋₆cycloalkyl; Het^(1a); —O-Het^(1b); —P(═O)—(C₁₋₄alkyl)₂; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; and C₁₋₆alkyl substituted with one R¹³; R₁₀ represents —NR^(11a)R^(11b) or Het²; Het^(1a), Het^(1c) and Het^(1d) each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N; or a 6- to 11-membered bicyclic saturated heterocyclyl, including fused cycles, containing one, two or three heteroatoms each independently selected from O and N; wherein said 4- to 7-membered monocyclic saturated heterocyclyl or said 6- to 11-membered bicyclic saturated heterocyclyl may optionally be substituted, where possible, on one, two or three ring N-atoms with a substituent each independently selected from the group consisting of C₁₋₄alkyl, C₁₋₄alkyl substituted with one, two or three halo atoms, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —C(═O)—OH, —C(═O)—NR^(22a)R^(22b) and —O—C₁₋₄alkyl; and wherein said 4- to 7-membered monocyclic saturated heterocyclyl or said 6- to 11-membered bicyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of oxo, halo and C₁₋₄alkyl; Het^(1b) and Het^(1a) each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl, attached to the remainder of the molecule of Formula (I) through any available ring carbon atom, said Het^(1b) and Het^(1c) containing one or two O-atoms; Het² represents a heterocyclyl of formula (b-1):

(b-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional N-atom; wherein in case (b-1) contains one additional N-atom, said N-atom may optionally be substituted with C₁₋₄alkyl; R^(11b) represents Het^(1e); C₁₋₄alkyl; or C₃₋₆cycloalkyl; R¹³ represents —O—C₁₋₄alkyl, —C(═O)OH, —C(═O)NR^(15a)R^(15b), —NR^(19a)R^(19b) C₃₋₆cycloalkyl, Het^(1d), Het⁷, —S(═O)₂—C₁₋₄alkyl, or —C(═O)—Het^(1f); R¹² represents —O—C₁₋₄alkyl or Het^(1e); Het^(3a) and Het^(1f) each independently represents a heterocyclyl of formula (c-1):

(c-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional N-atom; wherein in case (c-1) contains one additional N-atom, said additional N-atom may optionally be substituted with C₃₋₆cycloalkyl; and wherein (c-1) may optionally be substituted on one or two ring C-atoms atoms with one or two halo substituents; R^(11a), R^(15a), R^(19a) and R^(22a) each independently represents hydrogen, C₁₋₄alkyl, or C₃₋₆cycloalkyl; R^(15b), R^(19b) and R^(22b) each independently represents C₁₋₄alkyl or C₃₋₆cycloalkyl; p represents
 2. 4. The compound according to claim 1 or 2, wherein R^(6b) represents hydrogen; C₁₋₄alkyl; C₃₋₆cycloalkyl; —C(═O)—C₁₋₄alkyl; —C(═O)—C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH and —NR^(16a)R^(16b); or C₁₋₄alkyl substituted with one —OH substituent; R⁷ represents hydrogen, C₁₋₄alkyl, —C₁₋₄alkyl-NR^(8a)R^(8b), or —C(═O)—R⁹; R⁹ represents C₁₋₆alkyl, or C₁₋₆alkyl substituted with one substituent selected from the group consisting of —NH₂, and —COOH; R³ represents a 5-membered heteroaromatic ring containing one, two or three heteroatoms each independently selected from O, S, and N; wherein said 5-membered heteroaromatic ring may optionally be substituted, where possible, on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; C₃₋₆cycloalkyl; Het^(1a); R¹⁸; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; C₁₋₄alkyl substituted with one R¹⁸; C₂₋₆alkenyl; and C₂₋₆alkenyl substituted with one R¹³; provided that when Het^(1a) or R¹⁸ are directly attached to the N-atom of the 5-membered heteroaromatic ring, said Het^(1a) or R¹⁸ are attached to the N-atom via a ring carbon atom; and wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; cyano; C₁₋₆alkyl; —O—C₁₋₄alkyl; —C(═O)—R¹⁰; —O—C₁₋₄alkyl substituted with one, two or three halo atoms; —O—C₁₋₄alkyl-R¹²; C₃₋₆cycloalkyl; —O—C₃₋₆cycloalkyl; Het^(1a); —O—Het^(1b); R¹⁸; —P(═O)—(C₁₋₄alkyl)₂; —NH—C(═O)—C₁₋₄alkyl; —NH—C(═O)-Het^(1g); —NR^(17a)R^(17b); C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; C₁₋₄alkyl substituted with one R¹⁸; C₂₋₆alkenyl; and C₂₋₆alkenyl substituted with one R¹³; Het^(1a), and Het^(1d) each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N; wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted, where possible, on one, two or three ring N-atoms with a substituent each independently selected from the group consisting of C₁₋₄alkyl, C₃₋₆cycloalkyl, substituted with one, two or three halo atoms, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH, —C(═O)—OH, —C(═O)—NR^(22a)R^(22b) and —O—C₁₋₄alkyl; and wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of —OH, oxo, halo, C₁₋₄alkyl, cyano, —C(═O)—C₁₋₄alkyl, —O—C₁₋₄alkyl, —NH₂, —NH(C₁₋₄alkyl), and —N(C₁₋₄alkyl)₂; Het^(1b), Het^(1e), and Het^(1g) each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl, attached to the remainder of the molecule of Formula (I) through any available ring carbon atom, said Het^(1b), Het^(1e), and Het^(1g) containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N; wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted, where possible, on one or two ring N-atoms with a substituent each independently selected from the group consisting of C₁₋₄alkyl, C₃₋₆cycloalkyl, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —OH and —O—C₁₋₄alkyl; and wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of —OH, halo, C₁₋₄alkyl, cyano, —C(═O)—C₁₋₄alkyl, —O—C₁₋₄alkyl, —NH₂, —NH(C₁₋₄alkyl), and —N(C₁₋₄alkyl)₂; Het² represents a heterocyclyl of formula (b-1):

(b-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional heteroatom selected from O, S, S(═O)_(p) and N; wherein in case (b-1) contains one additional N-atom, said N-atom may optionally be substituted with C₁₋₄alkyl; and wherein (b-1) may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of halo, —OH, cyano, C₁₋₄alkyl, —O—C₁₋₄alkyl, —NH₂, —NH(C₁₋₄alkyl), —N(C₁₋₄alkyl)₂, and C₁₋₄alkyl-OH; R^(11b) represents hydrogen; Het^(1e); C₁₋₄alkyl; C₁₋₄alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and —O—C₁₋₄alkyl; C₃₋₆cycloalkyl; or C₃₋₆cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and —O—C₁₋₄alkyl; R¹³ represents —O—C₁₋₄alkyl, —C(═O)OH, —C(═O)NR^(15a)R^(15b), —NR^(19a)R^(19b), C₃₋₆cycloalkyl, Het^(1d), —S(═O)₂—C₁₋₄alkyl, or —C(═O)—Het^(1f); R¹² represents —OH, —O—C₁₋₄alkyl, —NR^(14a)R^(14b), —C(═O)NR^(14c)R^(14d), —S(═O)₂—C₁₋₄alkyl, C₃₋₆cycloalkyl; Het^(3a), and Het^(1f) each independently represents a heterocyclyl of formula (c-1):

(c-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional heteroatom selected from O, S, S(═O)_(p) and N; wherein in case (c-1) contains one additional N-atom, said additional N-atom may optionally be substituted with C₁₋₄alkyl or C₃₋₆cycloalkyl; and wherein (c-1) may optionally be substituted on one or two ring C-atoms atoms with one or two substituents each independently selected from the group consisting of halo, C₁₋₄alkyl, and C₃₋₆cycloalkyl.
 5. The compound according to claim 1 or 2, wherein R² represents C₁₋₆alkyl substituted with one R⁵; R⁵ represents Het^(3a), —NR^(6a)R^(6b), or —OR⁷; R^(6a) represents C₁₋₄alkyl; R^(6b) represents C₁₋₄alkyl substituted with one —OH substituent; R⁷ represents hydrogen, or —C(═O)—R⁹; R⁹ represents C₁₋₆alkyl; R³ represents a 5-membered heteroaromatic ring containing two or three heteroatoms each independently selected from O, S, and N; wherein said 5-membered heteroaromatic ring may optionally be substituted, where possible, on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; Het^(1a); C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; substituted with one R¹⁸; and C₂₋₆alkenyl; provided that when Het^(1a) is directly attached to the N-atom of the 5-membered heteroaromatic ring, said Het^(1a) is attached to the N-atom via a ring carbon atom; and wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; cyano; C₁₋₆alkyl; —O—C₁₋₄alkyl; —C(═O)—R¹⁰; C₃₋₆cycloalkyl; Het^(1a), —P(═O)—(C₁₋₄alkyl)₂; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; and substituted with one R¹³; R¹⁰ represents —NR^(11a)R^(11b) or Het²; R¹⁸ represents a 5-membered aromatic ring containing one, two or three N-atoms; wherein said 5-membered aromatic ring may optionally be substituted with one C₁₋₄alkyl; Het^(1a), and Het^(1d) each independently represents a 4- to 7-membered monocyclic saturated heterocyclyl containing one or two heteroatoms each independently selected from O, S, S(═O)_(p) and N; wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted, where possible, on one ring N-atom with a substituent each independently selected from the group consisting of C₄₋₄alkyl, C₁₋₄alkyl substituted with one, two or three halo atoms, and C₁₋₄alkyl substituted with one substituent selected from the group consisting of —C(═O)—NR^(22a)R^(22b) and —O—C₁₋₄alkyl; and wherein said 4- to 7-membered monocyclic saturated heterocyclyl may optionally be substituted on one, two or three ring C-atoms with one or two substituents each independently selected from the group consisting of oxo, halo, and C₁₋₄alkyl; Het^(1e) represents a 4- to 7-membered monocyclic saturated heterocyclyl, attached to the remainder of the molecule of Formula (I) through any available ring carbon atom, said Het^(1e) containing one or two O-atoms; Het² represents 1-piperidinyl; R^(11b) represents Het^(1e); C₁₋₄alkyl; C₃₋₆cycloalkyl; R¹³ represents —O—C₁₋₄alkyl, —C(═O)OH, —C(═O)NR^(15a)R^(15b), —NR^(19a)R^(19b), C₃₋₆cycloalkyl, Het^(1d), —S(═O)₂—C₁₋₄alkyl, or —C(═O)—Het^(1f); Het^(3a), and Het^(1f) each independently represents a heterocyclyl of formula (c-1):

(c-1) represents a N-linked 4- to 7-membered monocyclic saturated heterocyclyl optionally containing one additional N-atom; wherein in case (c-1) contains one additional N-atom, said additional N-atom may optionally be substituted with C₃₋₆cycloalkyl; and wherein (c-1) may optionally be substituted on one or two ring C-atoms atoms with one or two halo substituents; R^(15b), R^(19b) and R^(22b) each independently represents C₁₋₄alkyl; or C₃₋₆cycloalkyl; p represents
 2. 6. The compound according to claim 1 or 2, wherein R² represents C₁₋₆alkyl substituted with one R⁵; R⁴ represents hydrogen; R⁵ represents —OR⁷; R⁷ represents hydrogen, or —C(═O)—R⁹; R⁹ represents C₁₋₆ alkyl; R³ represents a 5-membered heteroaromatic ring containing two or three heteroatoms each independently selected from S, and N; wherein said 5-membered heteroaromatic ring may optionally be substituted, where possible, on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₆alkyl substituted with one R¹³; and C₁₋₄alkyl substituted with one R¹⁸; and wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; C₁₋₆alkyl; —C(═O)—R¹⁰; and C₁₋₄alkyl substituted with one, two or three —OH substituents; R¹⁰ represents —NR^(11a)R^(11b); R¹⁸ represents a 5-membered aromatic ring containing two N-atoms; wherein said 5-membered aromatic ring may optionally be substituted with one C₁₋₄alkyl; Het^(1d) represents a 4- to 7-membered monocyclic saturated heterocyclyl containing one or O-atom; R¹¹ b represents C₁₋₄alkyl or C₃₋₆cycloalkyl; R¹³ represents —O—C₁₋₄alkyl, —C(═O)NR^(15a)R^(15b), or Het^(1d); R^(11a) and R^(15a) each independently represents hydrogen or C₁₋₄alkyl; R^(15b) represents C₃₋₆cycloalkyl.
 7. The compound according to any one of claims 1 to 6, wherein R¹ represents methyl; R² represents methyl or —CH₂—OH.
 8. The compound according to any one of claims 1 to 5, wherein R⁴ is hydrogen or fluoro.
 9. The compound according to any one of claims 1 to 5, wherein R⁴ is hydrogen.
 10. The compound according to any one of claims 1 to 6, wherein R⁵ represents —OR⁷; and R⁷ represents hydrogen.
 11. The compound according to claim 1 or 2, wherein R³ represents pyrazolyl optionally substituted on one ring N-atom with a substituent selected from the group consisting of C₁₋₆alkyl; C₃₋₆cycloalkyl; Het^(1a); R¹⁸; R²¹; C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; C₁₋₄alkyl substituted with one R¹⁸; C₂₋₆alkenyl; and C₂₋₆alkenyl substituted with one R¹³; provided that when Het^(1a) or R¹⁸ are directly attached to the N-atom of the 5-membered heteroaromatic ring, said Het^(1a) or R¹⁸ are attached to the N-atom via a ring carbon atom; and wherein said 5-membered heteroaromatic ring may optionally be substituted on the ring carbon atoms with in total one or two substituents each independently selected from the group consisting of halo; cyano; C₁₋₆alkyl; —O—C₁₋₄alkyl; —C(═O)—R¹⁰; —S(═O)₂—C₁₋₄alkyl; —S(═O)(═N—R^(20a))—C₁₋₄alkyl; —O—C₁₋₄alkyl substituted with one, two or three halo atoms; —O—C₁₋₄alkyl-R¹²; C₃₋₆cycloalkyl; —O—C₃₋₆cycloalkyl; Het^(1a); —O-Het^(1b); R¹⁸; R²¹; —P(═O)—(C₁₋₄alkyl)₂; —NH—C(═O)—C₁₋₄alkyl; —NH—C(═O)-Het^(1g); —NR^(17a)R^(17b); C₁₋₄alkyl substituted with one, two or three halo atoms; C₁₋₄alkyl substituted with one, two or three —OH substituents; C₁₋₆alkyl substituted with one R¹³; C₁₋₄alkyl substituted with one R¹⁸; C₂₋₆alkenyl; and C₂₋₆alkenyl substituted with one R¹³.
 12. The compound according to claim 1, wherein the compound is selected from

tautomers and stereoisomeric forms thereof, and the pharmaceutically acceptable addition salts, and the solvates thereof.
 13. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
 14. A method of treating a B-cell malignancy selected from multiple myeloma, hodgkins lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia in a warm-blooded animal comprising administering to said animal an effective amount of a compound as claimed in claim
 1. 15. The method of claim 14 wherein the B-cell malignancy is multiple myeloma. 